The influence of dietary modifications and weight loss on plasma lipids and lipoproteins. by Harman, Nicola Louise.
Unit 3 Gabalfa Workshops Clos Menter Excelsior Ind. Est. Cardiff CF14 3AY
r- +44 (0) 29 2062 3290 F- +44 (0) 29 2052 5420 E' info@abbsybookbinding co uk W \vww abbeybookbinding co uk
Abbey Bookbinding
i-+-0'r •J" ’•! >
8598257
UNIVERSITY OF SURREY LIBRARY
All rights reserved
INFORMATION TO ALL USERS 
The qua lity  of this rep roduction  is d e p e n d e n t upon the qua lity  of the copy subm itted.
In the unlikely e ve n t that the au tho r did not send a c o m p le te  m anuscrip t 
and there are missing pages, these will be no ted . Also, if m ateria! had to be rem oved,
a n o te  will ind ica te  the de le tion .
Published by ProQuest LLC (2017). C opyrigh t of the Dissertation is held by the Author.
All rights reserved.
This work is protected aga inst unauthorized copying under Title 17, United States C ode
M icroform  Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 481 06 - 1346
The Influence of Dietary Modifications and Weight 
Loss on Plasma Lipids and Lipoproteins
This thesis has been submitted for the degree of
Doctor of Philosophy
By
Nicola Louise Harman BSc MSc
Faculty of Health and Medical Science 
Division of Nutrition and Food Safety 
University of Surrey
December 2007
© Nicola Louise Hannan 2007
Acknowledgements
Firstly I would like to thank Dr Bruce Griffin for the opportunity to conduct this 
research and for his guidance and support throughout I would also like to thank Dr 
John. Lodge for his support, supervision, and stimulating discussions at tea time. I 
would like to show my appreciation to: Dr Margaret Griffin for her continued hard 
work on the RISCK study, but more importantly for her friendship and for making a 
7am start all the more bearable (thanks for the coffee and kit kats!). Dr John Wright 
for his continued assistance on the RISCK study, and to all members of the RISCK 
team for their hard work. Also thanks to the staff of the CEDAR centre at the Royal 
Surrey County Hospital. Amanda Dinsmore and Julie Wilkinson for their work on 
the EDWINA study. Dr Ian Davies for his invaluable instruction in the use of 
iodixanol and for many enjoyable social events. A big thank you is also given to all 
of the volunteers involved in my research and also to the Food Standards Agency 
and the British Egg Information Service for funding the RISCK and EDWINA
studies respectively.
Thanks to the members of coffee club for their continued support, encouragement 
and friendship and to the staff and PhD students of the department who helped make 
my time at the University a happy one.
Finally thanks to my family and Damian, Sue and Kirstie for all of their support and
for putting up with me!
Abstract.
The studies presented in this thesis investigated dietary strategies to reduce 
cardiovascular (CV) risk associated with atherogenic dyslipidaemia. The thesis also 
describes the development of a new method for the separation of the principal HDL 
subclasses.
The ‘RISCK’ study five examined the effects of five diets, differing in the type and 
amount of dietary fat and carbohydrate, on plasma lipids in subjects at risk of 
developing metabolic syndrome. All diets showed a significant reduction in serum 
total, and LDL cholesterol. Whilst no diet was superior in its lipid-lowering effect, the 
two low fat diets reduced waist circumference and other CV risk factors, suggesting a 
link between a reduction in visceral adiposity and CV risk
The ‘EDWINA’ study addressed the effects of energy restriction and increased dietary 
cholesterol in the form of eggs, on body weight and plasma lipids. Energy restriction 
and energy restriction +2 eggs/day for 12 weeks achieved significant weight loss (3- 
4kg). Increased egg consumption had no significant effect on plasma LDL cholesterol, 
suggesting that weight loss negates the cholesterol raising potential of dietary 
cholesterol.
The weight loss and lipid response in the ‘EDWINA’ study was highly variable 
between subjects. Apo E genotype and serum non-cholesterol sterols (markers of 
cholesterol homeostasis) were measured to investigate the origin of this variability. 
Carriage of the s4 allele was significantly associated with higher serum sitosterol 
(marker of cholesterol absorption) at baseline, however, apoE genotype did not 
explain the heterogeneity in response to diet. There was some indication from 
reductions in serum lathosterol, that falls in plasma cholesterol were associated with 
reduced cholesterol biosynthesis.
The overall findings provide further evidence to support the CV health benefits of 
losing weight and especially visceral adiposity. They also highlighted the importance 
of dietary composition of energy restricted diets in modifying lipid mediated CV risk.
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CHAPTER 1 - GENERAL INTRODUCTION
Sum m ary______ _____________________ __ ____________________
Atherogenic dyslipidaemia is often accompanied by other metabolic disturbances 
that can include insulin resistance, central adiposity and elevated blood pressure. 
The clustering o f  these risk factors comprises the metabolic syndrome which is 
associated with increased CVD risk. This introductory chapter describes CVD risk 
factors associated with the metabolic syndrome with particular attention given to 
lipid and lipoprotein risk factors. The dietary and lifestyle interventions to 
ameliorate lipid mediated CVD risk are then reviewed.
1.1 C ardiovascu lar D isease
Recent statistics suggest that cardiovascular disease accounts for 31 %  of premature 
deaths (under the age of 65) in males and 23% of deaths in females (Allender et al 
2007). Cardiovascular disease (CVD) is a term used to describe all diseases affecting 
the heart and blood vessels. The main forms of CVD are coronary heart disease 
(CHD), and stroke. Over the past three decades deaths from CVD have been falling, 
however, despite this trend the UK still has one of the highest death rates from the 
disease. There is evidence to suggest that although CVD as a cause of death is 
declining, morbidity is increasing with approximately 2.68 million people in the UK 
living with the disease.
CVD occurs when there is complete or partial blockage of a blood vessel the 
underlying pathology of which is usually atherosclerosis, which can affect both large 
and medium sized arteries (Ball & Maim 1988). Atherosclerosis is a disease 
characterised by the accumulation of lipids in the arterial wall.
1
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CVD is a multifactorial disease and as such has a number of associated risk factors. 
Atherogenic dyslipidaemia comprises elevated triacyglycerol (TAG) and low density 
lipoprotein (LDL) cholesterol together with a reduction in high density lipoprotein 
(HDL) cholesterol. Whilst each of these represents an independent CVD risk factor 
their clustering is often associated with other risk factors which comprise the 
metabolic syndrome (MetS).
1.2 T he M etabolic Syndrom e
It is estimated that metabolic syndrome (MetS) will affect 25% of the population in 
the UK by the year 2010 (Tonkin 2003) a figure already attained in parts of the 
United States (Ford et al. 2002;Reilly & Rader 2003). The concept of MetS as a 
cluster of risk factors has been known since the 1920s (Kylin 1923) and from that 
time on has been identified by several names including syndrome X, dysmetabolic 
syndrome, Reaven’s syndrome, the deadly quartet and insulin resistance syndrome. 
MetS can be described as a clustering of cardiovascular disease risk factors which 
include: abdominal obesity; elevated TAG; small dense LDL, low HDL cholesterol, 
elevated blood pressure, impaired fasting glucose and a pro-thrombotic, pro- 
inflammatory state. It has been proposed that predisposition to the development of 
the factors involved in cardiovascular disease has its origins in pre-natal gene- 
environment interactions and in the redundant “thrifty genotype” which in the 
current environment of readily available food leads to a greater risk of disease due to 
insulin resistance (Gluckman & Hanson 2004).
1.2.1 D efin ition  o f  the M etabolic Syndrom e
In 1998 the American Diabetes Association (ADA) provided a definition of the 
metabolic syndrome, although this lacked diagnostic criteria. MetS was officially 
defined in 1999 by the World Health Organisation (WHO; 1999). A number of other 
definitions have followed including those of the European Group for the study of 
Insulin Resistance (EGIR; 1999); the American Association of Clinical 
Endocrinologists: (AACE; 2002), the National Cholesterol Education Programme
2
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Adult Treatment Panel III (NCEP ATP III; 2001) and the International Diabetes 
Foundation (IDF; 2005). The most recent definition of MetS was published in 2005 
by the American Heart Association/National Heart, Lung and Blood Institute 
(AHA/NHLBI) this criteria is based upon that of the ATP III in 2001, yet includes 
those who are already on medication for risk factors used in the diagnosis i.e. 
elevated BP, TAG glucose and reduced HDL. Detailed definitions are listed in table 
1.1.
1.3 M etabolic Syndrom e — A C lustering o f  R isk  F actors
There are a number of potential causative mechanisms underlying the development 
of metabolic syndrome. However, it can be argued that insulin resistance is the 
foundation of the cluster of risk factors linked with the condition and its association 
with CVD. Insulin resistance was defined by Berson and Yallow as... “ a state (of a 
cell, tissue, system or body) in which greater-than-normal amounts o f  insulin are 
required to elicit a quantitatively normal response” (Berson and Yalow 1970). In 
other words there is reduced sensitivity to insulin stimulation of glucose uptake 
and/or production (Fulop et al 2006).
Insulin resistance has numerous consequences related to the range of target 
organs/tissues. The primary consequence of insulin resistance is impaired glucose 
tolerance and therefore elevated fasting glucose (dysglycaemia). Insulin also acts 
upon adipose tissue, consequently resistance to its effect is also associated with 
dyslipidaemia, which includes: elevated TAG, decreased HDL and changes in the 
composition of LDL, which plays a major role in the development of atherosclerosis 
(Frayn & Coppack 1992; Howard 1999). The elevated TAG that results from 
insulin resistance may also result in visceral obesity as the capacity of the adipocytes 
to store TAG is exceeded (Kelley & Mandarino 2000) therefore whilst visceral 
obesity may be a cause of insulin resistance, it is also a consequence.
3
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A number of studies have linked MetS to increased cardiovascular* risk. Studies 
using the WHO criteria for the diagnosis of MetS have indicated a 3-4 fold increase 
in the risk of CVD in subjects with metabolic syndrome (Isomaa et al. 2001 ;Lakka et 
al. 2002), whilst studies selecting MetS based upon the NCEP ATP III guidelines 
have demonstrated a 1.4 - 3.6 fold increase in the risk of CVD depending in the 
length of follow up period (Lakka et al. 2002; Ford 2004; McNeill et al. 2004; 
Ginnan et al. 2004). The PROCAM study (Assmami et al. 2004) has shown a 2.3 
fold increase in risk of CVD in males (aged 35-65). However, this study does not use 
a recognised definition of metabolic syndrome.
More recently Jeppesen et al (2007) performed a prospective study in a Danish 
population to assess CVD risk in subjects defined as having MetS using both the 
ATPIII and IDF definitions. Both definitions were associated with increased risk 
following an average follow up of 9.4 years. Additionally the estimated risk was 
similar between the two definitions (Jeppesen et al 2007). The increased risk 
associated with MetS defined by the ATP III and IDF definitions was not as similar 
in the San Antonio heart study. Lorenzo et al (2007) demonstrated a greater risk of 
CVD in subjects defined as MetS using the ATP III criteria compared to those 
defined by IDF and WHO.
Studies have also investigated the effect of cumulative risk factors associated with 
MetS and the subsequent development of CVD, The duster of CVD risk factors 
associated with MetS was examined in the Framingham offspring study (Wilson 
2004). This study has shown a cumulative effect of risk factors (low HDL 
cholesterol, hypertension, elevated TAG and hyperglycaemia) on CVD risk, with the 
presence of 3 or more risk factors resulting in a 2 fold increase in CVD risk in men 
and 5 fold increase in women over a 16 year follow up period. The results of the 
DECODE study also suggest that the presence of cumulative risk factors is more 
detrimental in females compared to males with an additional risk factor having little 
effect on hazard ratios in men but resulting in -40% increase in risk in females (Hu 
et al 2004). This data together with findings from the National Health and Nutrition 
Examination Survey II mortality study suggest that CVD risk associated with 
metabolic syndrome may be more than the sum of its parts.
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Study MetS
Criteria
Follow-up
Period
Risk associated with MetS Comments
Meigs et al 2001 
Framingham offspring 
study
2 fold increase in males 
5 fold increase in females 
(with 3 or more risk factors)
Isomaa 2001 WHO 6.9years 3 fold increase
Lakka 2002 ATP III 
WHO 10 years
2.9-4.2 fold increase
2.9-3.3 fold increase
Assmann 2004  
PROCAM
t 4-10 years 2.3 fold increase in males
Girman et al 2004  
AFCAP/TEXCAPS  
Scandinavian 
Simvastatin Surival 
Study
ATP III
5 years 
5.4 years
1.4 fold increase
1.5 fold increase
Post Hoc analysis of 
patients receiving 
placebo in 4S and 
AFCAPS/TEXCAPS
Hu et al 2004  
DECODE study
t 8.8years MetS
factor
Hazard Ratio 6156 (m) 
5351 (f)
>2 ■1.75 (m) 
■ 1.56 (f)
>3 ■1.74 (m) 
■ 2.17(f)
Ford 2004 ATP III* MetS
factor
Hazard Ratio * BMI>30kg/m2 used 
instead of wait
National Health and 
Nutrition Examination 
Survey II Mortality study
1 1.71 circumference
2 1.66
3 2.16
4 2.01
5 3.59
McNeil et al 2005  
The ARIC study
NCEP 
ATP III
10 years 1.5-2 fold increase in risk
Jeppesen et al 2007 IDF 
ATP III
9.4 years 1.67
1.49
Prospective population 
based study of 2493  
Danish men and 
women
Lorenzo et al 2007  
San Antonio Heart Study
ATP III
IDF
WHO
7.4 years 2.00
1.69
1.73
N =2559
f  Three o f the following:
mBMl >29kg/nr (m) >27.5 kg/m'(f) mHDL <40mg/dL (m) <50mg/DI (f) ■ TAG >1.7mmol/L * 
Glucose 110-150 ■ Systolic BP >130mmHg, ■ diastolic BP >85mmHg 
/  Hyp erinsulinamia plus two o f the following
uBMI>30kg/m~ ■systolic >140 and or diastolic >90 mm Hg or medication 
•TAG>1.7mmol/L and or HDL <0.9mmol/L (m) <1 .Ommol/L )f) ■ impaired glucose 
regulation
Table 1.2 CVD risk associated with MetS
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1.4 L ip id  m ed iated  C ardiovascu lar D isease risk
All definitions of the metabolic syndrome include some aspect of dyslipidaemia in 
particular elevated TAG and reduced HDL-cholesterol. Whilst total and LDL 
cholesterol may remain unremarkable in subjects with MetS, dyslipidaemia often 
encompasses a preponderance of small dense LDL (sdLDL) and alterations in the 
predominant HDL subclass.
1.4.1 L ipoprotein  M etabolism
Lipoproteins are a diverse group of globular particles which are responsible for the 
transport of triacylglycerol (TAG) and cholesterol. Lipoproteins are composed of a 
core of cholesterol ester (CE) and TAG which is surrounded by free cholesterol, 
protein and phospholipid. The four major classes of lipoprotein may be characterised 
by their size (Bautovich et al, 1973), density (Hinton et al, 1974), electrophoretic 
mobility (Noble, 1968) and major apoprotein components (Table 1.3). The 
composition of lipoproteins in terms of TAG, cholesterol, phospholipid and protein 
differs between the lipoproteins (figure 1.1), although the composition of each is not 
static and instead lipoproteins are in a dynamic state with continuous exchange of 
components between classes.
Subclasses of the major lipoproteins also exist and include subclasses of very low 
density lipoprotein (VLDL) and LDL, HDL , intermediate density lipoprotein (IDL), 
lipoprotein (a) (Lp(a))
There are three main pathways of lipoprotein metabolism (figure 1.3 and figure 1.4):
© Exogenous pathway - transports dietary fat
Endogenous pathway - transports TAG from the liver to other tissues
O Reverse cholesterol transport - transports cholesterol from peripheral cells to
the liver
7
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Lipoprotein Diameter Density M ajor Lipid M ajor Function
(nm) (gIE) Component Apoproteins
Chylomicrons
80-1000 >0.95 Dietary TAG B48, Al, All, Transport of dietary
C, E fat
VLDL 30-80 <1.006 Endogenous
TAG
B100, C, E Transport of 
endogenous fat
LDL 20-22 1.02-
1.063V
Cholesterol 
and CE
B100 Transport of 
cholesterol to 
peripheral tissues
HDL 9-15 1.063-
1.210
CE and 
phospholipid
Al, All, C, E Reverse cholesterol 
transport
Table 1.3. Physiochemical properties of the major lipoproteins
VLDL
■ PROTEIN■ TAG ■ CHOLESTEROL ■ PHOSPHOLIPID
CHYLOMICRONS
Figure 1.1. Percentage composition of the major lipoproteins
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1.4.1.1 Exogenous Pathway
Dietary fat, TAG and cholesterol, are absorbed into the enterocytes of the small 
intestine where they are subsequently re-esterified to cholesterol ester (CE) and 
TAG. CE and TAG associate with apoproteins (Al, All, AIV and B48) and 
phospholipids to form chylomicrons which enter the exogenous pathway of lipid 
metabolism. Chylomicrons are secreted into the lymph and from there enter the 
circulation via the thoracic duct. Once in the circulation chylomicrons aquire 
addition apoproteins from HDL in exchange for cholesteryl ester. Acquisition of apo 
CII allows activation of lipoprotein lipase (LPL). LPL is a 52kDa enzyme found in a 
number of tissues, but predominantly in muscle and adipose tissue, where it is non 
covalently bound to the endothelium. LPL acts upon TAG, in adipose tissue and 
muscle, to release NEFA which is subsequently esterified and stored (adipose tissue) 
or oxidised (in muscle). As the chylomicron becomes depleted of TAG it becomes 
progressively richer in cholesterol and protein. Another exchange then occurs 
between the chylomicron where by phospholipids (PL), free cholesterol and apo C 
are transferred to HDL. The remaining chylomicron remnant contains apo B and 
apoE which target the particle for degradation via the LDL receptor or the LDL 
receptor related protein. The action of LPL on adipose tissue is modulated by insulin 
with insulin having a stimulatory effect on its activity. The presence of glucose 
increases insulin production and in doing so increases the uptake of fatty acids into 
adipocytes (after a period of about 3~4h). Thus, insulin increases the postprandial 
clearance of lipoproteins rich in TAG. LPL hydrolyses TAG and this produces 
smaller chylomicron remnants which are rich in cholesterol ester and are removed 
via interaction with liver receptors.
9
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1.4.1.2. Endogenous Pathway
The endogenous pathway of lipid metabolism transports TAG to other tissues via 
triglyceride rich lipoproteins (VLDL) synthesised by the liver and, to a lesser extent, 
the intestine. VLDL is cleared more slowly in comparison to chylomicrons with a 
half life of days compared to minutes or hours. Prolonged residence of VLDL in the 
plasma generates IDL through the action of LPL which is again activated by apo OIL 
IDL is then either removed from the plasma through receptor interaction or subject to 
farther lipolysis by hepatic lipase (HL) to generate LDL. Both chylomicrons and 
VLDL carry apolipoprotein B that is not exchanged between lipoproteins, however, 
the liver produces apoB 100 exclusively whilst the intestine secretes mainly apoB48 
(the N-terminal 48% of apoB 100). Therefore VLDL produced by the liver contains 
apo B100 whilst chylomicrons secreted by the intestine contain apo B48. LDL 
particles are cleared from the circulation through specific interaction of apoB 100 or 
apoE with the LDL receptor found in coated pits on the cell surface membrane. 
Alternatively LDL may be removed from the circulation through pinocytosis.
Control of plasma LDL concentration lies in the efficacy of its removal by receptor 
mediated uptake and pinocytosis although the latter may be of little importance when 
LDL-C concentrations are relatively low. Receptor mediated uptake is dependent 
upon the cholesterol requirement of each cell. Regulation of the LDL receptor 
pathway is achieved through feedback control mechanisms which prevent the over 
accumulation of cholesterol in the cell (figure 1.3). Once the cells’ cholesterol 
requirements have been met three key events take place: I: suppression of 3- 
hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthase, the main point of regulation, 
and HMG-CoA reductase, II: activation of acyl-CoA: cholesterol acyltransferase 
(ACAT) which promotes storage of cholesterol as cholesteryl ester droplets, III: 
suppression of LDL receptor synthesis. The essential role of the LDL receptor in 
cholesterol homeostasis is highlighted by the effects of mutations in the LDL 
receptor gene such as those observed in familial hypercholesterolemia (FH). In this 
autosomal dominant condition ineffective clearance of LDL results in elevated 
plasma LDL and a substantially increased risk of premature myocardial infarction.
10
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Reverse Cholesterol Transport 
Reverse cholesterol transport (RCT) represents the mechanism by which cholesterol 
is removed from non hepatic cells and transported to the liver for storage, VLDL 
formation or excretion as free cholesterol or bile salts, thus providing a metabolic 
balance (Von Eckardstein et al 2000, von Eckardstein et al 2001).
Lipid free apo Al or lipid poor pre-(3 HDL, secreted by the liver or intestine, interacts 
with ATP binding cassette Al (ABCA1) in cell membranes. ABCA1 has been 
shown to efflux cholesterol from peripheral cells, a process that is impaired in 
individuals with Tangier disease (Bodzioch et al 1999, Brewer et al 2004). 
Cholesterol efflux into lipid poor pre-j3 HDL produces nascent discoidal HDL 
particles, the unesterified cholesterol in these particles is rapidly esterifled by 
lecithin-cholesterol acyl transferase (LCAT). Esterification by LCAT results in a 
spherical particle (PIDL3) with a cholesteryl ester core (Nichols et al 1985). Reverse 
cholesterol transport can remove cholesterol from peripheral tissues in two ways. 
HDL3 removes cholesterol from the circulation through the scavenger receptor class 
B, type-1 (SR-B1) pathway representing a pathway of direct removal of cholesterol 
by catabolism of HDL3. Alternatively further accumulation of cholesteryl ester and 
the action of LCAT converts HDL3 into larger HDL2. HDL2 is capable of cholesteryl 
ester exchange for TAG from apo-B containing lipoproteins through the action of 
cholesteryl ester transfer protein (CETP) (de Grooth et al 2004). Cholesteryl ester 
transferred to apo B containing lipoproteins is then removed via interaction of the 
lipoprotein with the LDL receptor or LDL receptor related proteins (LDL-RPP 
(figure 1.4).
o
13
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Figure 1.4. Reverse cholesterol transport.
CE =  cholesteryl ester, UE =  unesterified , LCAT =  lecithin cholesterol acyl transferase, 
CETP =  cholesterol ester transfer protein, ABAZ!= ATP Binding Cassette Transport A l,
SR-B1 =  scavenger receptor B 1
Pre p-HDL
Nascent discoidal HDL
Peripheral
Tissues Free cholesterol
Free cholesterol -MABCA1
LDL-R
LDL-RRP
VLDL
CETP
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1.4.2 LDL-C and CVD Risk
In 1913 Anitschkow began a series of experiments that would lead himself and his 
colleagues to suggest that the extent of vascular lesions was proportional to the 
concentration of cholesterol in the blood and that cholesterol entered the artery wall 
from the blood (reviewed by Steinberg 2004). Since then a great number of studies 
investigating the role of cholesterol in atherosclerosis have been conducted.
Results from the Multiple Risk Factor Intervention Trial (MR-FIT) demonstrated a 
graded relationship between serum cholesterol and CHD risk (Neaton and 
Wentworth, 1992). This observation served to promote the use of lipid lowering 
therapy in CVD risk reduction. Early studies addressing the use of lipid lowering 
medication yielded results which suggested a reduction in CVD risk following a 
reduction in plasma lipids, however, such drugs were often poorly tolerated or 
associated with other adverse effects.
In 1978 a trial by the World Health Organisation (WHO) assessed the use of 
clofibrate, a fibric acid derivative which stimulates LPL activity, in the treatment of 
hyperlidaemia and subsequent risk reduction. This double blind study in middle aged 
men demonstrated a 9% reduction in serum cholesterol following treatment with 
clofibrate which was associated with a 20% reduction in coronary events; however a 
5% increase in mortality from all causes in the clofibrate group has lead to concerns 
over its use (A co-operative trial in the primary prevention of ischaemic heart disease using 
clofibrate, 1978, 1984). In 1984 the Lipid Research Clinic Coronary Primary 
Prevention Trial (LRC-CPPT) investigated the effects of cholestyramine in terms of 
lipid lowering in middle aged men. Cholestyramine is an anion exchange resin that 
sequesters bile acids in the intestine preventing their reabsorption. Treatment with 
this drug, in the LRC-CPPT, resulted in a greater reduction in both total and LDL 
cholesterol when compared to placebo; this was associated with a 19% reduction in 
CHD death or MI (The Lipid Research Clinics Coronary Primary Prevention Trial, 1984). 
However, cholestyramine was poorly tolerated resulting in poor compliance 
nevertheless data from this study provided convincing evidence that lipid lowering 
medication could reduce CVD risk.
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The development of the statins led to a change in clinical practice. The statins are a 
group of lipid lowering drugs which inhibit HMG Co-A reductase, the rate limiting 
step in cholesterol synthesis. The inhibition of cholesterol synthesis leads to an 
increased synthesis of LDL receptors and therefore increased clearance of LDL and a 
reduction in the concentration of plasma LDL-C. A number of studies conducted in 
the 1990s addressed the use of statins in both the primary and secondary prevention 
of CVD (table 1.4).
The Scandinavian Simvastatin Survival Study (4S) was a secondary prevention trial 
conducted in 4444 subjects was the first study to demonstrate a reduction in all cause 
mortality with lipid lowering therapy (Pedersen et al, 1994). The West of Scotland 
Coronary Prevention Study (WOSCOPS) followed in 1995 as the first primary 
prevention study to demonstrate a reduction in cardiovascular events in high risk 
subjects. In WOSCOPS subjects with an elevated baseline total and LDL-cholesterol 
received either pravastatin or placebo and were followed for five years. After the 
follow up period both total and LDL-cholesterol were reduced by 20 and 26% 
respectively, there was also a 32% reduction in cardiovascular mortality (Shepherd et 
al 1995).
WOSCOPS and 4S were primary and secondary prevention studies in high risk 
subjects with elevated total and LDL-cholesterol. In the mid nineties three additional 
studies investigating the role of statins in CVD risk were conducted, however, these 
studies selected subjects with lower baseline total cholesterol concentrations. The 
Cholesterol and Recurrent Events (CARE) (Sacks et al 1996) and the Longterm 
Intervention with Pravastatin in Ischaemic Disease (LIPID) (LIPID Study Group,
1998) studies both assessed the impact of pravastatin on cardiovascular events in 
subjects with established CHD and “normal” baseline total cholesterol 
concentrations (5.5 and 5.6 mmol/L in CARE and LIPID respectively). Both CARE 
and LIPID reported a 24% reduction in relative risk following treatment with 40mg 
of pravastatin daily. The AFCAPS/TexCAPS study, another primary prevention 
study, also included subjects with a normal total cholesterol concentration, however, 
these subjects were considered “healthy” in that that had no previous history of
16
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CHD. The results of this study were comparable with WOSCOPS with a 37% 
reduction in cardiovascular events (Downs et al 1998)
The Heart Protection Study (HPS) (MRC/BHF, 2002) was the largest secondary 
prevention trial which assessed simvastatin and coronary events over a five and a 
half year follow up in high risk patients. This study demonstrated a reduction in both 
total and coronary mortality across a spectrum of total and LDL-cholesterol 
concentrations.
Some more recent studies have also demonstrated a beneficial effect of aggressive 
lipid lowering therapy using high dose statin treatment (La Rosa et al 2005, Pedersen 
et al 2005).
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Statin Reference Study Subjects Baseline Follow % reduction Reduction
Type T-CHOL
(mmol/L)
up
period
in
T-CHOL
in
coronary
events
Simvastatin 4S Secondary N =4444 6.8 5 years -26% 34%
vs placebo (Scandinavian  
Simvastatin  
Survival Study 
Group 1994)
Prevention (81 % male). 
Previous 
history of 
CHD
(5.5-8.0)
Pravastatin WOSCOPS Primary 6596(100% 7.0 ( 5 years -20% 31%
vs placebo (Shepherd et 
al 1995)
Prevention male) 
5% with 
previous 
CHD
6.5-8.0)
Pravastatin CARE Secondary 4159(86% 5.5 5 years -20% 24%
vs placebo (Sacks et al 
1996)
Prevention male)
All with 
previous MI
Pravastatin LIPID Secondary 9014 (83% 5.6 6 years -18% 24%
vs placebo (LIPID study 
group 1998)
Prevention male)
With
previous
CHD
(4.0-7.0)
Lovastatin AFC APS/Tex Primary 6605 (85% 5.7 5 years -19% 37%
vs placebo CAPS
(Downs et al 
1998)
Prevention male)
No history 
of CHD
Simvastatin HPS Secondary 20 536 with 5.5 1 8 %
vs placebo (MRC/BHF
2002)
Prevention prior
coronary
disease
years
Table 1.4. The major statin trials.
Shown are the results the major statin studies in both primary and secondary prevention
18
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1.4.3 HDL-C and CVD Risk
Whilst the reduction in CVD risk associated with a reduction in total and LDL-C is 
irrefutable total cholesterol remains a poor discriminator of CVD risk within 
populations.
Prospective epidemiological studies have indicated an inverse and independent 
association between HDL-cholesterol and CVD (Gordon and Rifkind 1989). The 
increased risk associated with low HDL-C concentrations has also been shown to 
remain in the presence of low LDL-C concentrations (Gordon et al 1977) and it has 
been suggested that a high HDL-C concentration is more protective, in terms of 
CVD, risk than low LDL-C (Assmann and Schulte 1990). The role of HDL in the 
removal of cholesterol from peripheral tissues and atherosclerotic lesions represents 
one of its atheroprotective properties, additional anti-atherogenic attributes include 
anti-oxidant, anti- thrombotic and vaso-protective effects (Barter et al 1996, Barter 
2004). It has been estimated that for each 0.025mmol/L increase in HDL-C there is 
a 2-3% reduction in CHD risk (Gordon et al 1989)
Although the primary effect of statins is on total and LDL-cholesterol they have also 
demonstrated a modest HDL-cholesterol raising effect of between six and twelve 
percent depending on statin (Knopp, 1999) with rosuvastatin expressing the greatest 
HDL raising effect (Jones et al 2003). There is also evidence to suggest that baseline 
HDL-C concentrations contribute to the risk reduction achieved with statins. In the 
major statin trials of the 1990s subjects treated with a statin and with low HDL-C 
attained a CVD risk similar to subjects with higher HDL-C on the placebo arm 
(figure 1.5) (Chong et al 2002). The increased risk of low HDL-C remains even 
when elevated LDL-C has been treated (Barter et al 2007). In light of the increased 
risk associated with low HDL-C pharmacological and lifestyle interventions have 
been sought which increase plasma HDL-C concentration.
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Pravastatin
CARE
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J i i l
_1.0 <0.9 >1.1 1.1
Pravastatin Lovastatin Pravastatin 
LIPID AFCAPS/ WOSCOPS 
TexCAPS
HDL-C (mmol/L)
Figure 1.5. Reduction of coronary events with statin treatment according to baseline 
HDL-C concentration. Statin treatment reduced coronary events to a lesser extent in 
subjects with a low er baseline H D L-C . (Chong et a l 2 0 0 2 )
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Pharmaceutical agents that increase HDL concentration can be broadly grouped into 
two categories; those that increase HDL components or those that upregulate RCT 
(Singh et al 2007).
Nicotinic acid (niacin) represents the most effective HDL-raising pharmacotherapy. 
Early studies conducted prior to the emergence of the statins demonstrated a 27% 
reduction in MI after a six year follow up (Anonymous 1975). More recent studies 
have addressed the use of niacin in combination therapy where it has demonstrated 
HDL raising effects in the range of 20-30%. In the HDL-atherosclerosis treatment 
study (HATS), Brown et al (2001) explored the use of niacin in combination with 
simvastatin for the prevention of coronary disease. Treatment increased HDL-C 
concentration by 26% over a three year follow up. Whitney et a (2005)1 also 
observed 36% increase in HDL-C following treatment with niacin in combination 
with gemfibrozil and cholestyramine. However whilst niacin shows promise as a 
HDL raising agent its use is somewhat limited by associated adverse events. Niacin 
is poorly tolerated and may cause flushing, gastrointestinal disturbances and 
palpitations.
Gemfibrozil, a fibric acid derivative, has also been exploited for its HDL raising 
properties. Mono-therapy with gemfibrozil has shown increases in HDL-C between 
six and 21% (Frick et al 1987, Frick et al 1997, Rubins et al 1999).
Table 1.5 compares pharmacotherapies that aim to increase HDL-C concentrations 
and reduce CVD risk.
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Reference Drug Subjects HDL-C Comments -  
CVD reduction 
in study
HHS
Frick et al 
(1987)
Gemfibrozil vs 
placebo
n-4081
hypercholesterolaemic
Tl 1% 34% reduction in 
non fatal MI or 
CAD death after 5 
years follow up
VA-HIT 
Rubens et al 
(1999)
Gemfibrozil vs 
placebo
N =  2531 males with CHD 
and baseline HDL 
<1.0mmol/L
f6% 22% reduction in 
non-fatal MI after 
5 years follow up
HATS 
Brown et al 
(2001)
Niacin +  
simvastatin vs 
placebo
N =160 with CHD T26% The rate of major 
clinical events 
was 90% lower 
compared to 
placebo group
STELLAR  
Jones et al 
(2003)
Rosuvastatin vs 
atorvastatin, 
simvastatin, 
pravastatin
N =2431
hypercholesterolaemic
|9.6%
|4.4%
T5.2%
|5.6%
AFREGS 
Whitney et 
al (2005)
Niacin +  
gemfibrozil +  
cholestyramine
N=143 with coronary disease T 36%
FIELD  
Keech et al 
(2005)
Fenofibrate vs 
placebo
N-9795 with type II diabetes Tl.2% 11% reduction in 
CAD death or non 
fatal MI after 5 
years follow up
Table 1.5. Pharmacological interventions to elevate plasma HDL-C
tSignificant increase
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1.4.4 A therogen ic L ipoprotein  P henotype an d  CVD R isk
Low HDL-C concentration together with elevated TAG and a predominance of small 
dense LDL (sdLDL) encompasses an atherogenic lipoprotein phenotype (ALP) 
(Austin et al 1990). The low HDL-C is also often representative of a predominance 
of smaller HDL particles (HDL3)
In 1981 Shen et al described LDL as a “...spectrum of particles differing in 
molecular weight, ultracentrifugal flotation rate, and hydrated density” (Shen et al 
1981). In 1982 Krauss and Burke followed this research and identified four discrete 
LDL subclasses based upon their ultracentrifugation flotation rate (Sf°). LDL can be 
classified into 3 major sub populations (LDL-I, LDL-II and LDL III) and a minor 
group (LDL-IV) according to size and density (Griffin et al 1994, Swinkels et al 
1987) with LDL-I having the lowest density and LDL-III the highest density.
Heterogeneity of LDL arises due to differences in the CE content of the lipoprotein 
core which may occur as a result of the triglyceride rich pre-cursors of the VLDL- 
IDL-LDL delipidation cascade (Bemeis & Krauss 2002). VLDL is also 
heterogeneous with subclasses of this lipoprotein playing an important role in the 
production of sdLDL and HDL3 (figure 1.6). In healthy individuals, with plasma 
TAG concentrations below 1.5 mmol/L, VLDL produced by the liver tends to be 
smaller and cholesterol rich (VLDL2) where as with a plasma TAG greater than 
1.5mmol/L larger more buoyant VLDL particles are produced; VLDLi. VLDLi 
contributes to the production of sdLDL and HDL3 through increased exchange of 
TAG from VLDLi to LDL. This TAG rich LDL/HDL is then converted to a smaller 
more dense particle (sdLDL or HDL3) through the action of hepatic lipase (HL) 
(Griffin 1999, Krauss and Siri 2004). sdLDL becomes the predominant subclass 
when TAG concentrations exceed 1.5mmol/L (Griffin et al 1994) however, despite 
the change in subclass the total LDL concentration usually remains constant.
LDL subclasses can be categorised into LDL phenotypes; three patterns exist and are 
distinguished based upon the percentage of each LDL subclasses present (Austin et 
a l  1990):
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=> Pattern A - Large buoyant LDL I and LDL-II
=> Pattern B - More than 50% small dense LDL-III
=> Pattern I - 40-50% small dense LDL-III
Pattern B is characteristic of an ALP, it is heritable but its presence is also influenced 
by diet and in particular dietary fat (Krauss 2001). LDL subclass pattern B is 
associated with a 3-fold increase in CVD risk (Austin et a l  1988) it is also 
associated with other disease states including the metabolic syndrome and type II 
diabetes (Erkelens 1998, Lamarche et al 1999, Grundy 1998, Kwiterovitch 2002, 
Blackburn et al 2004).
Increased CVD risk associated with sdLDL may be attributable to a number of 
atherogenic properties including: reduced binding to the LDL receptor, increased 
penetrance of the arterial wall and increased susceptibility to oxidation (Griffin
1999). Additionally the association of sdLDL with MetS and insulin resistance 
suggests that increased CVD risk may also arise from the clustering of risk factors 
(Friedlander et al 2000, Hulthe et al 2000, Kathiresan et al 2006, Watson et al 2004). 
HDL particle size has also demonstrated a relationship with CVD risk, however, 
specific phenotypes have not yet been identified. In the Insulin Resistance 
Atherosclerosis Study, smaller HDL particles measured by nuclear magnetic 
resonance (NMR) were associated with insulin resistance (Festa et al 2005) 
suggesting an important role of insulin resistance in the generation of an ALP.
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1.5 D ietary S trateg ies to A m eliorate L ip id  M ediated CVD R isk
Whilst the use of pharmacotherapy for the treatment of atherogenic dyslipidaemia is 
essential in the secondary prevention of CHD, the associated side effects and 
economic cost suggest that lifestyle intervention should be the first approach in the 
primary prevention of CVD.
1.5.1 The D ietary C holesterol D ebate
The “cholesterol hypothesis” developed as the result of research that identified a 
relationship between the concentration of cholesterol, in particular LDL-eholesterol, 
in the plasma and that found in atherosclerotic lesions (Smith and Slater 1972). This 
then became the foundation of the belief that dietary cholesterol was directly related 
to plasma cholesterol concentration.
The independent work of Keys et al (1965) and Hegsted et al (1965) culminated in 
the generation of predictive equations to calculate the influence of dietary fat and 
cholesterol on plasma cholesterol concentration. The work of Keys et al in the Seven 
Countries study also led to the development of the “diet-heart hypothesis” (Keys et 
al 1970).
The small increase in total plasma cholesterol, demonstrated by a plethora of 
cholesterol feeding studies in humans, and its implications for increased CVD risk 
has led to much debate over the cholesterol content of our diet and to the 
investigation of its impact on CVD mortality.
Eggs are a major source of dietary cholesterol with one egg containing between 50 
and 250mg of cholesterol depending on size. As such the consumption of eggs and 
their influence on plasma cholesterol and CVD risk has been the subject of both 
epidemiological and intervention studies.
Epidemiological evidence originally demonstrated a linear relationship between 
dietary cholesterol and the incidence of CHD (Kromhout et al 1995), however, this
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linear regression analysis did not take into account confounding variables such as the 
intake of dietary fibre and fatty acid composition of the diet. Multiple regression 
analysis has since been used and has demonstrated no relationship between dietary 
cholesterol and CHD risk when confounding variables are controlled (figure 1.7) 
(Hegsted & Ausman 1988; Ascherio et al. 1996; Hu et al 1997; McNamara 2000).
0.00
DIETARY CHOLESTEROL (m^lOOO kcal)
132 163 188 217 273
Cholesterol (mg/1000 kcal)
Figure 1.7: Correlation between dietary cholesterol and CVD risk.
a. Significant correlation between dietary cholesterol and CHD risk following 
linear regression ((Kromhout etal. 1995)
b. Nurse's health study indicating no relationship between dietary cholesterol and 
CHD incidence (Hu FB et al. 1997)
Despite convincing evidence for a lack of relationship between egg consumption and 
CVD risk it must be considered that cholesterol-feeding studies have consistently 
shown significant but small increases in plasma cholesterol concentrations following 
high cholesterol diets Table 1.5 (Roberts et al. 1981;Zanni et al. 1987;Ginsberg et al. 
1994;Ginsberg et al. 1995). However, parallel increases in HDL-C frequently 
observed may mean that the ratio of total to HDL cholesterol is unchanged which in 
turn may not increase CVD risk.
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Although there is some evidence to suggest that dietary cholesterol has an effect on 
plasma cholesterol concentration, it is often the quality of dietary fat that has the 
greatest effect on plasma lipids.
Study Subjects Diet T-CHOL LDL-C HDL-C TAG
Roberts et al 
(1981)
N =16 
8 M 
8 F
Addition of 500mg 
cholesterol/day to habitual diet
T
Zanni et al 
(1987)
N =9  
females
15 day intervention.
4 diet s
130, 875mg cholesterol P:S 
2.14
875mg cholesterol P:S 0.64 
Vs
130mg cholesterol P:S 0.64
T T T
Ginsberg et al 
(1994)
N= 24 
males
4 way crossover 
8 week intervention 
0, 1,2 or 4 eggs/day 
(215mg cholesterol /egg)
T T <—>
Linear with f 
dietary cholesterol
Ginsberg et al 
(1995)
N =13  
females
3 way randomised crossover 
8 week intervention 
0,1 or 3 eggs/day
T | T I T
i i
Linear with | dietary 
cholesterol
Sehayek et al 
(1998)
N=18 
10 M 
8 F
High fat low cholesterol
vs
High fat high cholesterol 
3 week randomised crossover
T T <—>
Clifton et al 
(1998)
N=105 
55 M 
54 F
Low fat low cholesterol 
Vs
High fat high cholesterol 
(650ing/day)
t T T t
Table 1.6. Cholesterol feeding studies demonstrating an increase in plasma total and
LD L cholesterol
T= significant increase, no significant change, no symbol = no measurement
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1.5.2 Dietary Fat Quality
Fatty acids are simple lipids composed of a hydrocarbon chain that terminates with a 
carboxylic acid group. Fatty acids exist as saturated fatty acids (SFA) and as 
unsaturated fatty acids containing one, monounsaturated fatty acid (MUFA), or 
more, polyunsaturated fatty acids (PUFA), double bonds. The most common fatty 
acids in our diet are palmitic acid, oleic acid and a-linoleic acid, SFA, MUFA and 
PUFA respectively.
As previously mentioned the increase in plasma cholesterol observed through an 
increase in dietary cholesterol in epidemiological studies was insignificant when 
SFA was included in analysis. Numerous studies have indicated that dietary 
saturated fat is directly correlated to plasma cholesterol levels with an increased 
intake corresponding to increased total cholesterol. This increase in plasma 
cholesterol is largely due to an increase in LDL-C resulting from down-regulation of 
LDL receptors and therefore reduced receptor mediated clearance of LDL from the 
plasma (Grundy and Denke 1990).
It has been established that the reduction of SFA in the diet has beneficial effects on 
plasma lipids, with the reduction in SFA reducing plasma total and LDL cholesterol 
in a step wise manner (Ginsberg 1998). However, there has been uncertainty as to 
whether SFA should be substituted for unsaturated fatty acids or CHO. Guidelines 
from the American Heart Association (AHA) suggest reducing SFA intake in favour 
of complex carbohydrates with a total fat intake <30% of energy. However, the 
replacement of SFA with MUFA has demonstrated beneficial effects on plasma 
lipids. The replacement of 5% of energy from saturated fat with cis-unsaturated fatty 
acids has been shown to reduce blood cholesterol (primarily LDL cholesterol) by 
0.6mmol/L,(Clarke et al 1997). Cis-unsaturated fatty acids with a 
hypocholesterolaemic effect include; MUFA and n-6 PUFA. These fatty acids 
contain one (mono) or more (poly) double bonds, in a cis configuration, in their 
structure.
Interest in the benefits of MUFA in terms of CVD risk was first identified by the 
work of Keys et al in the Seven countries Study (1970). In this study certain
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Mediterranean populations demonstrated a low prevalence of CVD despite relatively 
high intakes in total fat (33-40% energy). In fact the contribution of SFA to energy 
intake was low (7-8% energy) and the increased fat intake was from sources rich in 
MUFA (16-29% energy) (Keys et al 1970). In comparison to a typical western diet 
(total fat 38%, SFA 17%, MUFA, 14%, PUFA 7%, carbohydrates 42%,) and low fat 
diets (total fat 30% SFA 10 % and total fat 20% SFA 7%) a Mediterranean style diet 
rich in unsaturated fatty acids is predicted to have the most beneficial effect on 
plasma total and LDL cholesterol (Sacks & ICatan 2002). Additional epidemiological 
studies have since reported a beneficial effect of MUFA on CVD risk. In the Nurse’s 
Health Study a five percent increase in energy from MUFA was associated with 
-20% reduction in CVD risk (Hu et al 1997).
High MUFA diets have been shown to consistently lower both total and LDL 
cholesterol, though many of these studies are relatively short term interventions 
(Kris-Etherton et al. 2000) (table 1.7). Dietary interventions with CHD death as a 
primary outcome have also demonstrated a beneficial effect of MUFA. The Lyon 
heart study has demonstrated a significant reduction in CHD death and non fatal 
myocardial infarction following a 27 month dietary intervention reducing SFA intake 
and replacing it with unsaturated fatty acids (Kris-Etherton et al 2001)
Moderate fat diets (-30% energy) rich in MUFA also appear to be beneficial in 
terms of preventing the reduction in HDL associated with weight loss. In a study by 
Pelkman et al (2004) the effects of two energy restricted diets on plasma lipoproteins 
were compared. A low fat (18.3% energy) energy restricted diet resulted in 
significant weight loss which was associated with significant reduction in TAG, 
total, LDL and HDL cholesterol. An energy restricted diet with moderate fat and rich 
ill MUFA (total fat 32 % energy, MUFA 14%) also resulted in significant weight 
loss and improvements in TAG, total and LDL cholesterol. However, in subjects 
following the high MUFA diet there were oo significant changes in HDL usually 
associated with active weight loss (Pelkman et a\ 2004).
Evidence suggests that beneficial effects of MUFA on CVD risk lie not only in 
associated reduction in LDL and total cholesterol but also in the maintenance or 
improvement of plasma HDL concentrations.
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Study TAG T-CH O L LD L-C HDL-C Comments
Spiller et al 
1998 <—> <—►
Randomised parallel design:
Olive oil based diet -  35% MUFA 
10%SFA
1 1 i 4-+ Almond based diet -30% MUFA 
4% SFA
t <—> <—> T Control -18% MUFA 32% SFA
Kris Etherton 
et al 1999
i 1 i 4-+ N=26
5 way crossover
3 high MUFA diets = 21% , 17% 
and 18% energy from MUFA
Vessby et al 
2001
The KANWU 
study
1 i i 4—► N=162 men and women 
High MUFA (21% MUFA, 10% 
SFA) vs high SFA (18% SFA, 
13% MUFA)
Montoya et 
al2002 t
<—► i i 4—> N=41
High SFA (17% energy) vs high 
MUFA (21% energy)
Rajaram et a I 
20011
i i u i 4—> 2 week randomised crossover. 
AHA step 1 diet vs diet enriched 
with pecans (18% energy as 
MUFA)
Muller et al 
2002f
<—> 1 T 1 N=25 females
20 day Randomised crossover.
Pelkman et al 
2004
1 I 1 N=53
Parallel 6 week intervention in 
overweight and obese males and 
females. Energy restriction-low fat 
vs energy restriction- high MUFA 
Weight loss 6.5-7 Kg
t Plasma lipids significantly different between high SFA and high MUFA diets
Table 1.7 Effects of MUFA enriched diets on plasma lipids and lipoproteins
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1.5.3 The Glycaemic Index
The replacement o f  dietary fat with CHO has been associated with an increase in 
plasma TAG. In 1960 a significant increase in TAG concentrations was observed 
after switching the habitual diet o f  45% energy from carbohydrate to 70% (Antonis 
and Bersohn 1960) this phenomenon has been reported by a number o f  other 
interventions using a high carbohydrate diet (Abbasi et al. 2000; Komiyama et al. 
2002; Komiyama et al. 2004), The increase in plasma TAG is believed to result 
from compositional changes in the VLDL lipoprotein fraction, with high 
carbohydrate diets increasing the amount o f  TAG per particle and increasing particle 
number (Schofeld 1970, Rudeiman 1971, Huff and Nestel 1982). Furthermore, 
studies that have shown a significant increase in TAG, following a high carbohydrate 
diet, have also reported simultaneous reduction in HDL cholesterol which in-tum 
increases CVD risk. It has been suggested that the deleterious effects o f  a high CHO 
diet may to some extent be ameliorated through the use o f  CHO with a low  
glycaemic index (GI)
Variation in postprandial glycaemic responses observed after ingestion o f different 
carbohydrate containing foods was first noted by Conn and Newburgh in 1939 (Conn 
and Newburgh 1939). However, it was not until 1981 that a method for quantifying 
this postprandial glucose response was used by Jenkins et al (Jenkins et a l  1981). 
The glycaemic index compares the postprandial glucose response after the ingestion 
o f  a carbohydrate over a period o f two hours relative to the postprandial response to 
white bread or, more commonly 50g glucose, in terms o f the area under the glucose 
response curve (using the trapezoidal rale). Foods are generally grouped according 
to:
3  High GI (>70GI points)
© M oderate GI (55-70 GI points)
© Low GI (<55 GI points) (Du et al 2006):
Glucose is a major fuel in the body that can be derived from the diet or produced 
endogenously by gluconeogenesis and glycogenolysis (glucose synthesis and stored
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glycogen breakdown respectively). The concentration o f  blood glucose is tightly 
controlled by homeostatic mechanisms, as it is essential for the maintenance o f  
cognitive function, so that in healthy subjects it is present at a concentration o f  
approximately 5mmol/L.
The maintenance o f  blood glucose is achieved through the actions o f a number o f  
hormones including insulin, glucagon, cortisol, growth hormone, adrenaline and 
noradrenaline.
Carbohydrates with a high glycaemic index tend to exaggerate the postprandial 
insulin response. The biological effects o f  this response persist into the mid 
postprandial period (2-4h after a meal) and result in the lowering o f  blood glucose. 
The body responds to this hypoglycaemia through gluconeogenesis and 
glycogenolysis to restore blood sugar levels to the normal reference range. In 
response to the low blood glucose there is an increase in the counter regulatory 
hormones; glucagon; catecholamines; growth hormone and cortisol. An increase in 
counter regulatory hormones also increases free fatty acid levels, which has 
important implications in the development o f  insulin resistance (Ludwig 2002). 
Carbohydrates with a low GI are absorbed more slowly from the gastrointestinal 
tract which will reduce the postprandial rise in gut hormones and insulin, whilst 
maintaining suppression o f NEFA and reducing blood sugar concentration (Jenkins 
et al 2 0 0 2 ).
Mixed results have been observed with respect to reducing lipid mediated CVD risk 
using a diet containing carbohydrate with a low GI (table 1.8). In a review by 
Ludwig (2002) o f  13 studies, 10 found that a low GI diet produced a reduction in 
TAG whilst 7 o f the 8  studies that measured LDL cholesterol showed a decrease in 
plasma concentrations following a low GI diet. Sloth et al (2004) have also shown a 
significant reduction in LDL following the ad libitum intake o f low GI 
carbohydrates. However, this study did not show improvement in other biochemical 
risk factors (Sloth et al. 2004). Two epidemiological studies have assessed the 
relationship between GI and plasma HDL-C concentrations. In a study o f  
participants in the Third National Health and Nutrition Examination Survey (1988-
_____________________________________________________________ 05______
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1994) high GI CHO was associated with lower HDL-C concentrations. This 
association remained when controlling for factors know to influence HDL-C 
including gender, ethnicity and activity levels (Ford and Liu 2001). Similar 
observations were also made by Frost (1999). Intervention studies using low GI 
CHO have, on the other hand, failed to demonstrate a relationship between GI and 
HDL-C, with the exception o f  a study in subjects with type II diabetes (Luscombe et 
al 1999)
Additional benefits o f carbohydrates with a low GI may include their effects on 
insulin sensitivity. Frost et al (1998, 2004) have demonstrated reductions in fasting 
insulin (with subsequent increased insulin sensitivity), glucose and TAG, both in 
subjects with, and at risk of, CVD, following a low GI diet (Frost et al. 1998; Frost 
et al. 2004). In the Framingham offspring cohort study, glycaemic index was shown 
to be positively correlated with the incidence o f metabolic syndrome and insulin 
resistance (MeKeown et al. 2004). An increase in insulin sensitivity and improved 
glycaemic control have also been associated with diets containing low GI 
carbohydrate (Ludwig et al. 1999; G off et al. 2003; Giacco et al 2000, Brand et al 
1991) this may be explained by the resulting lower postprandial glucose 
concentrations and subsequent lower demand for insulin production.
The evidence suggests a potential o f carbohydrates with a low GI to improve the 
plasma lipid profile makes them an attractive component o f  a diet aimed at reducing 
CVD risk.
Chapter 1 — General Introduction
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Study TAG T-CHOL LDL-C HDL-C Comments
HGI LGI HGI LGI HGI LGI HGI LGI
Phillipou et al
2007
4—► 4—► 4—► 4—► 4—► 4—> Randomised parallel design. 12 wk 
intervention, [body weight in LGI
Ostman et al 
2006
4—► 4—► 4—► Randomised crossover design in 7 
women with a history of gestational 
diabetes
Ebbeling et al 
2005
1 ii Randomised parallel design. Low 
GL vs low fat. Jbody weight both 
groups
Frost et al 2004 t 1 4—► 1 4—► 1 4—► 4—► Randomised parallel design. CHD. 
12 wk intervention. Jbody weight
Rizkalla et al 
2004
4—+ 4—► 4—► 1 4—> i 4—► 4—► Type 2 diabetic men. Randomised 
crossover design.
Bouche et al 
2002
Randomised crossover design in 11 
overweight males. 5 wk intervention
Helibron et al 
2002*
4—» 4—► i i i i 4—► 4—► Type 2 diabetics. Randomised 
parallel design. 8 wk intervention.
Dumesnil et al 
2001***
4—► 1 Parallel design in 12 healthy subjects 
with |BM1. 6d intervention
Giacco et al 
2000*
4—* 4—► 4—► 4—► 4—► 4—> Randomised parallel design in type 1 
diabetics. 24 wk intervention
Jarvi et a I
1999**
i i 1 1 1 1 i 1 Randomised crossover design in type 
2 diabetics.
Luscombe et al 
1999
<—► 4—► 1 T Randomised crossover. 12wk.Type 
2 diabetics.
Frost et al 1996 Randomised parallel design in 32 
subjects with advanced CHD
Jenkins et al 
1987a
4—> 1 4—> 1 4—► i 4—► i Randomised crossover design in 30 
hyperlipidaemic subjects, lmo 
intervention
Jenkins et al 
1987b
4—► 4—► 4—► 1 4—► i 4—► 4—► Randomised crossover design in 6 
healthy males. 2wk intervention
Table 1.8. Changes in lipid markers of CVD risk following low and high GI diets.
t = significant increase, [significant decrease, no significant difference. * Helibron et al 
included low or high GI as part of an energy restricted diet.** Giacco et al included higher 
fibre in LGI. *** Dumensil included higher protein in LGI.
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1.5.4 Energy Restriction
Although dietary modification may produce favourable effects on plasma lipids the 
negative effects o f increased body weight, as the result o f increased energy intake 
and reduced energy expenditure, should not be ignored.
The prevalence o f  overweight and obesity is increasing worldwide and as such has 
become a major health issue. Obesity is classified as a body mass index (BMI) 
greater than 30 kg/nr as defined by the World Health Organisation (World Health 
Organisation 2001).
Obesity can be considered an independent CVD risk factor (Rabkin e t a l. 1977) and 
it has been estimated that a 1 0  % increase in body weight, in males, would increase 
the risk o f coronary disease by 30% (Ashley and Kannel 1974). Obesity also 
exacerbates a number o f  other CVD risk factors including hypertension, elevated 
plasma glucose and dyslipidaemia (elevated TAG, low HDL etc). Relative risk o f  
mortality has been shown to increase with increasing BMI (figure 1.10)
Low risk Moderate risk High risk
BMI
Figure 1.10: Relationship between BMI and relative risk o f mortality.
(World Health Organisation 2001)
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The relationship between obesity and CVD suggests that weight loss is a major goal 
in risk reduction. Weight gain is often the direct result o f  positive energy balance, 
that is, more energy is consumed than is used. Diets that promote negative energy 
balance produce weight loss and may produce a concurrent reduction in CVD risk.
A reduction in energy intake o f  around 2MJ/day can be expected to result in weight 
loss o f ~0.5kg/week. Weight loss has been shown to produce favourable effects on 
lipid mediated CVD risk (Table 1.9).
A meta-analysis o f 70 studies addressing weight loss through dietary management 
has indicated a significant reduction in total-cholesterol, LDL-C and TAG (Dattilo & 
Kris-Etherton 1992). From this meta analysis it was predicted that every kg 
reduction in body weight resulted in a 0.05mmol reduction in total cholesterol, a 
0.02mmol/L reduction in LDL-C and a 0.015 reduction in TAG. The effect o f weight 
loss on HDL-C cholesterol was shown to be dependent on the stability o f weight 
loss, for those with a stabilised reduced weight HDL-C is predicted to increase by
0.009mmol/L for every kg reduction in weight. During active weight loss HDL-C is 
predicted to decrease by 0.007mmol/L per Kg weight loss.
Further studies that have addressed specific weight loss regimes have also concluded 
that weight loss results in a significant reduction in lipids and lipoproteins associated 
with increased CVD risk (table 1.8). Noakes and Clifton compared three energy 
restricted diets and their effect on plasma lipids. In this study very low fat (VLF), 
high SFA (HSF) and high unsaturated fat diets (HUF) were compared all o f  which 
contained similar amounts o f  total energy (NS difference between groups). While the 
energy restricted diets produced favourable effects on total cholesterol, LDL-C and 
TAG the reduction was significantly less in the HSF group compared to the VLF and 
HUF groups (Noakes & Clifton 2000). Krebs et al (2002) have shown a similar 
reduction in plasma lipids over 1 2  weeks using a milk based low energy diet, in this 
study obese women lost an average o f 91cg which was associated with significant 
reductions in lipid markers o f  CVD risk together with blood pressure (Krebs et al. 
2002).
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All definitions o f the metabolic syndrome include measures o f  overweight/obesity 
and/or central obesity. The co-existence o f  being overweight and obese with other 
components o f the metabolic syndrome suggests that weight reduction may 
favourably affect other risk factors associated with CVD and MetS. A meta-analysis 
o f  the effectiveness o f weight loss in adults with pre-diabetes suggested that lifestyle 
interventions (diet, physical activity and behavioural) produced a significant 
decrease in the incidence o f  diabetes (Norris et al. 2005). Case et al (2002) addressed 
the impact o f weight loss on MetS and found substantial prevalence o f  MetS in obese 
individuals. Case also showed that weight loss (~18kg) improved blood pressure, 
fasting glucose, TAG and total cholesterol together with a reduction in the 
components o f  MetS when assessed using the NCEP ATP III criteria (Case et al. 
2002).
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Reference Subjects Intervention Follow Weight T-CHOL LDL-C HDL-C TAG
Up Loss
Leenen et 
a l1993
N = 8 
Females 
11 Males
Energy deficit of 
4.2MJ/day 13wks 1.5 Kg I i T I
Dengel et 
al 1995
N =48 
BMI
>2 5 Kg/m2
AHA step 1 diet 
with weight loss
9
months HKg I 1 1 I
Di Buono 
et al 1999
N=6
moderately 
obese males
3 months AHA 
step 1 followed 
by 6 months AHA  
step 1 with energy 
restriction (11- 
12MJ/day)
9
months -6.1 Kg 1 I
4—► I
Noakes
and
Clifton
2000
N =62 
BMI
>24kg/nf
3 way parallel
VLF
HSF
HUF
6.5MJ
12wks ~8.6Kg i i 1 i
Krebs et 
al 2002
N=57
females
BMI
>2 5 Kg/m2
Milk based diet 
providing 3.3- 
3.8MJ /day 12 wks 9.9 Kg I I
4—► i
Case et al 
2002
N=125 
subjects 
with MetS
VLCD (2.5- 
3.3MJ/day) 4 wks 9Kg 1 I
Pelkman 
et al 2004
N=53
BMI
>25Kg/m2
Low fat + energy
restriction
Vs
moderate fat + 
energy restriction
6 wks
-1.2Kg
-1.09Kg
1 I 1 I
I i 4—► i
Table 1.9. Changes in plasma lipids associated with weight loss
VLCD = very low calorie diet, VLF= very low fat, HSF- high saturated fat, HUF= high
unsaturated fat
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1.6 Aims and Objectives
The worldwide prevalence o f  metabolic syndrome and obesity is increasing. 
Pharmacotherapy which targets lipid risk factors and in particular those which target 
LDL-C have demonstrated favourable effects on CVD risk. In recent years the focus 
o f risk reduction has turned to strategies which elevate HDL cholesterol, however, 
drag interventions have been poorly tolerated. Dietary strategies to ameliorate the 
lipid abnormalities should therefore be considered as the first line o f  defence against 
increased CVD risk. The overall aim o f this thesis was to investigate such dietary 
strategies with particular emphasis 0 1 1  their effects on lipid CVD risk factors and an 
ALP. Additional emphasis was placed on the role o f  HDL subclasses in CVD risk 
associated with the metabolic syndrome. Before undertaking the interventions 
detailed, a major objective was to establish a rapid, high throughput method for the 
separation o f the principal HDL subclasses, to further define the dyslipidaemia 
associated with the metabolic syndrome. The development and validation o f  this 
method is detailed in Chapter 3.
The dietary strategies for the amelioration o f  lipid mediated CVD risk that were 
investigated involved the manipulation o f  the quantity and quality o f  dietary fat and 
carbohydrate and energy intake. The aims o f  each dietary intervention undertaken 
were:
I The RISCK  Study: It is accepted that the reduction o f dietary SFA will 
improve plasma lipids, however, there is debate as to whether this energy 
should be replaced by MUFA or CHO. Low fat diets have demonstrated 
favourable effects on plasma total and LDL cholesterol, however, increased 
CHO intake is often associated with an increase in plasma TAG. It can be 
suggested that the quality o f  CHO has an important role in such diets and that 
CHO that has a low GI may improve the plasma lipid profile. Additionally 
MUFA has also shown positive effects in terms o f LDL-C reduction and has 
also been shown to elevate HDL-C. The aim o f the RISCK study (chapter 4)
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was to investigate the effects reducing SFA intake in subjects at risk o f  the 
metabolic syndrome and to assess the effects o f  replacing this energy with 
either MUFA, or in the case o f the low fat diets with CHO. Additionally the 
quality o f  CHO was investigated in both the high MUFA and low fat diets. 
This was achieved by providing subjects with staple carbohydrates, fats and 
oils and providing diet guidelines to alter the GI o f  dietary carbohydrate and 
the percentage fat intake and composition (SFA and MUFA) (Chapter 4)
Ha The EDW INA study: The RISCK describes the use o f a weight maintenance
dietary regimen to improve lipid mediated CVD risk. However, the 
prevalence o f  obesity is increasing and the benefits o f  weight loss in terms o f  
its effects on plasma lipids should not be ignored. The aim o f  the Eggs in a 
Diet for Weight loss in Normolipidaemic Adults (EDWINA) study was to 
examine the effects o f  an energy restricted diet with or without the addition 
o f two eggs per day. This was achieved by providing subjects with dietary 
guidelines for energy restriction and recipe suggestions for both those 
consuming or avoiding eggs (Chapter 5)
lib Responsiveness to dietary cholesterol and weight loss: The responses to
increased dietary cholesterol and energy restriction observed in the EDWINA  
study (Chapter 5) were highly individualised. The aim o f this study was to 
explore potential causes o f this variation including apolioprotein E (apo E) 
genotype and differences in cholesterol absorption and synthesis. This was 
achieved by retrospectively genotyping subjects o f the EDWINA study and 
measuring serum markers o f  cholesterol absoiption and synthesis
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CHAPTER 2 - M ATERIALS AND GENERAL M ETHODS  
2.1 M ATERIALS
Plasma lipids, lipoproteins and apoproteins (SpACE Auto Analyser)
Triglycerides Reagent Alfa Wasserman Inc
System Diluent 4 Henderson Drive
(sodium azide lg/L, Triton xlOO 0.5ml/L) West Caldwell
Apo B Reagent Randox Laboratories Ltd
Apo Al Reagent Diamond Road
Apo E Reagent Crumlin
Total Cholesterol Reagent
HDL-C Direct Reagent
LDL-C Direct Reagent
Quality control (QC) and calibration material
Co Antrim
MLT Insulin Assav
Insulin ELISA Kit MLT Research Limited 
5 Chiltem Close 
Cardiff Industrial Park 
Cardiff#
Luminometer Berthold Technologies 
Calmbacher Str 22 
Bad Wildbad 
Germany
Blood Collection
Vacutainer System Direct Medical Supplies 
Blacknest Business Park 
Alton 
GU34 4PX
Monovette System 
Ultracentrifugation
Sarstedt
6 8  Boston Road 
Beaumont Leys 
Leicester
Optiseal Ultracentrifuge Tubes Beckman Coulter UK
Polyallomer Ultracentrifuge Tubes Oakley Court
Ultracentrifuge -  XL-100-K and L-100-XP Kingsmead Business Park
Buckinghamshire
Optiprep Axis Shield Ltd 
Bicton Industrial Park 
Cambridgeshire
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Potsssium Bromide (ICBr) Sigma Aldrich
Sudan Black The Old Brickyard
Coomassie Blue New Road
Gillingham
Gradient Gel Electrophoresis
4-30% Gradient Gels CBS Scientific Company
Electrophoresis System California
USA
Regents for buffer, stain,
destain and fixing solution
Coomassie Blue R 250 Sigma Aldrich
Methanol The Old Brickyard
Glacial Acetic Acid New Road
Boric acid Gillingham
Sulphosalicylic Acid
General Chemicals
Sigma Aldrich
The Old Brickyard
New Road
Gillingham
All Chemicals and reagents were of analytical grade
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2.2 GENERAL M ETHODS
All kits for the SpACE autoanalyser were purchased from Randox laboratories Ltd,
o
County Antrim, UK. Elisa kits for the analysis o f insulin were purchased from 
Molecular Light Technologies, Cardiff, UK. Centrifuge tubes were purchased from 
Beckman Coulter (UK) Ltd, Buckinghamshire, UK, and gradient gels from C.B.S 
scientific company ltd, California, USA. All other chemical were o f  analytical grade 
and supplied by Sigma Aldrich, Poole, Dorset, UK.
2.2.1 Preparation o f  Plasma
Blood was taken by venepuncture or from an indwelling venous cannula by 
vacutainer, monovette or luer fitting syringes as appropriate. Samples were taken into 
vacutainer or monovette tubes containing suitable preservatives/anticoagulants 
(Table 2.1) and, with the exception o f serum, immediately centrifuged at 2000g for 
20 minutes at 4°C in a Heraeus Labofuge 400R. The plasma was aliquotted into 
labelled tubes and stored at -80 °C.
Vacutainer M easurem ent/Assay
K2EDTA
Fluoride oxalate (FO) 
Lithium heparin (LH)
Serum
Choi, TAG, LDL-C, HDL-C, Apo-B, Apo-AI 
Buffy coat stored for DNA extraction
Glucose
Insulin
Plasma Sterols
Lipid profile (RISCK study)
Table 2.1. Anticoagulants/Preservatives and Assays
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2.3 ASSAY PROCEDURES
Co-efficient o f  variation for all assay procedures is documented in Table 2.2.
Glucosemmol/L T-Cholmmol/L TAGmmol/L LDL-Cmmol/L HDL-Cmmol/L Apo Al g/L
ApoB
fi/L
Apo E 
g/L
Con
tro
l 
Leve
l 1
MeanSDCV% Intra-assay CV% Inter-assay
6.60.121.91.67
4.900.050.941.24
1.170.021.251.29
Con
tro
l 
Leve
l 2
MeanSDCV% Intra-assay CV% Inter-Assay
16.40.150.911.05
6.590.071.080.97
2.560.051.01.3
Lip
id 
Con
tro
l 
Leve
l 1
MeanSDCV% Intra-assay CV%-Inter-assay
3.480.092.593.42
0.880.022.274.02
1.350.053.704.52
0.700.023.024.83
Lip
id 
Con
tro
l 
Leve
l 2
MeanSDCV% Intra-Assay CV% Inter-assay
4.50.102.223.56
1.440.032.073.66
2.110.083.84.60
1.190.0484.073.45
0.0270.00072.623.51
Lip
id 
Con
tro
l 
Leve
l 3
MeanSDCV% Intra-assay CV% Inter-assay
5.540.091.622.95
1.890.042.123.72
1.570.063.822.88
0.0390.00184.564.48
Table 2.2. Inter and Intra-assay precision for clinical chemistry on the SpACE Auto­
analyser. A ll intra-assay variability n=20, inter-assay variability n=40
2.3.1 Glucose Measurement
Plasma glucose was measured in vitro using the Alfa Wasserman Gluc-Pap kit. The 
concentration o f glucose was determined in plasma containing fluoride oxalate 
preservative by the enzymatic oxidation o f glucose which takes place in the presence 
o f glucose oxidase. This produces hydrogen peroxidase which reacts with phenol and 
4-aminophenazone to form a red-violent quinoeime indicator dye that absorbs light 
between 505nm/692nm, with the absorbance being proportional to the glucose 
concentration o f the sample.
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Glucose oxidase
Glucose + 0 2 + H2 gluconic acid + H20 2
peroxidase
3 H20 2 + 4-aminophenazone + phenol quinenemine
+4H20
2.3.2 Triacylglycerol Measurement
Plasma TAG concentrations were measured using the Alfa Wassermann TAG 
analysis kit. The measurement o f  TAG uses a four-step reaction to liberate glycerol 
from TAG (a triester o f  glycerol and fatty acid). Glycerol is liberated by hydrolysis 
catalysed by microbial lipases; glycerol is then used as a substrate in the first o f a 
series o f enzymatically coupled reactions which generate a quioneimine indicator 
dye. The change in absorbance is measured biochromatically at 505/692nm and is 
directly proportional to the concentration o f  TAG in the sample.
Lipase
TAG + H20 Glycerol + Fatty Acid
Glycerol Kinase
Glycerol + ATP *  Giycerol-3-Phosphate + ADP
Glycerol Phosphate
Glycerol 3 Phosphate Dihydrohyacetone phosphate + 
H20 2
H20 2 + 4 Aminophenazone + 4-Chlorophenol
Peroxidase
>  Quinoeimine +
HCI + 4 H20
46
Chapter 2 - Materials and General Methods
2.3.3 Total Cholesterol Measurement
Total plasma cholesterol (free cholesterol and cholesterol acyl esters) was measured 
using the ACE cholesterol-PAP kit. The measurement o f  cholesterol uses a three-step 
reaction to liberate peroxide which then reacts with 4-aminoantpyrine and phenol to 
produce a quinoneimine dye, the change in absorbance is then measured 
biochromatically at 505/692nm and is proportional to the amount o f cholesterol
present in the sample. Cholesterol esterase
— ^
Cholesterol ester+ H20  cholesterol + fatty acids
Cholesterol oxidase
Cholesterol + 0 2 _________________________________ ». Cholestene-3-one + H20 2
Peroxidase
H20 2 + 4 Aminophenazone + 4-Chlorophenol ^  Quinoeimine + HCI +
4 H20
2.3.4 Direct LDL and HDL -cholesterol measurement
Plasma LDL-C and HDL-C were measured directly using Randox direct LDL and 
HDL kits respectively. The measurement o f both HDL and LDL involves two 
distinct steps.
1. The elimination o f  chylomicron, VLDL-C and LDL-C/HDL-C (as 
appropriate)
2. Specific measurement o f  HDL-C /LDL-C after its release through the 
action o f  detergents (the reagents used in this step differ for LDL-C and 
HDL-C)
The reactions produce a quinine pigment which is directly proportional to the 
HDL-C or LDL-C concentration when absorbance is measured at 600nm.
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Reaction step 1
Cholesterol esterase 
Cholesterol ester  ► Cholesterol + Fatty Acid
Cholesterol oxidase 
Cholesterol + 0 2 ^  Cholestenone + H20 2
Catalase
2H20 2 ^  2H20  + 0 2
Reaction step 2 -  LDL-C
Cholesterol esterase 
Cholesterol ester  ► Cholesterol + Fatty Acid
Cholesterol oxidase 
Cholesterol + 0 2 ^  Cholestenone + H20 2
2H20 2 +4AA + TOOS -----------peroxidase-------------- ►Quinone Pigment + 4 H20
Where 4-AA = 4-Aminoantipyrine
TOOS = (N-Ethyl-N-(2-hydroxy-3-sulphopropyl)-3-methylaniline 
Reaction step 2 HDL-C
Cholesterol esterase 
Cholesterol ester  ► Cholesterol + Fatty Acid
Cholesterol oxidase 
Cholesterol + 0 2 *  Cholestenone + H20 2
peroxidase
2H20 2 + 4AA + HDAOS ------------------------------------------> Quinone Pigment + 4 H20
Where 4-AA = 4-Aminoantipyrine
FIDAOS = N-(2-hydroxy-3-sulphopropyl)-3,5-dimethoxyaniline.
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2.3.5 Measurement o f  apolipoproteins A-I, B and E
Apo A-I, apo B and apo E were measured turbidimetrically using a suspension o f  
polystyrene latex particles o f uniform size coated with antibodies to either human 
apo A-I, apo B or apo E (Randox, UK). When serum containing the apoprotein is 
mixed with the latex reagent an increase in turbidimetry can be measured at 
340nm/692mn which is proportional to the concentration o f  apoprotein. A standard 
curve was constructed from an apo B and apo A-I standard using saline (0.9% w/v) 
with the range 0.0 -2 .20  and 0.0 -  2.15g/L for apo A-I and apo B respectively. Apo 
E was calibrated using a single calibration at 0.03 5g/L.
2.3.6 Insulin Measurement
Insulin was measured using a commercially available immuno-chemiluminometic 
assay (Molecular Light Technologies, Cardiff, UK). This method employs a two-site 
immunoassay that uses an insulin specific solid phase antibody (Ab) immobilised on 
microtitre wells and a soluble antibody labelled with a chemiluminescent acridium 
ester.
The plasma sample, containing lithium heparin as a preservative, was incubated 
simultaneously with the labelled Ab in a microtitre well; the plate was then washed 
to remove unbound labelled Ab before bound luminescence was quantified using a 
luminometer capable o f  in situ reagent addition.
Monoclonal antibodies are used in this assay to reduce any cross reactivity with 
biosynthetic precursors o f  insulin.
Assay Procedure
The insulin kit comprised o f a set o f standards (lyophilised recombinant insulin in a 
serum matrix), labelled antibody and antibody diluent, microtitre plates coated with 
monoclonal antibody and wash buffer concentrate (PBS containing detergent and 
0.09% sodium azide).
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All kit components were brought to room temperature before use. Standards were 
reconstituted with lrnl o f  RO water and allowed to stand for Sminutes before mixing 
to dissolve any remaining solid. Concentrated labelled antibody (900pL) was added 
to antibody diluent and mixed. Finally, 1 part wash buffer was added to 9 parts RO 
water.
Labelled antibody (lOOpL) was added to each microtitre well followed by 25 pL o f  
standard or sample (all standards and samples were run in duplicate). Plates were 
then sealed and incubated at 37°C for 2 hours before washing 3 times with wash 
buffer using an automated plate washer. Plates were read in a luminometer and 
results calculated using MicroWin software. Inter-assay CV’s for 3 levels o f  control 
were determined to be: 5.4% at 12mU/L, 4.8% at 40mU/L and 6.2% at 93mU/L. 
(Conversion mU/L to pmol/L = 7.5)
2.4 LIPOPROTEIN ANALYSIS
2.4.1 Ultracentrifugation Methods
<2
2.4.1.1 Preparation o f  total lipoprotein
Total lipoprotein was isolated using the sequential flotation method o f Havel et al 
(1955), in this method the density o f the plasma is raised sequentially by the addition 
o f solid (s) potassium bromide.
Whole plasma was adjusted to a density o f  1.21kg/L by the addition o f  KBr(s). The 
amount o f  KBr(s) added was determined using the following formula:
KBr (g) = Initial volume (ml) x [final density-initial density!
1 -[final density x 0.312]
0.326g o f  KBr was added to 1ml o f plasma and, transferred to a 12ml Beckman 
Ultra-clear centrifuge tube. Density-adjusted plasma was mixed with 11 mis o f  a
1.21kg/L KBr, 1% EDTA density solution. Tubes were housed in a Beckman 70.1 Ti 
rotor and centrifuged for 24h at 117,734g(av), 15°C. Following centrifugation, the
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upper yellow supernatant (lipoprotein top) was aspirated and used for subsequent 
analysis.
2.4.1.2 Measurement o f  LDL subclasses using iodixanol density gradient 
ultracentrifugation
LDL subclasses were determined by the method o f  Davies et al (2003), as validated 
for use in the NVT 65.2 rotor. Plasma was mixed with Optiprep7M (iodixanol at 60% 
(w/v)) and pre-stained with Coomassie Blue R 250 to give a final concentration o f  
12% (w/v) with respect to iodixanol. The 12% plasma solution was layered under a 
9% solution o f  OptipreprM and phosphate buffered saline (PBS). 1.5ml o f  the 
working sample was layered under 3.4ml o f  the 9% Optiprep™ in a 4.9ml Beckman 
optiseal centrifuge tube. The centrifuge tubes were housed in an NVT 65.2 near 
vertical rotor and centrifuged at 370,752g(aV), 16°C, acceleration program 5, 
deceleration program 5, for 2h 30min in Beckman Optima XL-100 and L-100 
ultracentrifuges. Samples were then photographed using a Nikon D1X digital camera 
(Nikon, Surrey, UK) and analysed using Totalab ID gelscan software (Nonlinear 
Dynamics, Newcastle upon Tyne, UK).
2.4.1.3 Validation o f  the NVT 65.2 Rotor
The use o f the NVT 65.2 rotor in this method, was validated by direct comparison 
with the NVT 65. An unstained sample was fractionated into 200j.iL fractions and the 
refractive index measured.
Calculating Density from  refractive index:
Six solutions o f  Iodixanol (5-30%v/v), with increasing densities, were prepared in 
duplicate using phosphate buffered saline (PBS) as a diluent. The refractive index o f  
each sample was measured using a Bellingham Stanley DR-103 refractometer and 
the density measured using a density meter (Parr Scientific, London) both using 
water as a standard (Rl = 1.332). The Rl and density values were plotted and a y  = 
mx + c curve constructed (figure 2.1). Both ‘nT and ‘c’ were calculated and 
corresponded to ‘a’ and ‘b ’ in the following formula:
51
Chapter 2 - Materials and General Methods
p = r| a -  b
Where p = density
r\ =  Refractive index 
a and b are constants
Determination of a and b Constants y-3 i^93x-3.56
Ft  = 0.9961
Refractive Index
Figure 2.1 Determination of a & b constants. Six concentrations of iodixanol were 
prepared (5-30% w/v in PBS) and both the density and RI measured. The readings were 
plotted and the y=mx+c equation used to determine a and b in the p = pa -  b equation
Linear regression analysis o f  the iodixanol data generated the following equation:
y =  3 .4193X  — 3 .5 6  equation 1
where y = p 
x = T| 
a = 3.4193 
b = 3.56
This equation was used to calculate the density o f each fraction collected from a 
blank sample prepared in 4.9 amd 11.2 mPOptiseal’ tubes.
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Fractionation o f  ‘Optiseal’ tubes
To establish a relationship between the distance migrated (Rf) to density, 4.9ml and
11.2ml optiseal tubes were fractionated into 200 and 400 pL fractions respectively, 
and the refractive index (Rl) o f each fraction measured. Rl was then converted to 
density using equation 1 .
Three 4.9ml Optiseal tubes were marked at 200pL intervals and then analysed using 
Totalab software. Total lab generated a relative fraction (Rf) value for each fraction. 
A blind, unstained plasma sample was also run in triplicate using a 9 and 12% 
gradient to separate LDL subclasses. Blind samples were then fractionated from the 
meniscus using a labonco autodensiflow and 200pL fractions collected using a 
Gilson FC203P fraction collector. The Rl o f  each 200pL fraction was measured and 
converted into density. R f values were plotted against their corresponding densities 
and linear regression performed to generate an equation for the conversion o f Rf into 
density (g/ml) (figure 2 .2 ).
Figure 2.2: Density profile of a 9-12% gradient in a 4,9ml Optiseal tube. Rl readings 
were taken for each 200pL fraction and converted to density. Density measurements were 
plotted against the Rf value generated by Total lab for each fraction. The gradient was 
curvilinear with an extended linear region between fractions 1 and 14(shown). The density 
values associated with the linear region were used for linear regression analysis.
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In a 4.9ml Optiseal tube density is determined by the equation
Y=0.0577x + 1.0023 equation 2
Where: density
Rf(mm)
The same procedure was performed for 11.2ml optiseal tubes in the NVT 65 rotor, 
however, due to the larger volume 400pL fractions were taken (figure 2.3).
Figure 2.3: Density profile of a 9-12% gradient in an 11.2ml Optiseal tube. Rl readings 
were taken for each 400pL fraction and converted to density. Density measurements were 
plotted against the Rf value generated by Total lab for each fraction. The gradient was 
curvilinear with an extended linear region between fractions 1 and 14(shown). The density 
values associated with the linear region were used for linear regression analysis.
In an 11.2ml Optiseal tube density is determined as:
Where:
Y = 0 .5 5 6 x +1.0054
density 
R f (mm)
equation 3
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To compare differences between the two rotors, 45 samples were collected from staff 
and students at the university o f  Surrey and from on-going dietary intervention 
studies. EDTA plasma samples were run in both the NVT 65.2 and NVT 65 and peak 
Rfs assigned using total lab. Both peak R f and peak density values were compared 
and plotted to produce a y=mx+c curve (figure 2.4).
Peak Density NVT 65 vs NVT 65.2
y=1.2489x-0.2528
oi 1.034 - 
<2 1.032 - 
z  1.030 -
5  1.028 -o>
£  1.026 -
1  1.024 -
| 1.022 -
« 1.020 - o>
1.018 - 
1.016 -
1.016 1.018 1.020 1.022 1.024 1.026 1.028 1.030
Peak Density (Kg/L) NVT 65
Figure 2.4: Comparison of LDL peak density in NVT 65 and 65.2 rotors. 45 samples 
were analysed for LDL subclasses using both rotors and the peak densities assigned. These 
were plotted and a y=mx+c equation used to detennine NVT 65.2 density from that
generated in the NVT 65 rotor.
The density in the NVT 65.2 rotor was related to the density in the NVT 65 using the 
following equation:
y=1.2799x -  0.2851 equation 4
Where y = NVT 65.2 density (kg/L)
x = NVT 65 density (kg/L)
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Using the density intervals determined by Davies et al (2003) (table 2.3) it was 
possible to determine the R f cut-off value for sdLDL in the NVT 65.2 rotor (table
2.4).
LDL Subclass Rf Density (kg/L)
LDL I 0.26-0.32 1.022-1.025
LDL II 0.32-0.40 1.025 -1.028
LDL III 0.40-0.56 1.028-1.036
LDL IV >0.56 >1.036
Table 2.3 LDL subclass densities in the NVT 65 rotor (Davies et al 2003)
In the NVT 65, the cut-off for sdLDL was at a density o f 1.028 kg/L this corresponds 
to a density o f  1.031 kg/L. The Rf cut-off corresponding to a density o f  1.031 kg/L in 
the 4.9ml optiseal tube was calculated using equation 2. This gave an Rf cut-off 
value o f 0.50 in the Optima XL-100-K ultracentrifuge.
LDL Subclass NVT 65 Rf (mm)
NVT 65 
Density (Kg/L)
NVT 65.2 
Rf (mm)
NVT 65.2 
Density (kg/L)
LDL I 0.26-0.32 1.022 -1.025 0.36-0.43 1.023-1.027
LDL II 0.32-0.40 1.025 -1.028 0.43-0.50 1.027-1.031
LDL III 0.40 - 0.56 1.028-1.036 0.50-0.67 1.031-1.041
LDL IV >0.56 >1.036 >0.67 >1.041
Table 2.4. Comparison of LDL subclass densities. N V T  65.2 densities w ere calculated  
from the N V T  65 density using y = l .2799x -  0.2851 where y =  N V T  65.2  density and x =
N V T  65 density.
The density profile generated by the NVT 65.2 rotor in the Optima L-100-XP was 
also investigated (figure 2.5). An unstained sample was fractionated as previously 
described and the density at each fraction calculated from the refractive index. Small 
differences in the gradient generated were observed, however, this was accounted for 
by standardising the density cut-off and adjusting the Rf cut-off accordingly (table
2.5)
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_ , . . .  _ y = 0.0615x+1.0013Density Profile L-100-XP NVT 65.2 1 ,
R2 = 0.9913
Rf (mm)
Figure 2.5: 4.9ml tube 9-12% density profile in the Optima L-100-XP. The 9-12%  
gradient in the N V T  65.2 rotor was fractionated fo llow ing ultracentrifugation in the Optima 
X L -100-K  centrifuge. Small differences w ere observed betw een the L -100-X P and X L -100- 
K centrifuges resulting in a difference in the R f cut o f f  for sdLDL.
LDL Subclass NVT 65.2 Density 
(kg/L)
L-100-XP Rf 
(mm)
XL-100-K Rf 
(mm)
LDL I 1.023-1.027 0.35-0.42 0.36-0.43
LDL II 1.027-1.031 0.42-0.48 0.43-0.50
LDL III 1.031-1.041 0.48-0.65 0.50-0.67
LDL IV >1.041 >0.65 >0.67
Table 2.5 Comparison of LDL density profiles in Optima L-100-XP and XL-100-K
Ultracentrifuges.
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2.4.2 Gradient gel electrophoresis fo r  separation o f  HDL subclasses
HDL subclasses were analyzed using pre-cast, non-denaturing acrylamide gradient 
gels (4-30%) using a pore gradient gel lipoprotein electrophoresis system (PGGE, 
C.B.S. Scientific Company Inc, Del Mar, California). Separation o f  HDL by this 
method uses gradient gels comprised o f  increasing concentrations o f  polyacrylamide 
to produce progressively smaller pore size. During electrophoresis, particles migrate 
until they reach an “exclusion limit” at which point their migration within the gel is 
retarded. Resolution o f  the HDL subclasses is obtained using polyacrylamide gels 
with a 4-30% linear gradient, HDL subpopulations may be visualized by lipid or 
protein staining.
Protein staining required an initial separation o f  the lipoproteins by flotation to 
remove interfering proteins present in whole plasma. Total lipoprotein samples were 
prepared by ultracentrifugation (section 2.5.1.1); lOOpL o f  the lipoprotein fraction 
was pre-stained with bromophenol blue to give a final concentration o f  5% w/v. 
lOpL o f  pre-stained sample was then loaded on to a pre cast 4-30% acrylamide gels 
that had been equilibrated at 70V, 65mA for 30 minutes. Gels were then mn for 20 
minutes at 20V, 50mA, followed by 30 minutes at 70V, 65mA and finally for 24 
hours at 120V, 100mA. Following electrophoresis, gels were removed and fixed with 
a solution o f  10% w/v sulphosalicylic acid for 30 minutes. The fixative was poured 
o ff and the gels immersed in protein stain (0.1% w/v coomassie blue R250, 
methanol, glacial acetic acid, RO water in a 5:1:4 ratio) for 1 hour. Gels were 
destained with a solution o f  methanol: glacial acetic acid: RO water (50:75:875ml) 
for 24hours. Gels were then photographed using a Nikon D1X digital camera and 
analyzed using TotaLab software.
Alternatively, whole plasma could be used directly i f  it was pre-stained with Sudan 
black, a lipid specific stain. 50pL o f  whole plasma was mixed with 50pL 2% w/v  
Sudan Black in ethylene glycol. 20f.iL o f  pre-stained plasma was then loaded onto an 
equilibrated 4-30% gradient gel. Identical electrophoresis conditions were used. 
Following electrophoresis, gels were directly photographed and analyzed using 
TotaLab ID software, with no further staining required.
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2.5 APOE E GENOTYPING
The ApoE gene exists as three alleles s2, s3 and e4 resulting in 6  possible genotypes 
s2/s2, e2/s3, e3/e3, s3/s4 and s4/s4. The three common alleles give rise to three 
isoforms o f  ApoE which differ by one amino acid at positions 112 and 158.
Apo E genotyping was performed using an adapted version o f the method described 
by Hixson and Vernier 1990. DNA was extracted from buffy coat samples using a 
GFX genomic blood purification kit (Amersham biosciences). Following extraction, 
5pL o f purified DNA was mixed with 1 pL o f  Taq and 20pL o f  master mix (125pL  
buffer, 75pL MgCl, 25pL dNTPs, 62.5pL DMSO, 25pL ApoE F , 25pL ApoE R, 
657.5pL H2 0 ) . The DNA sequence containing positions 112 and 158 was then 
amplified by the polymerase chain reaction (PCR) in a thermal cycler for 30 cycles 
(94°C 30seconds, 60°C 30seconds, 72°C 30seconds) using oligonucleotide primers 
(TAGN):
Primer sequences:
5’-ACAGAATTCGCCCCGGCCTGGTACAC-3’ 
5’-TAAGCTTGGCACGGCTGTCCAAGGA-3’
After amplification, lOpL o f product was mixed with Hha\ (New England BioLabs) 
and incubated at 37°C for lh  30min. The reaction mixture was then loaded onto an 
8 % polyacrylamide gel and electrophoresed for 30 minutes under a constant current 
(35mA). The gel was then stained with ethidium bromide (lOOpL o f 0.5pg/ml) for 10 
mins, followed by destaining with RO water for 10 mins. DNA fragments were 
visualised and photographed using a digital camera under high intensity UV  
illumination. The fragments generated by Hhal were identified using a DNA ladder 
o f markers o f known size. The nucleotide substitutions at positions 112 and 158 in 
the apoE gene produce DNA fragments o f different sizes after Hhal digestion, giving 
rise to specific fragment patterns that depend on genotype.
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Figure 2.6. Examples of ApoE restriction isotyping. Distinct fragmentation patterns 
fo llow in g H hal restriction digest occur due to polym orphism s at positions 112 and 158. 
Taken from H ixson  and Vernier 1990
2.5 HEIGHT AND BODY COM POSITION
Height was measured using a wall mounted stadiometer. Body weight was measured 
without shoes; body composition was assessed using a Tanita 330GS body 
composition analyser using standard settings for clothing weight and body type. The 
Tanita 300GS uses bioimpedance to estimate percentage body water and body fat. 
Waist circumference was measured at the mid-point between the lower rib margin 
and the iliac crest, with the waist uncovered, using a standard tape measure.
2.6 BLOOD PRESSURE
Blood pressure and heart rate were measured using an OMRON 705CPII automated 
digital sphygmomanometer with the volunteer seated, legs uncrossed and feet flat on 
the floor. Blood pressure was measured twice, with an interval o f 5 minutes, and an 
average taken.
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CHAPTER 3 -  SEPARATION OF THE PRICIPAL HDL SUBCLASSES  
U SIN G  IODIXANO L ULTRACENTRIFUGATION
Abstract
Background _______________ ___________________________________ ___
A constellation o f  lipid risk factors contribute to increased risk o f  cardiovascular 
disease. The undeniable evidence linldng reduction o f  LDL-C to a reduction in CVD 
mortality has resulted in the importance o f  other lipid markers being somewhat 
overlooked. HDL-C has been shown to be predictive o f  CVD risk even at low 
concentrations o f  LDL-C (Gordon et al 1977). HDL exists as a number o f  discrete 
subclasses the relative abundance o f  which show a variable relationship with CHD 
risk. The measurement o f  HDL subclasses is often expensive and time consuming. 
The aim o f  the current study was to develop a high throughput, cost effective method 
fo r  the measurement o f  the principal HDL subclasses in plasma.
Hypothesis _____ _______ _  _______
Iodixanol density gradient ultracentrifugation (IxDGUC) has been previously 
applied to the separation o f  total lipoproteins and LDL subclasses. This study 
hypothesized that the principal HDL subclasses could be separated by IxDGUC, 
using the same rotor and centrifugation conditions as those previously described fo r  
LDL subclasses.
Methods _____ ______________________ ______ __ ___________ _______ ___________
The principal HDL subclasses were separated in a run time o f  2h30min from lipid 
stained plasma using a 3-step iodixanol gradient. Following centrifugation HDL 
subclass profiles were identified using digital photography and TotaLab ID gelscan 
software. Plasma samples from 96 subjects displaying a spectrum o f  plasma lipids 
were used to optimise the gradient. Samples from 48 o f  these subjects were 
compared to lipid and protein stained gradient gel electrophoresis to validate the 
gradient.
Results     ____________________ ____
HDL subclass profiles generated by IxDGUC were comparable to those separated by 
o f  GGE as indicated by a significant association between areas under the curve fo r  
both HDL2 and HDL3 /HDL2 1-0.896 (r2=80.2%) p<0 .0 1 , HDL3 1-0.894 (r2=79.9%) 
p<0 .iy. The method was highly reproducible with intra and inter-assay CV% <5 fo r  
%AUC HDL 2 and HDL3, and <1% fo r  peak  R f and peak density.
Conclusions___________________________________________ _____________________ __
This method provides a rapid, high throughput and cost effective technique fo r  the 
detection o f  the principal HDL subclasses which can also be used preparatively to 
isolate HDL2 and HDL3
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3.1 Introduction
Lipid-associated CVD risk has largely focused on the impact o f  LDL-C, and in 
particular, the atherogenicity o f  small dense LDL particles (sdLDL). However, whilst 
the decreased risk associated with LDL-C reduction following statin therapy is 
undeniable, it can be said that the atheroprotective role o f  HDL-C has been 
somewhat overlooked, largely because statins have little effect 0 1 1  HDL. Several 
epidemiological and prospective studies have identified low HDL-C as an 
independent risk factor for CVD. In the Framingham study HDL-C was shown to be 
predictive o f  CVD risk even at low LDL-C concentrations, with CVD risk increasing 
by 2-4% for every 0.03mmol/L reduction in HDL-C (Gordon et al 1977, Castelli 
1986). hi addition, whilst statins have been proven to reduce CVD risk through 
reduction in LDL-C, the use o f gemfibrozil in the Veterans Affairs High Density 
Lipoprotein Cholesterol Intervention trial (VA-HIT) showed that an increase in 
HDL-C during treatment significantly correlated with a reduction in CVD risk but 
alterations in LDL-C did not (Rubins et al 1999).
HDL shows heterogeneity and exists in the body as a number o f  subclasses with 
differing lipid and protein compositions. HDL subclasses were first described in 
1954 on the basis o f  their physical separation by density in the ultracentrifuge 
(Delalla et al. 1954). Subsequently a number o f  other properties have been used to 
identify HDL subclasses including size/molecular mass (Blanche 1981) charge 
(Gidez 1982) and apoprotein composition (Cheung 1987, Koren 1987).
The work o f DeLalla et al, (1954), using the analytical ultracentrifuge, demonstrated 
3 subclasses o f  HDL; HDLt HDL2  and HDL3, with HDL2  and HDL3 recognised as 
the principal HDL subclasses (DeLalla et al 1954). Initial fractionation o f the 
principal subclasses suggested delineation at a density o f 1.125kg/L (HDL2  1.063- 
1.125kg/L and HDL3 1.125-1.21kg/L). However, Kostner and Alaupovic reported an 
improved separation using a density o f  1.100 kg/L (Kostner and Alaupovic 1972), 
Anderson et al were to subsequently separate the HDL2  subclass into HDL2b and 
HDL2a, with a demarcation occurring at l.lOOkg/L (Anderson et al 1977). The initial 
separation o f  lipoproteins using density gradient ultracentrifugation (DGUC) relied
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on the yellow colouration o f the lipoprotein bands for their identification. Pre­
staining o f  lipoproteins with Sudan Black, a lipophilic stain, was introduced by 
Terpstra et al. (1981) Pre-staining o f  plasma permits the visualisation o f lipoproteins 
and their subclasses within the ultracentrifuge tube facilitating their identification 
and removal without the need to adhere to strict density intervals which may vary 
depending on technique and species (Terpstra et al 1981).
The evolution o f  a range o f  analytical techniques has resulted in the identification o f  
further subdivisions o f  the principal H D L  subclasses. Gradient gel electrophoresis 
(GGE) has been used widely to separate H D L  subclasses. Pre-cast polyacrylamide 
gels with a graded pore size (4-30%) were used initially to identify H D L i ,  H D L 2 and 
H D L 3 However, the densitometric scans o f gels resulted in further resolution o f  
H D L  into H D L 2 b , H D L 2 a , H D L 3 a , H D L 3b , and H D L 3c subclasses (Blanche et al 1981, 
Rainwater et al 1992). H D L  subclass properties are described in table 3.1.
H DL2b H DL2a HDL3a HDL3b HDL3c
Diameter (mn) 10.4 10.3 9.9 8 7.3
Density (kg/L) 1.099 1.107 1.123 1.155 1.186
Mr
(kDa)
410 400 360 200 160
Plasma Level 
(UM)
1.7 1.8 1.9 1.3 1
mmol/mol HDL
Apoproteins
Apo A-I 4-5 4 3-4 3 2-3
Others <2 <2 <2 1 <1
Surface Lipids
Phospholipid 130 140 120 45 25
Free cholesterol 70 40 25 15 10
Core lipids
Cholesteryl ester 180 160 140 70 40
Triacylglycerol 30 20 15 10 5
Table 3.1 Heterogeneity in the physiochemical properties of HDL. Differences in the 
composition of HDL subclasses form the basis for the differing methodologies for their 
separation. Densities are those reported from salt gradients.
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Ultracentrifugation methods and GGE have both advantages and disadvantages; 
ultracentrifugation allows for a quantitative analysis, though the techniques are 
labour intensive, time consuming and as a result are low throughput. Additionally, 
salt gradients can potentially cause disruption o f associated apoproteins. GGE 
requires a small sample size and is less labour intensive, but the technique is 
primarily qualitative, and due to the small sample volumes, the method is unsuitable 
for the preparation o f  HDL subclasses. Techniques involving protein staining, 
following separation, require initial sample purification W hile these gels were 
commercially available they have now become obsolete in the UK.
Alternative methods developed to identify HDL subclasses include the vertical 
autoprofile-II method (VAP-II) and nuclear magnetic resonance (NMR). The VAP 
II method (Kulkarni et al 1994) uses short path length, vertical rotors and continual 
analysis o f  the gradient to quantify the cholesterol in lipoprotein classes. The 
quantification o f  HDL subclasses using this technique has been described previously 
(Kulkarni et al 1997) but this method requires deconvolution o f  the cholesterol 
absorbance curve. Whilst this method is rapid (47 minutes ultracentrifugation), it 
requires the use o f sophisticated mathematical modelling to identify HDL subclass 
peaks, this program also relies upon fixed sub-curve peak parameters which may 
potentially affect the results from subjects with unusual profiles. Proton-NMR (*H- 
NMR) was developed in the 1990’s (Otvos et al 1992, Ala-Korpela 1994) this 
method is quantitative, rapid, requires a small sample volume and is non destructive. 
However, this technique requires expensive equipment and cannot be used to prepare 
lipid subclasses for further analysis. Recent evidence also suggests that the accuracy 
o f ’H-NMR is highly variable across subclasses. The greatest accuracy was observed 
for VLDL and HDL3 but was considerably less for the HDL2  subclasses as well as 
the smaller LDL's (Ala-Korpela 2007)
Graham et al (1996) have utilised iodixanol, a derivative o f  triiodobenzoic acid, in 
conjunction with vertical and near vertical rotors, to separate plasma lipoproteins in a 
1 0 1 1 1  time o f 3 hours (Graham et al 1996). Iodixanol (5,5 -[(2-hydroxy-1,3- 
propanediyl)- bis (acetylimino)] bis- [N,N bis(2,3dihydroxypropyl)-2,4,6-triiodo- 
benzenedicarboxamide) is non-toxic to cells, non-inhibitory to enzymes and iso-
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osmotic at all densities (Ford et al 1994) this reduces the potential for the 
dissociation or disruption o f apolipoproteins, that has been associated with salt 
gradient techniques, and allows the use o f gradient fractions for supplementary 
analysis without prior dialysis. The use o f  iodixanol has been adapted to further 
separate LDL into its principal subclasses. Davies et al (2003) have used self 
generated gradients o f iodixanol in near vertical rotors to generate LDL subclass 
profiles comparable with those generated by salt DGUC and GGE in run times o f 2h 
30min and 3 hours.
Drexel et al have shown HDL2  to be strongest predictor o f the extent o f coronary 
artery disease (Drexel et al 1992), however, the number o f  studies investigating 
associations o f HDL subclasses with CVD risk is relatively small. Despite this there 
is a general consensus that low total HDL cholesterol associated with increased CVD 
risk is primarily due to a reduction in reduction in the HDL2  fraction with little or no 
change in FIDL3 (table 3.2).
The use o f HDL subclasses in the assessment o f  CVD risk within large nutritional 
interventions and clinical trials has been limited by the arduous nature o f  the 
separation techniques. The aim o f  this study was to separate the principal HDL 
subclasses using a self-generated gradient o f  iodixanol. The objectives were to 
develop a procedure that resolves HDL subclasses in the same rotor and run time as 
that used for the separation o f  LDL subclasses (Davies et al, 2003); to ensure that the 
method is reproducible and suitable for high throughput analysis; and to validate the 
method by direct comparison with established GGE.
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Study Subjects Study Design HDL Subclass HDL Subclasses
__________________________________________________ Methodology______________________
Salonen et al 
1991
1799 randomly 
selected men aged 
42-60 years.
Baseline examination 
of a population study 
of eastern Finnish 
men (the Kuopio 
Ischemic Heart 
Disease Risk Factor 
Study)
Centrifugation at 
1.12kg/L. HDL2 
calculated by difference 
(total -  HDL3)
HDL2 had a significant 
inverse correlation with 
the risk of acute 
myocardial infarction.
Buring et al 
1992
340 case 
controlled pairs. 
Cases were 
Caucasian males 
and females <76 
years of age with 
first M I 
(confirmed by 
CK)
Case controlled study 
of patients
hospitalised with first 
MI, samples taken 8 
weeks post discharge.
Dextran sulphate 
precipitation 
(Gideze al 1982)
Cases had lower total 
HDL together with 
lower HDL2 and HDL3
Sweetnam et 
al
1994
Males 45-59 Caerphilly and 
Speedwell 
collaborative study.
Precipitation followed by 
ultracentrifugation of 
supernatant
HDL2 and HDL3 were 
inversely associated 
with ischemic heart 
disease, however, the 
association was 
strongest for HDL3
Williams et al 
1995
93 male subjects 
with
angiographically 
confirmed CAD 
but free from 
cigarette use, 
drugs affecting 
lipid metabolism 
and diabetes.
Baseline Data for the 
Stanford Coronary 
Risk Intervention 
Project
GGE (4-30%) using 
density< 1.20 Kg/L 
fraction followed by 
protein staining of 
subfractions
Significant inverse 
correlation of HDL 2a 
and 2b with fasting 
insulin and of 2b with 
BMI
Yu et al 
2003
2225 men from 
the Caerphilly 
cohort
1st re-examination of 
men recruited as part 
of the Caerphilly 
study.
Dextran sulphate 
precipitation (Gidez et al 
1982)
HDL3 was inversely 
associated with risk. 
CHD subjects had 
significantly lower 
HDL3 than controls
Asztalos et al 
2004
169 CHD 
1277 without 
CHD
Male participants of 
the Framingham 
offspring Study 
(1995-1998)
Two-dimensional non­
denaturing gel 
electrophoresis, 
immunoblotting and 
image analysis.
CHD subjects had 
significantly lower 
levels of a-1 particles 
compared to both non- 
CHD subjects and non- 
CHD HDL matched 
controls.
Asztalos et al 
2005
398 with previous 
CVD events 
1097 without 
(recruited from 
the VA-HIT trial)
Males recruited with 
a history of CHD. 
Placebo controlled 
parallel design.
Two-dimensional non­
denaturing 
electrophoresis
Subjects with new 
CVD events had lower 
HDL-C, apo Al and 
large HDL2
a-1 and a-2 HDL 
particles were 
significant negative 
risk factors for CVD.
Table 3.2: Studies investigating the relationship between HDL subclasses and CVD.
Variation in m ethodology and subject groups has produced disparity in the relationship 
between H D L subclasses and C V D  risk. Additionally, the methodologies used differentiate 
H D L subclasses based on different properties which may affect the interpretation o f  these
results
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3.2 Materials
A total o f  50 blood samples from normal, healthy male and female volunteers who, 
on the basis o f  their blood lipids, were expected to show a range o f  HDL subclass 
patterns, were used to establish optimal gradient conditions. These samples were also 
used to compare subclass patterns generated by IxDGUC and GGE. HDL subclasses 
were separated from a total o f  548 plasma samples from healthy volunteers to 
examine associations between HDL subclass profile and other plasma lipids and 
lipoproteins. Volunteers were members o f  university staff and subjects recruited for 
dietary inteivention studies. Blood was collected from fasted subjects by 
venepuncture into vacutainers containing IC2 EDTA, and plasma harvested by low  
speed centrifugation (2000g for 20mins at 4°C); Plasma was stored in 2ml aliquots at 
-80°C before analysis.
3.3 Methods
3.3.1 Development o f  a self-generated iodixanol gradient fo r  the separation o f  
HDL subclasses.
The methodology employed to separate HDL subclasses was based upon previous 
methods developed for the separation o f  total lipoproteins and LDL subclasses, as 
described by Graham et al (1996) and Davies et al (2003) respectively. In the method 
o f Graham et al, lipoproteins were separated using a two step gradient. Briefly, 5ml 
o f  serum, adjusted to 12.5% w/v with respect to iodixanol, was layered under 5ml o f  
6 % w/v iodixanol in tris-buffered saline (TBS) in a 11.2ml Optiseal tube, and topped 
with TBS. Tubes were then centrifuged in an VTi 65.1 vertical rotor at 33 000g(av) at 
16°C for 3h, using slow acceleration to 600rpm and 1 1 0  brake during deceleration.
Davies et al used the principles o f iodixanol DGUC described by Graham to separate 
subclasses o f LDL. In this technique a near vertical rotor was used with 11.2ml 
Optiseal tubes to separate LDL subclasses in a run time o f 3hours. The gradient used 
was a two-step gradient consisting o f  3 ml o f 12% pre-stained plasma, layered under 
7.9ml o f  a 12% (w/v) iodixanol solution in phosphate buffered saline (PBS). No
67
Chapter 3 -  Separation o f HDL Subclasses Using IxD G UC
additional PBS or iodixanol cushion was added to the tubes. Tubes were then 
centrifuged at 341 000g(av) for 3hours (NVT 65 rotor) using slow acceleration and 
deceleration.. While Davies et al also adapted this technique for the NVT 65.2 rotor, 
using 4.9ml Optiseal tubes and a mn time o f 2 hours and 30 minutes, 371 000g(av), , 
this modification was not validated in the original paper (validation data presented in 
Chapter 2). The method o f  Davies et al (2003) also employed a detection technique 
which used digital photography and gelscan software to identify LDL subclass 
profiles.
In the present study, the gradient was adapted to a 3-step gradient, reducing the 
volume o f  each layer and increasing the density. The rationale for this was to create a 
shallow gradient that would separate the principal HDL subclasses and still allow  
banding o f  plasma lipoproteins so as not to interfere with the HDL profile. In the 
method o f  Davies et al (2003), LDL subclasses were visualised using coomassie 
blue, to stain the protein component o f LDL, and tubes photographed and analysed 
using TotaLab Gelscan software. The presence o f other plasma proteins in the same 
density region as HDL, precluded the use o f  coomassie blue as a protein stain. The 
technique o f  Terpstra et al (1981), which uses Sudan black in a solution o f ethylene 
glycol to stain lipids, was modified and used as an alternative stain for HDL 
subclasses. As this method is similar to that o f  Davies in separating pre-stained HDL 
bands within the tube, the HDL subclasses could also be photographed with a digital 
camera and the images analysed with TotaLab software.
3.3.2 Preparation o f  the iodixanol gradient
The iodixanol gradient was a 3 -step gradient; the bottom layer was a 23% w/v  
iodixanol solution, the middle layer a 17.6% w/v solution o f plasma, iodixanol and 
stain whilst the top layer was a 15% solution o f iodixanol.
Plasma was mixed with Optiprep™ (iodixanol at 60% w/v) and either pre-stained 
with Sudan Black (80pL o f  2g/100ml in ethylene glycol) or non-stained (80pL o f  
PBS added in place o f  stain solution), to give a final concentration o f 17.6% (w/v) 
with respect to iodixanol. For example, plasma (1.4ml) was added to Optiprep™
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(0.6ml) and 80jj,L o f  Sudan Black or PBS to provide a working sample o f  2mls. The 
lower layer was prepared by mixing Optiprep™ with PBS to provide a 23% 
iodixanol solution (final density 1.118Kg/L). The upper layer was also prepared by 
mixing Optiprep with PBS; to give a 15% w/v iodixanol solution (final density 
1.108ICg/L).
To prepare the gradient, 1.7ml aliquots o f  the 15% iodixanol solution were dispensed 
into 4.9ml Optiseal centrifuge tubes, 1.5ml o f the pre-stained working sample was 
then carefully under-layered using a steel cannula and syringe. Finally, 1.7ml o f the 
23% iodixanol solution was under layered, again using a cannula and syringe. 
Centrifuge tubes were housed in a Beckman NVT 65.2 rotor and centrifuged at 
371 000g(av), 16°C, acceleration program 5, deceleration program 5, for 2h 30min in 
Beckman Optima L-100 and X L -100 ultracentrifuges.
J. 3.3 Measurement o f  gradient density.
In order to determine the density profile o f  the gradient, an unstained plasma sample 
was prepared and the gradient generated was fractionated into 200j.iL fractions using 
a labonco autodensiflow and Gilson FC203P fraction collector. The refractive index 
o f  each fraction was determined using a Bellingham Stanley DR -103 digital 
refractometer. In addition, a blank tube was marked at 200j.iL intervals 
corresponding to each fraction.
The refractive index was converted to density using the formula:
p = t |a  -  b
Where p = density
rj = Refractive index 
a = 3.4193 
b = 3.56
The derivation o f this formula is detailed in Chapter 2.
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These lion-stained fractions were also used to determine the apoprotein profile o f  the 
lipoprotein separation and to confirm the nature and position o f  the HDL classes 
using gradient gel electrophoresis.
HDL subclasses were detected using TotaLab ID gelscan software in the same 
manner as LDL subclasses (Davies et al 2003). Briefly, Optiseal tubes containing 
lipid stained HDL subclasses were photographed against a vertical light box using a 
Nikon D1X digital camera set at the highest resolution. Photographs were 
downloaded to a PC and R f values assigned to the HDL peaks. These R f values were 
then converted to density by cross reference to the densities assigned to fractions in 
an unstained tube. The software also calculated areas under the curve.
3.3.4 Analytical Performance
Blood samples (60ml) were taken from two fasted volunteers to examine the 
precision o f the HDL separation both within and between rotors. To examine intra- 
(within) rotor variability, 1 0  replicate profiles were prepared from these two 
individuals, an additional 1 0  replicates were prepared from the same individuals in a 
separate ran to examine inter- (between) rotor variability. Within rotor variability 
was also examined using four replicate HDL profiles for a males and females that 
exhibited a range o f  different HDL-C concentrations, and thus variable HDL 
subclass profiles.
3.3.5 Comparison with GGE
To validate the iodixanol method, HDL subclasses were co-isolated using an 
established GGE method. Plasma HDL subclasses were separated from 48 subjects 
by both iodixanol ultracentrifugation and GGE (as described in Chapter 2). This 
provided a quantitative (AUC) determination o f the correspondence between HDL 
subclass methods; lipid-stained HDL profiles on iodixanol gradients being compared 
directly with lipid-stained HDL profiles on gradient gel.
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3.3.6 Analysis o f  HDL fractions and plasma lipids
The 200(liL fractions o f  the HDL gradient were also analysed for their concentration 
o f total cholesterol, apo A-I and apo B using the SpACE autoanalyser and kits 
purchased from Randox, UK, as previously described (Chapter 2)
3.3.7 Statistics
All data was analysed using SPSS version 14 (SPSS Inc Chicago USA). All data was 
checked for normality using the Kolmogorov- Smirnov test, data that was not 
normally distributed was log or square root transformed. Differences between groups 
were assessed by one way analysis o f  variance. Associations o f  plasma lipids with 
HDL subclasses were assessed using Pearson’s correlation.
3.4 Results
3.4.1 Gradient Characteristics
The gradient produced was shown to be curvilinear, with an extended linear region 
between fractions 1-14 (Figure 3.1). The apoA-I profile showed a bimodal 
distribution which corresponded to the HDL2  and H D L 3  subclasses, as indicated by 
both IxDGUC and GGE. The cut-off density and corresponding R f for HDL2  was 
determined by the separation o f  the sample on GGE and IXDGUC and the separation 
o f both lipid and protein stained fractions on 4-30% PGGE.
The results from the unstained fractionated tubes showed the density cut-off between 
LIDL2  and H D L 3  to be set at -1 .059  kg/L. This value was then used subsequently in 
the analysis o f  HDL subclass distribution o f 48 subjects displaying a variety o f  
profiles.
71
Pixe
l I
nte
nsi
ty
Chapter 3 -  Separation o f HDL Subclasses Using IxD G UC
HDL2 HDL 3
Lipoprotein Top 5 6 7 8 9 10 11 12 13 14 15
HDL2
HDL3
HDL2 
HDL3 ----- ►
Protein Stained GGE (Coomassie Bl
Lipid Stained GGE (Sudan Black)
2
51
c41Q
Rf (mm)
ApoA1 Density IxDGUC Profile GGE Profile
Figure 3.1 Density gradient and distribution of plasma apoproteins. An unstained 
samples was fractionated into equal fractions of 200|FL. Apo A-I and density profiles are 
shown (red and blue respectively) together with PGGE (4-30%) for fractions 5-15. The HDL 
profile generated by iodixanol DGUC and TotaLab analysis is shown in purple, the 
equivalent profile from GGE is shown in orange. The apoA-I profile was bimodal and 
corresponded to the HDL subclass profile generated by IxDGUC and with the fractions run 
using GGE. Delineation occurred at a density of ~1,059Kg/L corresponding to an Rf of
0.52mm.
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3.4.2 HDL Heterogeneity in Iodixanol
HDL subclasses separated from pre-stained plasma displayed variability in banding 
patterns both within and between subjects. The HDL separated from pre-stained 
plasma o f eight individuals by IxDGUC and GGE are shown in Figure 3.2. There 
was clear evidence o f  variability in HDL subclass banding patterns between 
individuals, which were apparent in both methods. HDL profiles obtained by GGE 
and IXDGUC for these eight individuals were generally comparable but with some 
subtle differences (Figures 3.2 and 3.3). Profiles generated by gradient gel 
electrophoresis showed pronounced points o f  inflexion or ‘shoulders’ on the HDL2  
subclass in subjects with low HDL-C, these shoulders were not observed using 
IxDGUC.
The percentage area under the curve for both HDL2  and FIDL3 was determined for 48 
subjects using a density cut o ff o f  1.059kg/L. The percentage AUC for each subclass 
was compared to those o f  GGE for the same samples. There was a significant 
correlation between HDL subclasses for both GGE (lipid stained) and IxDGUC 
methods as measured by area under the curve [HDL2  r=0.896; P<0.01; HDL3 r=0.894 
p<0.01]. A linear regression analysis o f  the data is shown in Figure 3.4.
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Iodixanol profile GGE profile Iodixanol and GGE
overlaid profiles
Figure 3.3. IxDGUC and GGE profiles for eight subjects with varying total HDL-C.
Density profiles from IxDGUC are shown on the left, the centre column are GGE lipid 
stained profiles for the same subjects. Particle size was detennined using a set of protein 
standards of known molecular mass and diameter to calibrate the gel. The column on the far 
right depicts overlaid IxDGUC and GGE profiles
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Relationship between % HDL2from GGE and IxDGUC
30 40
% A U C  HDLz G G E
60
%AUC HDL3 GGE
Relationship between %HDL3from GGE and IxDGUC
Figure 3.4 Relationship of %AUC generated by GGE and IxDGUC. % HDL2 and % 
HDL3 generated by IxDGUC was significantly correlated with the %AUC as determined by 
GGE. [HDL2 r=0.896 (r2=80.2%) p<0.01, HDL3 r=0.894 (r2=79.9%) p<0.01]
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3.4.3 Relationship with other CVD biomarkers
The relationship between the percentage AUC and peak density for HDL2  were 
compared with other markers o f cardiovascular risk, including, plasma total 
cholesterol, LDL-C, HDL-C, apo A-I and LDL peak density. In the overall group o f  
548 subjects, HDL2  (AUC) correlated positively with total HDL-C, and apo A-I, and 
negatively with plasma TAG and LDL-C (table 3.3 and Figure 3.5a and 3.5b). There 
was no association with plasma total cholesterol.
Plasma lipids according to HDL subclass pattern (IxDGUC % HDLA
Plasma
Lipid/apoprotein
Pearson 
correlation [r]
P Pattern
I
>60% 
N= 105
Pattern
II
40-60%
N=161
Pattern
III
<40%
N=282
One way ANOVA 
between groups 
P
T-CHOL (mmol/L) -0.41 NS 5.63 5.60 5.62 NS
TAG (mmol/L) -0.348 <0.01 1.18 1.37 1.68 <0.0001
HDL-C (mmol/L) 0.571 <0.01 1.70 1.43 1.23 <0.0001
LDL-C (mmol/L) -0.149 <0.01 3.40 3.54 3.63 0.034
Apo A1 (g/L) 0.328 <0.01 1.38 1.22 1.13 <0.0001
Table 3.3. Correlation of % HDL2 with plasma lipids and apo A-I. Plasma lipids and 
apoproteins were correlated with % HDL2 measured by IxDGUC, samples were grouped 
according to patterns described by differing percentages of HDL2. n= 548
The percentage o f HDL2  was also inversely associated with percentage o f small 
dense LDL (sdLDL) and LDL peak density.
Unlike LDL, HDL subclasses have not been described in terms o f a phenotypic 
pattern. Table 3.5 shows a ‘K-means cluster analysis’ o f %HDL2. This technique 
identifies clusters in a large data set with the number o f clusters pre-defined. Each 
data point is assigned to its nearest cluster until cluster centres are detennined. In 
order to determine patterns o f low medium and high risk 3 clusters were chosen.
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Cluster
1 2 3
%HDL2 38.51 62.42 18.40
Table 3.4. K-means Cluster Analysis of % HDL2 with 3 clusters. The 3 centre clusters are 
the average of the data points in that cluster.
Cluster analysis indicates that HDL subclass patterns could be subdivided into three 
distinct patterns: Patterns ‘I* (>60% HDL2), TI’ (40-60% HDL2) and ‘III’ (<40% 
%HDL2). When grouped according to subclass pattern, significant differences were 
observed between groups for plasma TAG, HDL-C, LDL-C, and apoA-I. There was 
no difference observed for total cholesterol. Table 3.5.
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3.5A TAG vs % HDL,
r=-0.348, rJ=0.121 p<0.01 
n= S48
i20 OOIo oo
— I—20 00
r=0.308, r2=0.095 p<0.01 
n= 548
2 50 -
2 00 -
1 50
1 00 -
0 50 -
— I0 00
%HDL2 IxDGUC
Apo A l vs % HDL2
40 00 60 00
%HDL2 IxDGUC
Figure 3.5A & B Relationship of %HDL2 with plasma lipids and apoproteins.
3.5 A: %HDL2 was inversely correlated with plasma TAG (r=-0.44 [r2=0.121], p<0.01)
3.5 B: %HDL2was positively correlated with apoA-I (r=0.31 [r2=0.095] p<0.01).
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3.4.4 Reproducibility o f  HDL separation
Intra-(within) rotor variability: within rotor CVs for HDL2  (AUC), at two percentage 
levels, were 2.5% (HDL2=46%; p = 1.046Kg/L) and 3.93 % (HDL2=14% p=1.049). 
Inter-(between) rotor variability: there was non-significant variation in %HDL2  and 
peak density values from two subjects (peak densities 1.046kg/L and 1.064kg/L ). 
Between rotors variability for %HDL2  (2x10 %HDL2  = 46.88 ± 1 .1 7  versus 45.96 ± 
1.15 [ CV = 2.64%] and 2 xlO %HDL2  = 14.36+0.44 versus 14.52 ±0.54 [CV = 
3.73%]) the CV% for HDL peak density was 0.09% (p = 1.046kg/L) and 0.07 (p = 
1.064kg/L).
Within rotor CVs calculated from replicate (x4) HDL profiles, taken from four males 
and four females, was <4% and <1% for HDL2  (% AUC) and HDL2  peak density 
respectively (Table 3.5).
Subject Gender Total HDL-C % h d l 2 HDL2 peak CV CV HDL2 peak
(mmol/L) density h d l 2 density
DV 177 Male 1.3 5.59 1.055 3.77 0.06
AW 135 Female 1.3 25.86 1.052 3.43 0.25
RP 079 Male 1.6 28.14 1.050 1.55 0.03
TM 075 Female 1.2 32.87 1.050 2.13 0.08
DL 136 Male 1.6 38.62 1.043 3.98 0.03
MN 130 Female 1.3 62.70 1.045 1.21 0.10
KT 150 Male 2.2 69.59 1.035 1.73 0.14
MG 157 Female 2.1 70.12 1.032 1.10 0.10
Table 3.5. W ithin rotor variation. Within rotor variation for 8  subjects (4 males 
and 4 females) who displayed a range o f  HDL patterns and total-HDL
concentrations.
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3.5 Discussion
The concentration o f total plasma HDL cholesterol has been shown to be predictive 
o f CVD risk, even in the presence o f low total LDL-C (Gordon et al 1977). There is 
also a body o f  evidence which suggests that it is not only the quantity o f  HDL-C but 
also the quality that influences CVD risk. The number o f  studies that have 
investigated the impact o f  HDL subclasses on CVD risk is comparatively small and 
are often difficult to interpret due to the variety o f  techniques and definitions used. 
While methods for the measurement for HDL subclasses are labour intensive, time 
consuming and expensive, some o f the latest techniques including VAP-II auto­
profiling and proton NM R have overcome these problems, but these too are not 
without disadvantages. The VAP-II autoprofiling system has reduced 
ultracentrifugation time to 47minutes, though the method requires analysis o f  the 
cholesterol content o f  the gradient followed by the application o f  complex equations 
to quantify HDL subclasses. Proton NMR was described by two different groups in 
the early 1990s (Otvos et al 1992, Ala-Korpela et al 1994), NM R has the advantage 
o f requiring a small sample volume and being capable o f  high sample throughput. 
However, the equipment is expensive and the method cannot be used preparatively. 
The aim o f this study was to develop a rapid technique for the isolation o f  the 
principal HDL subclasses using iodixanol as a density media.
Iodixanol is an iodinated density media that is iso-osmotic and non-toxic to cells. 
Graham et al (1996) have described the separation o f lipoprotein classes using a two- 
step gradient o f  iodixanol. This method was further developed by Sawle et al (2002) 
who used an iodixanol gradient coupled with fractionation to identify the major 
lipoprotein classes together with the principal LDL subclasses. Davies et al (2003) 
developed this method further by designing a gradient that would specifically 
identify LDL subclasses. In this method plasma was pre-stained with Coomassie blue 
and tubes analysed by digital photography and gel scan software. The present HDL 
method used the principles o f  this LDL subclass separation to separate HDL 
subclasses. This method required the preparation o f  a 3-step gradient in which pre- 
stained plasma was “sandwiched” between two solutions o f  iodixanol with differing 
densities. Previous methods have used centrifugal separations followed by an elution
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o f  the gradient and continuous spectrophotometric detection o f  the separated 
fractions to generate lipid profiles, Davies et al used digital photography followed by 
gelscan software to generate LDL subclass profiles. The use o f  digital photography 
eliminates the need for time consuming fractionation, whilst also improving the 
reproducibility o f the method and was therefore adopted for the identification o f  
HDL subclasses.
The pre-staining o f plasma with a protein stain such as coomassie blue, has been 
used by others to visualise lipoprotein bands once separated, (Swinkels et al 1987, 
Davies et al, 2003). However, since HDL co-migrates with other plasma lipoproteins 
this made the use o f  protein stains unsuitable. To overcome this problem, a lipid- 
staining method first described by Terpstra (1981) using a solution o f  Sudan black in 
ethylene glycol was adapted and used to pre-stain plasma. Pre-staining with sudan 
black at physiological pH, followed by digital photography, produced profiles 
displaying HDL heterogeneity that was visible within both males and females, across 
a range o f  total plasma HDL-C concentrations. The percentage o f the principal HDL 
subclasses as measured by the AUC correlated well with the established GGE 
methods, profiles were on the whole very similar, but IxDGUC detected less HDL2  
in subjects with low HDL-C and predominantly small HDL3 compared to lipid- 
stained GGE. This may be, in part, due to the molecular sieving effect on 
electrophoretic gels that produces a greater resolution o f  HDL subclasses by GGE. 
Nevertheless, a spectrum o f  samples were analysed using IXDGUC and results were 
found to be significantly correlated with those o f  GGE.
To date no classification o f HDL subclasses has been defined in terms o f CVD risk. 
LDL subclasses on the other hand can be categorised into LDL phenotypes; three 
patterns exist and are distinguished based upon the percentage o f each LDL 
subclasses present (Austin et al. 1990):
S> Pattern A - Large buoyant LDL I and LDL-II
D Pattern B - More than 50% small dense LDL-III
D  Pattern I  - 40-50% small dense LDL-III
Pattern B is known to be a heritable trait and a characteristic o f an ALP, but its 
presence is also influenced by diet and in particular dietary fat, (Krauss 2001).
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sdLDL becomes the predominant subclass when plasma TAG concentrations exceed 
1.5mmol/L (Griffin et al 1994,). However, despite this change in LDL subclasses, 
the total LDL concentration usually remains constant. The classification o f LDL 
subclasses into phenotypes has been shown to have clinical utility as a risk marker, 
with LDL subclass pattern B being associated with a 3-fold increase in CVD risk 
(Austin et al. 1988). A  similar situation does not exist for HDL subclasses. In this 
study, subjects were separated according to the percentage HDL2  into the three 
patterns using K-means cluster analysis. When separated according to these patterns, 
subjects exhibited significant differences between total HDL-C, apo A-I and TAG. 
The elevated TAG in pattern III (mean 1.68mmol/L) supports previous obseivations 
o f  an inverse relationship between TAG and the abundance o f HDL2  (Syvanne et al 
1995, Xu and Fu 2003, Yang et al 2005), and suggests that elevated TAG not only 
increases the predominance o f  sdLDL but also that o f smaller dense HDL3. While the 
three patterns o f  HDL subclasses displayed differences in some lipids and 
apoproteins, there were no significant differences between groups for total 
cholesterol, supporting previous studies that have shown an increase in the 
prevalence o f sdLDL at TAG concentrations greater than 1,5mmol/L with no change 
in total cholesterol concentration. Previous reports have defined an atherogenic 
lipoprotein phenotype (ALP) as a cluster o f  elevated plasma TAG, low HDL-C and a 
predominance o f  sdLDL (Austin 1990) The correlation between HDL2  plasma TAG 
and sdLDL suggests that a predominance o f  HDL3 should also be included in the 
definition.
Without a definitive classification o f HDL phenotypes, the validation o f IxDGUC in 
terms o f its ability to predict increased CVD risk is limited. IxDGUC is rapid, 2h 
30min in the NVT 65.2 rotor and reproducible. The centrifugation parameters used 
are the same as those described for the NVT 65.2 and separation o f  LDL subclasses, 
thus giving the added advantage o f  being able to determine both LDL and HDL 
subclass profiles simultaneously. This should be advantageous in determining CVD 
risk, particularly in groups with “normal” concentrations o f  total plasma and LDL 
cholesterol. In summary this method provides a rapid, high throughput and cost 
effective technique for the detection o f the principal HDL subclasses which can also 
be used preparatively to isolate HDL2  and HDL3.
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CHAPTER 4 - THE RISCK  STUDY
Abstract
Background
The metabolic syndrome (MetS) is a clustering o f risk factors which is estimated to affect ~20% 
o f the UK population. Dyslipidaemia associated with MetS includes elevated TAG, low HDL-C 
and a predominance o f sdLDL which are typical o f an atherogenic lipoprotein phenotype. The 
modification o f dietaiy fat and carbohydrate has been shown to produce variable effects on 
lipid mediated CVD risk factors. Thus, there is no current consensus in terms o f the optimal diet 
to reduce CVD risk associated with this condition.
Study Aim and Hypothesis_________ ______________ _____________________
The removal o f saturated fat from the diet has been shown to produce favourable effects on 
serum lipids. However, the removal o f  SFA as part o f a weight maintenance diet necessitates a 
need to increase either dietary carbohydrate or unsaturated fatty acids. The aim o f the current 
study was to identify the optimal diet, in terms o f the type and amount o f dietaiy fat and 
carbohydrate, for the reduction o f lipid mediated CVD risk in subjects at risk o f the MetS. The 
worldng hypothesis was that the replacement o f SFA with MUFA either with or without a 
reduction in total fat intake, would increase insulin sensitivity and correct dyslipidaemia o f 
MetS,
M ethods  ______ _______________________ ____________________________________
Subjects at risk o f the metabolic syndrome were identified with a screening tool that scored the 
risk o f developing MetS according to insulin sensitivity, dyslipidaemia, body composition and 
blood pressure. 548 subjects were recruited and randomly allocated to one o f five diets: a 
control diet (Diet A), a diet high in MUFA with either high (Diet B) or low (Diet C) GI 
carbohydrate and a low fat diet with either high (Diet D) or low (Diet E) GI carbohydrate (Diet 
E). Subjects followed a one month run in diet (diet A) and then attended the centre for baseline 
measurements. Subjects then followed their allocated diet for six months before returning to the 
centre for final measurements.
Results ______________ ___________ ___________________
The overall dietary targets for each intervention group were achieved. All diets resulted in a 
significant and equal reduction in HDL-C compared to control, though in both high MUFA 
(B&C) and low fat (D& E) diets this was accompanied by significant and equal reductions in 
total and LDL cholesterol. There were no changes in serum TAG, or the relative abundance o f  
sdLDL and HDL2, with the exception o f the high MUFA diet (Diet B) in which there was a 
significant increase in sdLDL and LDL peak density. The low fat, low GI diet (Diet E) was 
associated with a significant improvement in insulin sensitivity in all subjects, while HOMA-IR 
was significantly improved in the low fat diet with a higher GI in females alone.
Conclusions ______ ___________ _____ _________________________________
The present study aimed to identify the optimal diet in terms o f dietary fat and glycaemic index 
for amelioration o f lipid mediated CVD risk in subjects at risk o f MetS. All diets, with the 
exception o f the control diet, produced similar favourable effects on serum lipids, suggesting 
that the replacement o f SFA with MUFA had a beneficial outcome on atherogenic 
dyslipidaemia, regardless o f changes in total fat and carbohydrate. Diet E, low fat low GI, 
resulted in significant weight loss and a significant improvement in HOMA-IR. Without equal 
weight loss in the high GI group it is not possible to determine whether the improvement in 
insulin sensitivity was due to the type o f CHO or energy restriction. These findings suggest that 
a reduction in body weight and central adiposity is o f primary importance in reducing CVD risk 
associated with MetS and that the dietary regimen followed to attain this goal may be 
insignificant unless it includes energy restriction.
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4.1 INTRODUCTION
4.1.1 Background
The metabolic syndrome (MetS) can be described as a clustering o f  CVD risk factors 
which includes insulin resistance, central obesity (elevated waist circumference), 
elevated blood pressure and dyslipidaemia. While the concept o f  MetS as a 
collection o f  risk factors has been known since the 1920s (ICylin 1923), there has 
been much debate over the classification o f  MetS that has led to disparity in its 
definition. The absence o f  a universal definition o f  the metabolic syndrome together 
with differences according to ethnicity and gender, has made it difficult to estimate 
its prevalence. Current estimates suggest that the prevalence o f MetS is around 20% 
in UK Caucasian populations, yet the prevalence may be as high as 46.3% in South 
Asian males as defined by the WHO criteria (Tillin et al. 2005). In the USA  
estimates based on the IDF and NCEP ATP III criteria are between 35 and 40% 
(Ford 2005). Despite differences in the characterisation o f MetS, a number o f  
components are central to all criteria, namely insulin resistance, elevated waist 
circumference, low HDL-C and elevated serum TAG.
Qiao et al calculated an overall hazard ratio o f  1.6 as an estimate o f increased CVD 
risk in the MetS using the NCEP ATP III criteria (Qiao et al, 2007). However, 
hazard ratios ranged from 1.09 to 2.09 depending on criteria and gender (Qiao Q et 
a l  2007). In light o f the increased CVD risk associated with MetS, a number o f  
therapeutic strategies have been investigated which aim to reduce risk by correcting 
one or more CVD risk factors.
4.1.2 Dyslipidaemia o f  Metabolic Syndrome
The increased CVD risk attributed to MetS is partly due to the associated 
dyslipidaemia. The dyslipidaemia o f  MetS is thought to begin in childhood (Kohen- 
Avramoglu et a l  2003) and consists o f  an atherogenic lipoprotein phenotype (ALP). 
An ALP is characterised by elevated serum TAG, low HDL-C and a predominance 
o f  sdLDL. All o f  which, either individually or in combination, have been shown to 
confer increased risk o f  CVD.
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The attention given to lipid-mediated risk reduction in MetS has tended to focus on 
decreasing the concentration o f serum TAG, since this represents a major 
determinant o f  the abnormalities found in LDL and HDL (Griffin 1994). While the 
success o f pharmacological intervention with statins to lower total and LDL-C is 
well documented , the evidence base for the effects o f  drugs such as fibrates and 
nicotinic acid on serum TAG and HDL-C is less well established. The side effects 
associated with such drugs together with economic cost creates a need to develop 
dietary strategies in the o f  primary prevention o f  CHD risk associated with MetS.
4.1.3 Dietary strategies fo r  the correction o f  dyslipidaemia in MetS
The cholesterol-raising properties o f  SFA are well established. Keys and Hegstead 
independently identified SFA as a hypereholesterolaemic fat, whilst MUFA and 
CHO had relatively neutral effects on total cholesterol (Keys et al 1965, Hegstead et 
al 1965). A wealth o f  evidence from both epidemiological and intervention trials 
supports the hypothesis that a reduction in dietary SFA improves the serum lipid 
profile and consequently has favourable effects on CVD risk. In addition, there is 
evidence to suggest that the removal o f  SFA from the diet not only improves 
dyslipidaemia but also increases insulin sensitivity when it replaced by unsaturated 
fatty acids (Vessby et al 2001, Perez-Jimiez et al 2001, Summers et al 2002). A  
recent factor analysis o f serum fatty acids identified a significant difference in SFA 
between subjects with and without MetS as defined by the NCEP, suggesting that the 
quality o f dietary fat has an important role in the development o f  MetS (Warensjo et 
al 2006).
In a situation where body weight is maintained, the removal o f  SFA from the diet 
often results in an increase in the percentage energy provided by dietary 
carbohydrate or unsaturated fatty acids. However, there is still debate as to which o f  
these has the most beneficial effect on lipid mediated CVD risk.
©
Monounsaturated Fatty Acids
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Intervention studies that have addressed the impact o f the substitution o f  SFA with 
MUFA have demonstrated significant reductions in the concentration o f  both total 
and LDL cholesterol with maintenance o f  HDL cholesterol. Alternatively, while the 
replacement o f  SFA with dietary CHO has also been shown to decrease LDL 
cholesterol, it elicits an increase in serum TAG and reduction in HDL cholesterol 
and consequently an increase in CVD risk (reviewed by Parks and Hellerstein 2000). 
Intervention studies that have directly compared diets enriched with MUFA with low  
fat high CHO diets, have shown either no effect or in some cases a reduction in 
serum TAG following a high MUFA diet. Grundy et al (1986) examined the effects 
o f  a liquid diet that was either high in SFA, MUFA or CHO as part o f  a 4 week 3 
way crossover study. Both high MUFA and high CHO diets reduced total and LDL- 
C compared to the high SFA diet. Though, these reductions were o f  a greater 
magnitude following the high MUFA diet. The low fat, high CHO diet also induced 
a reduction in HDL and increase in serum TAG that was not observed in the MUFA 
leg (Grundy et al, 1986). A  study in females by Colquhoun et al (1992) 
demonstrated no effect o f  a low fat diet on either total or LDL cholesterol and TAG, 
yet there was a significant reduction in HDL-C. On the other hand, a diet high in 
MUFA (20% energy) reduced total and, LDL-cholesterol and apo B but had no 
effect on HDL-cholesterol (Colquhourn et al 1992)
Tanasecscu et al (2004) have concluded that the replacement o f  SFA with MUFA 
may be more effective in reducing CVD risk. Data from the Nurses’ Health Study 
has estimated that replacement o f  5% energy from SFA with MUFA lowers CVD 
risk by 27%, while the equivalent replacement with CHO was only associated with a 
22% reduction in risk. (Tanasecscu et al 2004)
It has also been suggested that dietary MUFA may improve glycaemic control in 
type 2 diabetics (Ros 2003). Intervention studies have demonstrated a beneficial 
effect o f  MUFA on insulin resistance, a metabolic abnormality common to all 
definitions o f  MetS. An intervention study with insulin therapy in NIDDM by Garg 
et al showed a significant reduction in fasting glucose and insulin requirement 
following a high fat, high MUFA (33% energy) diet (Garg et al, 1988). More 
recently, Perez-Jiminez et al (2001) showed an increase in insulin sensitivity in 
response to a high MUFA diet, thus confirming earlier observations made by
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Vessby et al (2001) in the KANWU study, though, this effect was only observed in 
subjects with a mean dietary fat intake o f  <37% o f total energy.
Glycaemic Index
Studies that have demonstrated a potentially negative effect o f  low fat high CHO 
diets on CVD risk have in general failed to describe or take into account the quality 
o f  dietary CHO. Carbohydrates may be classified according to their structure or by 
the postprandial glucose response that they elicit. It has been proposed that foods 
with a low glycaemic index produce favourable effects on CVD risk factors (Jenkins 
et al 1985, Jenkins et al 2002). Observational studies have demonstrated an inverse 
relationship between glycaemic index and HDL-C concentration (Frost et al, 1999). 
Intervention studies have produced inconsistent results with respect to the effects o f  
GI on serum lipids. Jenkins et al demonstrated a significant reduction in total 
cholesterol, LDL-C and TAG concentrations following a 4- week intervention with a 
low GI diet, as compared to a diet with a high GI (Jenkins et al 1987). Sloth et al 
(2004) also demonstrated a similar effect o f  a low GI diet on total and LDL-C in 
overweight women following a 10 week intervention (Sloth et al 2004). In contrast, 
Frost et al, demonstrated no effect o f  a low GI diet on serum lipids following a 12 
week intervention in patients with CHD, (Frost et al 2004).
Additional beneficial effects o f  low GI CHO in risk associated with MetS include 
markers o f insulin resistance. Dietary interventions, in subjects with varying risk o f  
CVD, have shown an improvement in fasting insulin or HOMA-IR following the 
consumption o f  a low GI diet (Dumesnil et al 2001, Pereira et al 2004, Brynes et al 
2003). GI has been positively associated with the risk o f T2DM in prospective cohort 
studies (Hodge et al 2004, Salmeron et al 1997b, Schultze 2004).but other studies 
have failed to show a relationship between GI and insulin sensitivity (Liese et al 
2005, van Dam et al 2000).
The substitution o f  SFA with MUFA or CHO has been associated with a reduction in 
both total and LDL-C. However, in some studies low fat diets that are high in CHO 
have also been associated with a reduction in HDL-C and an increase in serum TAG 
nevertheless in such studies only the quantity o f the CHO and not quality was
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described. Diets containing CHO with a low GI have demonstrated favourable 
effects on both serum lipids and insulin sensitivity. In light o f  this evidence it has 
been suggested that a diet high in MUFA with a low GI may help to preseive insulin 
sensitivity and reduce the risk o f  type 2 diabetes (Hung et al 2003)
4.2 AIM S AND OBJECTIVES
The aim o f the RISCK study was to investigate the effects o f  changing the type and 
amount o f dietary fat and carbohydrate on insulin sensitivity and the lipid mediated 
cardiovascular disease risk associated with the metabolic syndrome.
The principal hypothesis was that the substitution o f dietary SFA with MUFA, with 
either high or low background intakes o f  fat, will improve insulin sensitivity and 
correct the dyslipidaemia associated with MetS. Secondly, that the positive effects o f  
this dietary modification o f  CVD risk factors will be further improved by a diet with 
low GI carbohydrate.
The objectives were to screen and recruit volunteers at risk o f  developing MetS for a 
dietary intervention study and to develop a control diet, representative o f the current 
UK average, and four test diets that will test the combined effects o f  substituting 
SFA for MUFA at 38% and 28% total energy as fat, and high and low GI 
carbohydrates. Subject would then follow the control diet for four weeks before they 
were randomised to one o f the five diets for a period o f six months.
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4.3 M ATERIALS AND METHODS
4.3.1 Biochemical Analysis
All biochemical measurements for the initial screening o f  volunteers, and 
apolipoprotein B, apo A-I, LDL subclasses and HDL subclasses at baseline and after 
6  months were determined at the University o f  Surrey using methods previously 
described in either Chapters 2 or 3 (HDL subclasses). Baseline and end-point 
measures o f  serum lipids and insulin sensitivity were completed at Kings College 
London and HNR-MRC-Cambridge respectively (Chapter 2).
4.3.2 Body Composition
Body composition was measured at each centre using standardized techniques as 
detailed in Chapter 2.
4.3.3 Blood Pressure
Blood pressure was determined at each centre using an automated digital 
sphygmomanometer and taken as the mean o f  three measurements.
4.3.4 Subjects
Male and female subjects aged 30-70 years were recruited, from newspaper 
advertisements and from general practices at each o f the five centres (Reading, 
Imperial, Surrey, HNR-MRC-Cambridge and Kings College London). Volunteers 
completed an initial screening questionnaire and, providing they did not meet any o f  
the exclusion criteria (Appendix I), were invited to attend a screening visit. At the 
screening visit a number o f  measurements were taken including; height, weight, 
waist circumference and blood pressure. Participants also provided a 20ml fasting 
blood sample for the measurement o f  plasma glucose, total-cholesterol, HDL-C and 
TAG. Subjects were then scored using the RISCK MetS criteria and the information 
collected at screening (Figure 4.1).
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Screening criteria
Score> 4 to enter the 
study 
(max 10)
Figure 4.1 RISCK Screening Criteria. To be classified as at risk of the metabolic 
syndrome subjects were required to score 4-10 points based on the screening criteria.
4.3.5 Study Design
The RISCK study was funded by the Food Standards Agency (ISRCTN29111298). 
The study was o f  a single-blind, parallel design in free living subjects, and was 
conducted at five centres across the UK. The study received MREC approval on the 
30th April 2004 (MREC 04/ MRE01/2). A minimisation programme (MINIM-1 
supplied by MRC-HNR), which controlled for gender, age, waist circumference and 
HDL cholesterol, was combined with the randomisation procedure to assign subjects 
to one o f  the five intervention diets. Four experimental diets (B-E) were compared to 
a control diet (A), these diets differed in the quantity o f total fat and composition o f  
fatty acids (SFA versus MUFA) and total carbohydrate and its composition (high GI 
versus low GI) [table 4.1].
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UK Average Intervention Diets
Male Female Diet A Diet B Diet C Diet D Diet E
[High 
SFA, high 
GI CHO]
[High
MUFA, high 
GI CHO]
[High
MUFA, low 
GI CHO]
[low fat, 
high GI 
CHO]
[low fat, 
low GI 
CHO]
% Energy as
Total Fat 33.7 33.9 38 38 38 28 28
SFA 12.6 12.8 18 10 10 10 10
MUFA 11.3 11 12 20 20 11 11
PUFA 5.9 6.1 6 6 6 6 6
Carbohydrate 44.6 46.6 45 45 45
(11 GI point 
lower than 
diet B)
55 55 
(13 GI 
points lower 
than diet D)
Table 4.1 RISCK intervention diets. The composition of the intervention diets, in terms of 
percentage energy intake of fat and carbohydrate, together with the type of carbohydrate, 
compared with UK mean intakes assessed by the NDNS 2003.
The diets were designed to assess the impact o f dietary fat and carbohydrate on 
various risk factors associated with the metabolic syndrome. In order to achieve the 
required dietary changes, subjects were provided with specific study foods including 
fats/oils, carbohydrate and snacks (Appendix I). All products, with the exception o f  
oils and spreads, were commercially available. Fat and oils were formulated and 
manufactured by Unilever to meet the specific compositions required to achieve the 
desired changes in dietary fat (the composition o f fats and oils used are detailed in 
Appendix I). Subjects collected batches o f  foods on a fortnightly basis, (cooking 
fats/oils and staple carbohydrates (potatoes, rice, and pasta) in sufficient quantities 
for the household).
All subjects completed a run-in period o f one month during which they followed diet 
A (control diet). After this run-in period, subjects returned to the centre for baseline 
measurement and intra-venous glucose tolerance test (IVGTT). Subjects were then 
randomised to one o f  the five experimental diets for six months, after which they 
returned to the centre for assessment and IVGTT.
92
Chapter 4 -  The RISCK Study
Dietary advice was provided on a one to one basis, for each separate diet before the 
run-in and intervention periods. Dietary compliance was also monitored at each food 
collection, and subjects provided with a standardized written dietary guidelines 
(Appendix I)
4.3.6 Compliance
Habitual dietary intake and dietary compliance to the intervention was assessed by 
the completion o f four-day food diaries (FD) at intervals throughout the study. 
Subjects were asked to record all food and drink consumed over three week days and
one weekend day. FD1 and FD2, habitual and run in diaries respectively, were
returned and briefly assessed at the baseline visit to determine the quality o f  the 
initial information provided. FD3 was returned and assessed at the final study visit 
(post-intervention) [figure 4.2]. All diet diaries were coded and analysed at MRC- 
Cambridge.
■ FD1 = - 6  week habitual diary
■ FD2 = -2 week (run in diet diary)
■ FD3 = 24 week diary (intervention diet diary)
FD1 FD 2
- A _ J L
FD 3
| | Run in (diet A high SFA, High GI)
Intravenous g lu cose  tolerance test, and fasting m easurem ents  
(0 and 24  w eek s)
24 w eek  intervention diet A, B, C, D or E
Figure 4.2. RISCK Study Design. Habitual diet together with compliance to the run in and 
intervention diets was assessed using 4 day food diary at intervals throughout the 24 week
intervention.
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4.3.7 Statistical Analysis
Baseline data was screened for outliers according to the screening criteria. Subjects 
with values outside a range of ±3SD for glucose, insulin, body weight, BMI, blood 
pressure, HDL-C and TAG were removed from the analysis, as were subjects with a 
mean fasting glucose of greater than 7mmol/L.
Data was screened for normality using the Shapiro-Wilks test and then log or square- 
root transformed where necessary, and the normality re-checked. HDL-C was not 
normally distributed following transformation and was assessed using non- 
parametric tests.
Differences between groups at baseline and end point were assessed using a one way 
ANOVA. Within group differences between gender or time point were assessed 
using paired t-test. Kruskal-Wallis and Mann-Whitney U tests were used as non 
parametric equivalents to a one way ANOVA and paired /-test respectively. 
Associations between variables were assessed using Pearson’s and Spearman’s 
correlations for parametrically and non-parametrically distributed data respectively.
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4.4 RESULTS
A total of 547 subjects completed the study but only 492 were included in the 
analysis after the removal of outliers.
4.4.1 Baseline Characteristics
Baseline anthropometric data is shown in table 4.2. The overall mean age was 52.1 
years; this did not differ significantly between dietary groups or between genders. 
No significant differences were observed between dietary groups for body weight, 
BMI, waist circumference or blood pressure. There were, however, differences 
within dietary groups between genders. Overall males had significantly higher body 
mass than females, 88.1kg and 75.9kg respectively. Likewise males exhibited greater 
waist circumference, systolic and diastolic blood pressure
There were no significant differences in baseline fasting lipids between groups; 
HDL-C was greater in females compared to males in all groups and TAG elevated in 
males.
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Diet A Diet B DietC Diet D Diet E
Male
N=33
Female
N=44
Male
N=39
Female
N=61
Male
N=43
Female
N=57
Male
N=46
Female
N=59
Male
N=43
Female
N=67
Age 53.2 51.5 53.2 52 51.5 52.9 53.5 52.4 52.3 49.5
(years) (±10 .2) (± 8 .3 ) (±10 .6) (±10 .2) (±9 .3 ) (±9 .9 ) (±11 .1 ) (±9 .5 ) (±10 .1) (±8 .8 )
Body Weight 87.4 73.7** 84.6 84.6* 91.4 74 4** 89.9 75.6** 86.8 78.4**
(Kg) (±10 .4) (±13 .5) (±11 .3) (±11.3) (±11.3) (±13.8) (±13 .4) (±12.0) (±10 .8) (±13 .7 )
BMI 28.5 27.7 27.1 27.1 29.4 27.9* 29.3 28.3 28.1 29.2
(Kg/m2) (±3 .4 ) (± 4 .1 ) (±3 .1 ) (±3 .1 ) (±3 .9 ) (±4 .3 ) (± 4 .0 ) (±4 .2 ) (±2 .6 ) (± 5 .1 )
Waist 100.9 93.7* 100.3 94.4* 102.6 g] 9** 102.4 93.8** 101.6 94.5**
Circumference
(cm)
(±9 .6 ) (±11 .4) (± 8 .0 ) (±13 .0) (±10.1) (±10.3) (±11 .1) (±11.1) (± 8 .1 ) (±11 .7 )
Systolic Blood 138 120** 128 123 133 127* 133 128* 135 123**
Pressure
(mmHg)
(±16 .4 (±1 1 ) (±16) (±13) (±14 ) (±15) (±14) (±16) (±13 ) (±1 5 )
Diastolic 84 75** 80 77 81 76* 82 78* 83 78*
Blood
Pressure
(mmHg) __
(± 9 ) (± 9 ) (± 9 ) (± 9 ) (± 9 ) (± 9 ) (±1 0 ) (± 9 ) (± 8 ) (±10)
Table 4.2. Baseline anthropometric measurements.
There were no between group differences for gender, however, significant within group 
differences were observed for body weight, waist circumference and blood pressure. Values 
are mean±standard deviation. *P<0.05**p<0.01 significant difference within group
between gender
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4.4.2 Dietary Information
Changes in dietary intakes during a one month run in
All subjects followed diet A during the run in period of one month. Diet A was high 
in both total fat and the contribution of SFA to energy intake therefore it was 
important to assess any changes in serum lipids that may be induced by the run in 
period. Habitual dietary information and dietary intake following the one month mn 
in are shown in table 4.3. There were no significant differences between groups pre 
or post mn in. However, there was a significant increase in total fat and SFA in all 
diet groups and in the total group, 6.6% and 26.6% increases respectively. In the 
whole group there were also significant reductions in the percentage energy from 
carbohydrate and PUFA. The proposed intake of percentage energy as total fat, 
MUFA, PUFA and carbohydrate was achieved, and the percentage energy as SFA 
approached the planned intake. The average GI of the carbohydrate consumed during 
the mn in period was 61 (high GI), this did not differ from the GI of the carbohydrate 
habitually consumed.
Chapter 4 -  The RISCK Study
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The influences o f a one month run in on serum lipids
The impact o f  the ran in diet on serum lipids was assessed in a small sample 
population from the University o f  Surrey. 26 subjects were chosen at random from 
the first 60 to complete the study. Seram samples taken at screening and baseline 
were stored at -80°C prior to simultaneous analysis o f lipids. Follow ing the one 
month ran in period w ith  diet A  there were small but insignificant reductions in total, 
L D L  and H D L  cholesterol and in serum TAG  (figure 4.3). No significant differences 
were observed in blood pressure and anthropometric measures (table 4.4)
KJ.KJKJ
T-CHOL LDL-C HDL-C TAG
■  Screening 6.84 4.35 1.69 1.77
■  Post Run In 6.40 4.08 1.55 1.70
Figure 4.3 Changes in serum lipids following a one month run in with diet A.
26 subjects were selected at random from the first 60 participants and screening and 
post ran in samples analysed simultaneously. No significant differences in serum 
lipids were observed pre and post ran in. Bars represent mean ±SEM
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Screening Post Run In
Age (years) 58.5
Weight (kg) 77.22 (±15.10) 76.70 (±15.75)
BMI (kg/m2) 27.44 (±4.34) 27AT (±4.64)
Waist Circumference (cm) 93.3 (±13.51) 93.28 (±13.45)
Systolic BP (mmHg) 141 (±20) 136 (±17)
Diastolic BP (mmHg) 87 (±12) 81 (±8)
Table 4.4. Changes in Anthropometric and blood pressure measurements 
following a one month run in with diet A. Values are mean± standard deviation.
Changes in dietary intakes pre and post intervention
At baseline (visit B) there were no significant differences in dietary intake between 
groups.
The proposed and achieved macronutrient intake for each o f the dietary interventions 
is shown in table 4.5. The percentage energy as total fat was achieved in diets A, D 
and E whilst the intake in diet C and B approached the proposed percentage. SFA 
targets were achieved in all groups with the exception of the control group (diet A) 
where SFA contributed a lower percentage of total energy than proposed. The 
percentage energy from MUFA was increased in diets B and C compared to the 
control and low fat interventions, however, the achieved intake was lower than that 
proposed. The increased CHO intake resulting from a decrease in the percentage 
energy from total fat in diets D and E were achieved, 53 and 55% respectively.
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Percentage Energy
Diet Total Fat SFA MUFA PUFA CHO GI
A
Proposed 38 18 12 6 45
Achieved 38 (±6) 16 (±3) 12(13) 6 (±2) 44 (±8) 65 (±4)
B
Proposed 38 10 20 6 45
Achieved 36 (±7) 10 (±3) 16 (±5) 7 (±2) 47 (±7) 63 (±4)
C
Proposed 38 10 20 6 45
11 points 
lower than
Achieved 34f±6) 9 (±3) 16 (34) 1(32) 48 (±7) B
55 (±4)
D
Proposed 28 10 11 6 55
Achieved 21 (±7) 9 (±3) 10 (±3) 5 (±2) 53 (±9) 65 (±4)
E
Proposed 28 10 11 6 55
13 points 
lower than
Achieved 26 (±6) 8 (±3) 9.5 (±3) S(±2) 55 (±8) D
56 (±3)
Table 4.5 Proposed and Achieved Macronutrient Intakes.
Values are mean +standard deviation
Baseline and endpoint dietary data together with the percentage change are shown in 
table 4.6. At baseline there were no significant differences between groups.
Differences in the type and amount o f dietary fat and carbohydrate at 24 weeks are 
shown in figures 4.4 and 4.5. At 24 weeks diets B, C, D and E were significantly 
different from the control diet (diet A) in the percentage energy from total fat, SFA, 
MUFA. The percentage energy from MUFA was significantly lower in diet A 
compared to all diets, however, the contribution of MUFA to total energy was 
significantly higher in diets B and C compared to A, D and E (p<0.01)No significant 
differences were observed in the percentage energy from PUFA.
The percentage energy from carbohydrate in diets C, D and E was significantly 
different from the control diet (diet A). Percentage energy from CHO in diets D and 
E was also significantly greater than diets B and C. The GI of the carbohydrate in 
diets C and E was significantly lower compared to diets A, B and D (p<0.01).
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Figure 4.4 Endpoint Differences in the Type and Amount of Dietary Fat and 
Carbohydrate. Panel A shows differences in dietary fat. The contribution of MUFA as 
percentage energy was significantly higher in diet B and C. The percentage energy from 
total fat was significantly lower in diet D and E. Panel B shows end point differences in 
the contribution of CHO to percentage energy and the average GI of the carbohydrate 
consumed. The contribution of CHO to percentage energy was significantly higher in diets 
D and E. The average GI was significantly lower in diets C and E. * significantly different 
from control diet (A) p<0.0. f  significantly different from diets B and C p<0.01  Boxes 
represent the inter-quartile range (50% of cases), whiskers the smallest and largest values. The median
is shown as a black line within the box
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Figure 4.5 Dietary Intakes of Individual Saturated and Unsaturated Fatty Acids.
1 =  Significant Difference between groups, 2 =  significant difference between control and 
treatment groups, 3= Significant difference between high MUFA diets (B& C) and low fat 
diets (D&E) 4= Significant difference between diets B and E 5 = Significant difference 
between B&C. Boxes represent the inter-quartile range (50% of cases), whiskers the smallest and 
largest values. The median is shown as a black line within the box
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4.4.3 Changes in Components o f the RISCK MetS screening criteria
When data was analysed as a whole i.e. males and females together no differences in 
end point measurements of components of the RISCK MetS screening criteria were 
observed between groups (Table 4.7).
Body weight remained stable in subjects following diets A and C, however, there 
were significant reductions in body weight in subjects following diets B, D and E 
(-0.8, 0.9 and 1.6% respectively). The increased weight loss in subjects following 
diet E translated into a significant reduction in waist circumference of 1.4cm
(p<0.01).
Diets C and D had favourable effects on systolic blood pressure (p<0.05), however 
there were no significant changes in diastolic blood pressure.
Plasma glucose was reduced by 2% in diets B (p<0.05), C and D (p=<0.01) with the 
reduction in diet E (1.3%) approaching significance (p=0.082). The reduction in 
plasma glucose in diet D was accompanied by a significant 3.8 % reduction in 
fasting plasma insulin (p<0.05). Although the reduction in plasma glucose in diet E 
only approached significance there was a significant concomitant reduction in fasting 
insulin of 6% in this diet (p<0.05).
There was a significant reduction in HDL in all diets and no significant changes in 
serum TAG
When subjects were separated by gender, females exhibited no significant 
differences in any of the CVD risk factors included in the definition of MetS. Males, 
on the other hand, showed significant differences between diets for plasma glucose 
and body weight (p=0.003and 0.026 respectively). Post hoc analysis showed end 
point fasting glucose concentrations to be significantly higher in diet D compared to 
diet A and E. Body mass was also significantly higher at end point in subjects 
allocated diet B compared to diet C.
Additionally no significant differences were observed in total groups for total and 
LDL cholesterol.
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4.4.4 Changes in HOMA-IR as a m arker o f  insulin sensitivity
At baseline there were no significant differences in HOMA-IR between intervention 
groups. There were no significant differences between groups at endpoint, however, 
within group comparisons identified a significant reduction in HOMA-IR in diet E. 
Factorial analysis identified a significant main effect of gender, with a significant 
reduction in HOMA-IR in females in diet D. There was an increase in HOMA-IR in 
males following diet A which approached significance (p=0.093). However, there 
was no diet x time or gender x diet interaction. HOMA-IR at baseline and endpoint 
are shown in table 4.8. Differences in response according to gender are shown in 
figure 4.6.
Diet Baseline HOMA-IR Endpoint HOMA IR pTT
Total Male Female Total Male Female Total Male Female
A 2.04 2.12 1.98 2.19 2.18 2.02 .134 .093 .662
(±0.99) (±0.98) (±0.99) (±1.26) (±1.12)
B 2.09 2.21 1.99 2.08 2.17 2.13 .515 .670 .394
(±0.93) (±0.91) (±0.94) (±0.98) (±0.78)
C 2.23 2.50 2.07 1.87 2.47 2.13 .279 .797 .315
(±1.20) (±1.21) (±1.21) (±1.47) (±1.65)
D 1.99 2.08 1.90 2.16 2.01 1.75 .215 .730 .034
(±1.00) (±1.17) (±0.84) (±1.34) (±0.84)
E 2.34 2.57 2.20
____
2.11 2.47 1.96 .029 .302 .055
(±1.33) (±1.41) (±1.26) (±1.36) (±1.38) (±1.32)
Table 4.8 Changes in HOMA-IR. Values are means ± standard deviation. pTT =
paired t-test within group.
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Fem ales
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— A 
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 -D
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Figure 4.6 Changes in HOMA-IR according to Gender. The response in females and 
males are shown in the top and bottom panels respectively. The reduction in HOMA-IR 
following diet D was significant in females(p<0.05). The increase in HOMA-IR observed in 
males following diet A approached significance (p=0.093)
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4.4.5 Changes in Lipoprotein Subclasses and Apoproteins.
Baseline and endpoint measurements of total and LDL cholesterol, apoproteins and 
lipoprotein subclasses are shown in table 4.9. There were no significant differences 
between groups, at baseline, for lipids, lipoproteins or apoproteins. Analysis of 
whole groups (males and females) identified no significant differences in end point 
measurements of the percentage AUC of sdLDL and HDL2. There were also no end 
point differences in LDL peak density, apo B or apo Al. However, apo B was 
significantly lower in all diets, following intervention, compared to the control diet, 
diet A (p=0.023).
When data was analysed according to gender there were no significant differences in 
end point measurements in either males or females.
Tests of changes within groups revealed a significant reduction in apo B in all diets 
with the exception of diet A (B, C, D p<0.05 E p<0.01). A small but significant 
increase in the percentage AUC of sdLDL was observed in diet B with a concurrent 
increase in peak particle density (p<0.05). A significant increase in peak particle 
density was also observed in diet D (p=0.037), however, the increase in percentage 
AUC of sdLDL in this group merely approached significance (p=0.055).
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4.4.6 Correlations o f Insulin Resistance Markers and Dyslipidaemia
The main improvements seen, in all inteivention groups compared to control, were in 
fasting glucose, total and LDL cholesterol and apo B. When markers of insulin 
resistance were compared with components of the dyslipidaemia associated with 
MetS and an ALP significant correlations were observed (table 4.10).
Fasting glucose and insulin together with HOMA-IR were significantly associated 
with an ALP and with apoproteins. The exception was fasting glucose which was not 
associated with either total HDL-C or with the percentage AUC of HDL2 
Both total and percentage AUC HDL2 showed a significant negative association 
with both the percentage AUC of sdLDL and LDL peak density.
4.4.7 Correlations o f Anthropometric Components o f MetS Criteria with an ALP
Improvements in body weight, waist circumference and blood pressure were 
observed in some intervention groups together with changes in markers of insulin 
resistance and an ALP. Anthropometric measures that formed part of the MetS 
inclusion criteria were found to be associated with markers of an ALP (table 4.11). 
Body weight was significantly associated with TAG, HDL-C and apo Al (p<0.01). 
Waist circumference was associated with all lipids, with the exception of apo B. 
Negatively associated with HDL-C, apo Al and percentage AUC of HDL2, and 
positively with TAG, sdLDL and LDL peak density. Systolic and diastolic BP were 
positively correlated with one another, with serum TAG concentration and with the 
percentage AUC of sdLDL.
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4.5 DISCUSSION
The main aim of the present study was to explore the impact of varying the type and 
amount of dietary fat and carbohydrate on lipid CVD risk factors characteristic of 
MetS and an ALP. The study assessed the effect of exchanging SFA with either 
MUFA or CHO with low or high GI and attempted to identify which combination 
had the most beneficial effect on lipid CVD risk factors.
The composition of the diets investigated in the RISCK study was achieved using 
commercially available foods with the exception of cooking oils and spreads that 
were manufactured by Unilever and designed to meet the requirements of each diet. 
Despite the difference in dietary intake there were no differences in serum lipids post 
run in when assessed as part of a small pilot study. The measurement of screening 
lipids at individual centres followed by the separate and central analysis of baseline 
and end point measurements meant that it was not possible to accurately assess the 
impact of the four week ran in period on serum lipids in all subjects. At baseline no 
significant differences were observed in dietary intakes between intervention groups, 
however, this baseline value was significantly different from the habitual intakes of 
subjects. Following the initial run-in period of four weeks intakes of total fat, SFA 
and CHO were significantly increased whilst the intake of PUFA was reduced. 
Following the 24 week intervention the percentage energy from fat was lower than 
the proposed values for all diets with the exception of diet A, the control diet. The 
lower percentage energy from total fat was reflected in the contribution of both SFA 
and MUFA to total percentage energy which were, on the whole, lower than the 
anticipated values.
In diets B and C (high MUFA with high and low GI CHO respectively) the reduction 
in energy from fat was compensated for by an increase in energy from CHO. 
Consequently there was no change in total energy intake between baseline and 24 
weeks. Both low fat interventions with either high or low GI CHO, diets D and E 
respectively, were high in carbohydrate (>50% percentage energy), however, the 
reduction in fat intake above the proposed value was not accompanied by a further 
increase in CHO consumption. The result was an overall energy deficit of 0.8 and 
1.3MJ in diets D and E respectively. The glycaemic index of CHO has been
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proposed as an aid to weight loss with increased weight loss resulting from low GI 
foods through the promotion of satiety and/or other mechanisms including increased 
metabolic rate, reduced postprandial glycaemia and higher fat oxidation (McMillan- 
Price and Brand-Miller 2006). De Graff et al (2004) have suggested that the slower 
digestion of low GI foods can result in partially digested food reaching the ileum and 
stimulating the secretion of satiety signals such as glucagon like peptide l(GLP-l). 
The increased secretion of cholesystokinin, an anorexic hormone, has also been 
observed following the consumption of mixed meals with a low GI. Other properties 
of low GI foods may also contribute to increased satiety, for example, volume, fibre 
content and palatability. In the RISCK study both low fat diet groups achieved a 
small but significant reduction in body weight, 0.85% and 1.6% in diets D and E 
respectively. Whilst diet D and E shared similar fat contents they differed in the GI 
of the CHO consumed with the CHO of diet E ~9 points lower than D at 24 weeks. It 
can be proposed that the low GI CHO promoted satiety which resulted in a greater 
energy deficit with subsequent weight loss in diet E.
Fatty acid composition of the diets was on the whole achieved, diet A rich in SFA, B 
and C rich in MUFA and diets C and D low in fat mainly from the reduction of SFA. 
Diets B and C had a significantly higher proportion of energy from MUFA 
compared to diets A, D and E which was also observed in the individual fatty acid 
analysis. All diets achieved a significant reduction in SFA compared to the control 
diet. As expected PUFA contents of the intervention diets remained unchanged.
4.5.1 The influence o f fatty acids on serum lipids
The relationship between dietary SFA and serum lipids is well established with the 
initial work of Keys (1965) and Hegsted (1965) confirmed by a number of 
subsequent studies (Mensink and Katan 1992). The reduction of dietary SFA has 
consistently been associated with a reduction in serum total and LDL cholesterol, 
however, the relative cholesterol raising potency of individual fatty acids has been 
shown to be variable (Hegsted et al 1965, Mensink and Katan 1992, Yu et al 1995). 
In the current study a reduction in SFA was achieved through a reduction in both 
neutral SFA (stearic acid) and SFAs with a hypercholesterolaemic effect (myristic, 
palmitic and lauric acids). It is of note that the control diet (A) which contained a 
relatively high proportion of energy from SFA produced no unfavourable effects on
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serum lipids, with the exception of a small but significant reduction in HDL-C (- 
O.lmmol/L), p<0.05). This finding is somewhat different to earlier studies addressing 
the impact of SFA on serum lipids.
Diets B and C were high in MUFA with oleic acid contribution to 15.5 and 14.9% of 
total energy respectively. These diets resulted in significant reductions in total, LDL 
and HDL cholesterol and apo B, however, these reductions did not differ 
significantly from those achieved by their low fat counterparts. Additionally diet B 
(high MUFA, high GI) demonstrated an unfavourable effect on both percentage 
AUC for sdLDL and LDL peak density. Montoya et al (2002) compared a diet high 
in SFA (17%) to an isoenergetic diet with high MUFA (9% SFA, 21% MUFA). 
These intakes are similar to those proposed in diets A, B and C in the current study 
with the exception that the quality of CHO was not documented. Montoya et al 
demonstrated a significant reduction in total and LDL cholesterol following a five 
week intervention with the high MUFA diet compared to the high SFA diet with no 
changes in serum TAG or HDL-C. Despite a significant within group reduction in 
total and LDL-C the change in lipids did not differ between the high SFA diet (A) 
and the high MUFA diets (B&C) in the current study. The study by Montoya et al 
was short, 5 weeks, in comparison to the 24 week intervention of the RISCK study. 
Studies comparing high MUFA diets with low fat diets have, on the whole, shown 
diets rich in MUFA to have beneficial effects on serum total and LDL-cholesterol 
with the effect on serum TAG and HDL-C variable. The reduction of total and LDL- 
C observed following a high MUFA intervention has been repeated in the current 
study, likewise no significant effect on serum TAG was observed which is in 
concordance with earlier research. The reduction in HDL-C in the high MUFA diets 
was not expected, the significant weight loss observed in diet B may account for the 
reduction in HDL-C in this diet as HDL-C is known to fall in line with other serum 
lipids during active weight loss (Dattilo & Kris-Etherton 1992). This does not, 
however, account for the reduction in HDL-C observed in diet C.
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The major statin trials of the 1990s established that a reduction in LDL-C was 
associated with a reduction in CVD risk, though attention has recently focused on the 
benefit of raising HDL-C. (Shepherd et al 1995, Sacks et al 1996, Downs et al 
1998). Both the Framingham heart study and the PROCAM studies have identified 
low HDL-C concentrations as an independent risk factor for coronary artery disease 
(CAD) (Gordon et al 1989, Assman & Schulte 1992). It has also been suggested that 
HDL-C is more important in determining CVD risk than LDL-C. The Veterans 
Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) compared the effects 
of gemfibrozil versus placebo on CVD risk in male subjects with both CHD and low 
HDL (Rubins et al 1999). In VA-HIT HDL-C was significantly correlated with CHD 
event reduction, however, this was not true for LDL-C or TAG. HDL-C exists as a 
number of subclasses and it has been proposed that these show a variable 
relationship with CVD risk. If this is the case then dietary strategies that aim to 
improve atherogenic dyslipidaemia through the reduction of LDL and elevation of 
HDL should also assess changes in lipoprotein subclasses.
In the RISCK study a new ultracentrifugation procedure was used to analyse the 
percentage AUC of the principal HDL subclasses, HDL2 and HDL3. (detailed in 
Chapter 3). Total HDL-C was reduced following all dietary interventions in the 
RISCK study, however, this was not associated with significant changes in 
percentage AUC of HDL2 suggesting that the reduction in HDL was the result of 
equal reduction in HDL2 and HDL3. Berglund et al (1999) evaluated the effect of 
dietary fat on HDL subclasses in healthy subjects as part of the DELTA (dietary 
effects in lipoproteins and thrombogenic activities) study. The DELTA study 
investigated 3 diets as part of a randomised crossover design with an 8 week 
intervention period. The three diets differed in total fat and saturated fat, however, 
the MUFA content was unchanged between diets. In the DELTA study HDL 
decreased, in a step wise manner, with the reduction in dietary total and saturated fat. 
Analysis of HDL subpopulations identified a larger reduction in HDL2 compared to 
HDL3. In the present study diets D and E had a similar fat content and composition 
to the American Heart Association (AHA) step 1 diet used in the DELTA study, 
however, whilst there was a significant reduction in total HDL of a similar 
magnitude no changes in HDL subclasses were observed, this may in part be due to 
the insignificant effects of the low fat diets on TAG concentration which showed a
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significant increase in subjects of the DELTA study. Clifton et al (1998) also 
demonstrated a significant increase in TAG following a three week intervention with 
a low fat (20% energy) diet, which was coupled with a reduction in both total HDL 
and HDL2. However, in the study by Clifton et al there was also a reduction in HDL3 
suggesting no overall change in subclass distribution. Lovejoy et al (2002) have 
more recently demonstrated no effect of a low fat (26% total energy) on HDL 2b and 
HDL 2a despite a significant increase in TAG.
In an ALP concentrations of LDL-C are often unremarkable, however, a 
redistribution of the predominant LDL subclass to sdLDL, representing a pattern B 
phenotype is associated with increased CVD risk. Dreon et al (1998) compared the 
effects of a low fat diet (24% of total energy, 6% SFA) with a high fat (46% of total 
energy, 18% SFA) on LDL subclass distribution. A reduction in serum TAG 
following the high fat diet was associated with an increase in the concentration of 
larger more buoyant LDL with the opposite true for the high CHO diet. In the 
present study the percentage AUC of sdLDL was unchanged by the control, high 
MUFA with low GI and low fat diets. In the high MUFA high GI diet (diet B) there 
was a small but significant increase in percentage AUC sdLDL coupled with an 
increase in LDL peak density. LDL peak density was also significantly elevated in 
the low fat diets, however, there was no significant change in percentage AUC 
sdLDL. In the current study low fat diets with high and low GI had unfavourable 
effects on serum lipids which supports the findings of Dreon et al (1998), however, 
the quality of CHO was not described in this study. The negative effect of a high 
MUFA high GI diet (diet B) on LDL subclasses in the current study suggests that the 
type of CHO may also influence lipid subclasses. A similar association with high GI 
CHO has not been described by other studies, however, Dumensil et al (2001) have 
shown a reduction in sdLDL following intervention with a low GI diet.
4.5.2 The influence o f glycaemic index on serum lipids
I11 a cross sectional study by Frost et al (1999) dietary glycaemic index expressed a 
significant negative correlation with serum HDL-C, other dietary variables, 011 the 
other hand, did not show a relationship including dietary fat. Liese et al (2007) have 
recently evaluated the relationship between glycaemic index and serum lipids in the 
Insulin Resistance Atherosclerosis Study (IRAS). GI was significantly and inversely
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associated with HDL, however, a relationship between other lipids was not observed. 
Conversely, in a recent prospective study by Oxlund and Heitmann (2006) no 
association of GI with HDL was observed over a 6 year follow up in Danish adults. 
There was, however, a weak association with LDL in males. Dietary interventions 
have also shown a variable effect of GI on serum lipids.
In the present study diets with low GI CHO did not differ to diets with high GI CHO 
in tenns of their effects on serum lipids. This may in part be due to a small difference 
in GI between the groups (~9 points). Foods are generally categorised as low, 
medium or high GI based on GI values <55, 55<GI<70 or 70> relative to glucose 
with a GI of 100. Previous intervention studies that have examined the effects of GI 
on CVD risk factors have used diets which have a greater difference in GI points 
between those classified as “low” or “high” GI. Additionally in the RISCIC study the 
average GI of both low and high GI diets fell into the medium GI category 
suggesting that there may not have been a sufficient difference between the diets to 
elicit a difference in lipid response.
4.5.3 Dietary fatty acids and insulin resistance
It can be said that the central metabolic disturbance in MetS is insulin resistance and 
that this contributes to metabolic dyslipidaemia through increased FFA flux to the 
liver, resulting from increased TAG lipolysis, and hepatic insulin resistance which 
gives rise to increased production of VLDL (ICohen et al 2006)
Numerous studies have confirmed the negative influence of SFA on serum lipids 
with a number also demonstrating a negative effect on fasting insulin concentrations 
(Marron et al, 1991, Parker at al 1993) and insulin sensitivity (Hu et al 2001). 
Additionally, in a number of prospective studies, SFA has shown a positive 
relationship with the incidence of type 2 diabetes (Marshall et al 1994, Feskens et al 
1995, Vessby et al 1994). Diets rich in MUFA, on the other hand, not only improve 
the dyslipidaemia of MetS but have also been implicated in improved glycaemic 
control when compared to high CHO diets (Wright 1998) and diets high in SFA 
(Rivellese and Lilli 2003). Garg et al (1988) assessed the impact of a high CHO diet 
(60% of energy) with a diet high in MUFA (35% of energy from CHO, 33%
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MUFA). Following a 4 week intervention, in subjects with type 2 diabetes, fasting 
plasma insulin was lower in subjects following the high MUFA diet.
The reduction of SFA in favour of MUFA and the subsequent effect on insulin 
sensitivity was investigated in the KANWU study ( Vessby et al 2001). The 
KANWU study was a 3 month intervention in healthy subjects with either a high 
SFA diet (SFA as 17% of energy, MUFA 14%) or a high MUFA diet (SFA 8% of 
energy, MUFA 23%) which were equal in the contribution of total fat to total energy 
intake (37%). Insulin sensitivity assessed by IVGTT was reduced by 10% following 
the high SFA diet (p<0.05), MUFA did not affect insulin sensitivity index (Si) in the 
total group, however, in subjects with a lower fat intake (34% of energy) MUFA has 
a favourable effect of Si when compared to the high SFA diet. In the RISCK study 
the contribution of total fat and SFA to energy intake in the control and high MUFA 
diets was similar to the diets of the KANWU study. In the present study insulin 
sensitivity, assessed by HOMA-IR, showed no improvement following intervention 
with high MUFA diets. Additionally the control diet which was high in both total 
and saturated fat had no adverse effect in insulin sensitivity. Insulin sensitivity was 
also assessed by IVGTT in the RISCK study, however, the modelling of data is still 
outstanding. HOMA-IR is a crude marker of insulin resistance and Si data may 
identify associations that remain uncertain with the present data.
4.5.4 Glycaemic index and insulin resistance.
Some studies have identified a less favourable effect of high CHO diets on markers 
of insulin resistance when compared to diets high in MUFA (Garg et al 1988), 
however, few studies have commented on the type of CHO in high CHO diets. 
Perhaps one of the most notable effects of GI is on postprandial glucose, which 
contributes to GI classification, and insulin responses. A number of prospective 
studies have considered the influence of dietary GI and risk of type 2 diabetes. Both 
the Nurses’ Health Study (Salmeron et al 1997a) and the Health Professionals 
Follow up Study (Salmeron et al 1997b) demonstrated a significant positive 
correlation of GI with the incidence of type 2 diabetes. A similar finding was 
observed in the IRAS cohort (Schulz et al 2006), however, the positive association 
was confined to subgroups of the study and in particular those without elevated waist 
circumference.
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Conversely no association between GI and incidence of type 2 diabetes, in 
Caucasians, was observed in the Atherosclerosis Risk In Communities (ARIC) study 
(Stevens et al 2002). Intervention studies, as previously mentioned, have also shown 
a variable response of markers of insulin sensitivity in both healthy subjects and 
those with T2DM.
The favourable effects of low fat diets on fasting insulin were observed in both diets 
D and E which were high and low GI respectively. Diet E also resulted in a 
significant improvement in HOMA-IR, however, whilst the weight loss in both these 
diets was relatively small the known influence on lipid risk factors and markers of 
insulin resistance makes the interpretation of results difficult. Case et al (2002) 
demonstrated an improvement in blood pressure, fasting glucose, TAG and total 
cholesterol, following weight loss of ~18ICg, together with a reduction in the 
components of MetS when assessed using the NCEP ATP III criteria.(Case et al. 
2002).
The overall conclusion of the RISCK study was an improvement in several lipid risk 
factors with the reduction in SFA intake. Neither high MUFA or low fat diets were 
revealed as a superior diet for the reduction of lipid mediated CVD risk. Likewise GI 
did not significantly affect outcome. Although the diets did not differ significantly in 
terms of their effect on CVD risk markers it can be proposed that diet E had the most 
beneficial effects on CVD risk due to the significant reduction in body weight and 
waist circumference which was coupled with significant improvements of both 
markers of insulin resistance and serum lipids. However, due to unequal weight loss 
between diets D and E it remains unclear whether this improvement was due to the 
glycaemic index of dietary CHO or weight loss resulting from energy restriction. 
Elevated waist circumference has been associated with elevated serum TAG 
(Lemieux et al 2001) which in turn is associated with and ALP and the formation of 
sdLDL (Griffin et al 1994). It can be proposed that, in individuals with the metabolic 
syndrome, weight loss resulting in a reduction in visceral adiposity has the most 
benefit in terms of risk reduction, however, further research is required to identify 
the optimal diet for weight loss in these “at risk” groups. The correlations of MetS 
criteria with lipid risk factors underline the multi-factorial nature of CVD risk 
associated with MetS and the need for a lifestyle intervention that improves all of 
these components.
121
Chapter 5 —The EDWINA Study
CHAPTER 5 - Eggs in a Diet for Weight-Ioss in Normolipidaemic Adults -  
The EDWINA study.
Abstract
Backsround____________________________________ _______________ _
The observation that high intakes of dietaiy cholesterol can increase plasma 
cholesterol in a number o f species, has led to the belief that the intake o f dietary 
cholesterol in humans should be restricted. Eggs are a major source of dietary 
cholesterol containing between 50 and 250mg depending on size, AHA guidelines 
suggest that healthy individuals should limit egg consumption to 1 egg/day (<300mg 
cholesterol). However, energy restricted diets, that may contain relatively high 
proportions of fat and cholesterol, have been shown to produce neutral or even 
favourable effects on plasma cholesterol.
Study Aims and Hypothesis  ______________________________
Since weight loss has been frequently associated with beneficial changes in blood 
lipids the primary aim of this study was to test the hypothesis that weight loss may 
negate the potentially adverse effect o f increased dietary cholesterol on plasma LDL 
cholesterol. A secondary aim was to examine whether egg-feeding coidd promote 
additional weight loss thus supporting recent evidence that eggs increase satiety. To 
investigate this hypothesis a randomly controlled, parallel study was performed in 
two groups of free living volunteers.
M e t h o d s _______________ _____________________________________
A total of 45 subjects were recruited (n=24; consuming two eggs/day, n=21; no eggs 
=  control) and examined on 4 occasions over a 13 week period (12 week intervention 
with a one week wash-out). Both groups were given dietetic counselling and 
instructed to follow the BHF guidelines on uhow to lose weight for good” with or 
without the inclusion of two eggs per day.
Results________________________________________________________
Both groups achieved a significant reduction in energy intake which was reflected in 
significant and predicted weight loss; -3.3kg (p<0.05) and -4.4 9kg (p<0.05), in the 
egg-fed and control groups respectively). Even though the group consuming two 
eggs per day significantly increased their intake o f dietary cholesterol (+  
304mg/day), there was no significant effect on either total plasma cholesterol or LDL 
cholesterol (-5.2% and -5.14% respectively).
Conclusions___________________________________  __
This study demonstrated that an increased intake of dietary cholesterol, from two 
eggs per day, has no significant effects on plasma total or LDL cholesterol when 
accompanied by moderate weight-loss achieved through energy restriction.
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5.1 INTRODUCTION
The prevalence of being overweight and obesity in the UK and USA has reached 
epidemic proportions, with over 50% of all adults in England having a BMI 
>25kg/m2. (International Association for the Study of Obesity, 2007). Elevated body 
weight and a BMI >25kg/m2 pre-disposes to a number of CVD risk factors including: 
elevated total plasma and LDL cholesterol, elevated plasma TAG and reduced HDL- 
C. Of these risk factors, total plasma cholesterol and LDL-cholesterol are, without 
doubt, the most extensively studied, in terms of CVD risk reduction. The reduction in 
LDL-C as the result of statin therapy, and the subsequent reduction in CVD mortality 
has firmly established LDL as a major atherogenic lipoprotein (Shepherd et al 1995, 
Sacks et al 1996, Anonymous et al 1998, Downs et al 1998).
Total body cholesterol is determined by the rate of endogenous cholesterol 
production, absoiption of dietary cholesterol and the excretion of cholesterol. It has 
been proposed that the effectiveness of these mechanisms, and their interaction, 
control our response to dietary cholesterol. However, Lin and Connor in 1980 
showed only partial compensation, in plasma lipid concentrations, for increased 
dietary cholesterol, and subsequently an increase in total plasma cholesterol in both 
LDL and HDL fractions (Lin DS & Connor WE 1980). Since the initial observations 
made by Anitschkow in 1913 the role of dietary cholesterol in 
hypercholesterolaemia, atherosclerosis and CVD risk has been the subject of 
numerous studies (reviewed by McNamara 2000). The consistency of the overall 
response in cholesterol feeding studies in humans, has fuelled much debate over the 
cholesterol content of our diet, and to the investigation of its impact on CVD 
mortality.
5.1.1 Epidemiological eviden ce
The influence of dietary cholesterol on blood cholesterol has been the focus of a 
number of epidemiological and intervention studies. Epidemiological evidence 
supporting the role of dietary cholesterol as a predictor of CVD first arose following 
rationing associated with World War II. The limited availability of eggs, meat and
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butter was thought to account for the reduced mortality from CVD during these years 
(Henschen 1947). However, like many epidemiological studies that were to follow, 
the change in the consumption of saturated fat (SFA) was not considered.
Egg consumption and serum cholesterol was examined in the Framingham Heart 
Study. While no differences were observed in serum cholesterol between tertiles of 
egg consumption, those in the highest tertile were shown to have an increased risk of 
CHD, though this elevated risk was not significant and the data had not been adjusted 
for confounding variables such as SFA intake (Dawber et al 1982). Hu et al (1999) 
specifically examined the relationship between egg consumption and CHD, in the 
Health Professionals Follow-up Study and the Nurse’s Health Study. In both of these 
prospective cohort studies, there was no significant association between egg 
consumption and CVD risk. Ascherio et al (1996) did find a positive association 
between dietary cholesterol and CVD risk. However, when dietary fibre was 
considered as a confounding covariate, this association was no longer significant 
In the seven countries study there was a significant correlation between dietary 
cholesterol intake and CHD risk in terms of 25 year mortality. While this association 
was originally based on simple linear regression analysis of the data, the confounding 
variables of SFA and fibre intake were not accounted for in this analysis. A 
multivariate analysis, which corrected for these variables, found no significant 
association between dietary cholesterol and CVD risk (Kromhout et al, 1995). In the 
20 countries study, simple linear regression found significant positive associations 
between dietary cholesterol, SFA and CVD risk, and negative associations with 
PUFA intake. The associations between SFA and PUFA intake remained significant 
on multivariate analysis, but dietary cholesterol was no longer associated with CVD 
risk (Hegsted and Ausman,1988).
Epidemiological studies have provided convincing evidence to support the 
hypothesis that egg consumption does not affect CVD risk, yet the results of many 
studies are difficult to interpret due to presence of confounding variables. 
Intervention studies that have attempted to control for other dietary components, 
have also provided important information on the effects of dietary cholesterol on 
plasma cholesterol, but the outcome of many of these studies has been equivocal.
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5.1.2 Intervention Studies
Dietary interventions can be broadly grouped into acute and long term interventions, 
and these groups further subdivided according to the source of dietary cholesterol i.e. 
crystalline cholesterol or eggs. Eggs are the main source of cholesterol in the diet 
with one medium egg containing on average 250mg, this has resulted in their 
exclusion or limitation in diets aimed at reducing CVD risk, as for example in the 
AHA Step 1 Diet (Krauss et al, 2000).
The interpretation of early cholesterol feeding studies was limited by the failure to 
control for confounding variables and SFA intake.
Studies that have controlled for the effects of dietary SFA and fibre have shown 
mixed results. Studies by Edington et al (1987) which examined the addition of eggs 
to a low fat, high fibre diet found no significant effects of an increase in dietary 
cholesterol, by consuming up to nine additional eggs per week, on total or LDL 
cholesterol following eight weeks of intervention. However, in another study, the 
same authors observed a significantly higher plasma cholesterol level after four 
weeks on a diet containing seven eggs/week compared to a diet containing two eggs 
per week, this effect was not observed at the end of the 8 week intervention, 
(Edington et al, 1989). Porter et al (1977) considered the addition of one whole egg 
per day to the diet of normolipidemic men, and found no significant increase in 
plasma cholesterol following a 12 week intervention period. Whilst this study 
reported no differences in total fat between intervention periods, the results for SFA 
intake were not reported. The results described by Porter et al were further examined 
by Flynn et al, (1979) who investigated the effects of two eggs per day on plasma 
cholesterol in free living subjects and found no significant increase in plasma 
cholesterol. In this study the diets of cross-over periods differed significantly only in 
cholesterol content with no differences in SFA.
Not all cholesterol feeding studies have had such positive outcomes. Roberts et al 
(1981), demonstrated a significant increase in plasma cholesterol following an 
increase in cholesterol intake of 500mg/day from homogenised whole egg when 
compared to an egg substitute. However, the two products differed in their SFA, 
MUFA and PUFA content, with the egg product containing proportionately more 
SFA and less PUFA per lOOg. In addition, this study used a relatively short
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intervention period of four weeks, the increase in plasma cholesterol observed by 
Edington et al after four but not eight weeks of intervention suggests that there is a 
transient increase in plasma cholesterol before metabolic adaptation. 
Brongeest-Schoute et al (1979 ) studied the removal of eggs from the diet rather than 
the addition of eggs, and found a significant reduction in plasma cholesterol. 
However, this was again only a short term intervention of three weeks which may not 
have been sufficient to examine plasma cholesterol following any metabolic 
adaptation to the dietary intervention.
Of the cholesterol feeding studies two of the most methodical are those of Ginsberg 
et al in healthy young men (Ginsberg et al, 1994), and healthy young women 
(Ginsberg et al, 1995). A dose response relationship was observed in males 
following cholesterol intakes of between 128-85 8mg/day, with an average increase in 
total plasma cholesterol of 0.038mmo/L per lOOmg of cholesterol, this response was 
also apparent in LDL-C with an average increase of 0.036mmol/L per lOOmg 
cholesterol.
Ginsberg also demonstrated a similar dose-response relationship in women. 
However, in this group HDL-C was also significantly increased (Ginsberg et al 
1995). It has been proposed that any increase in LDL cholesterol produced by 
increased dietary cholesterol or egg consumption has no effect on CVD risk since 
there is a compensatory increase in HDL-C.
Sehayelc et al (1998) have also demonstrated a change in plasma cholesterol of 0.3 
mmol/L per lOOmg/day cholesterol. This change was greater than that observed in 
previous studies but may be accounted for not only by an increase in cholesterol in 
the diets but also increased intake of saturated fat (Sehayek et al 1998).
5.1.3 The potential role o f eggs in promoting weight loss
Low carbohydrate diets are often used in the management of weight loss and obesity, 
and have been shown to promote superior weight loss compared to low fat and low 
fat, high carbohydrate diets (Foster et al 2003, Sahama et al 2003 Gardner et al 
2007). The effectiveness of low carbohydrate diets is thought to be the result of 
either increased satiety, increased thermogenesis or simply a reduction in energy 
intake because it imposes a limit on food choice (Eisenstein, 2002). The increased
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consumption of meat and eggs as part of a low carbohydrate diet results in a diet that 
is relatively high in SFA and dietary cholesterol when compared to national 
recommendations. Despite containing more SFA and cholesterol, low carbohydrate 
diets have been shown to have neutral or favourable effects on lipid markers of CVD 
risk, suggesting that weight loss may override any potential cholesterol-raising effect 
of dietary SFA or cholesterol (reviewed by Volek, Sharman and Forsythe, 2005). 
Increased satiety associated with low carbohydrate diets has been ascribed to the 
high contribution of protein to energy intake. Holt et al (1995) measured the satiety 
index of common foods using iso-energetic portions and a seven point scale to assess 
subjective satiety. In this study, protein as grams per serving was positively 
associated with satiety index. Eggs are high in protein, and as such, have a high 
satiety index (Holt et al 1995, Holt et al 2001) but have a relatively low energy 
content, making them an ideal component of a weight-losing diet. The consumption 
of whole eggs and egg yolk has been previously associated with delayed gastric 
emptying and an increased levels of cholecystokinin (CCK) (Pelletier 1996). Since 
CCIC is a gut peptide hormone that is recognised as being anorexigenic, this might 
explain how increased levels of CCK following egg consumption contribute to 
increased satiety (Moran 2000). A recent study that examined the effect of eggs on 
satiety in overweight and obese subjects, showed that eggs eaten at breakfast are 
significantly associated with reduced energy intake until lunch the following day. 
Satiety scores were also greater following an egg compared to a bagel-based 
breakfast but only up to 90minutes post-breakfast (Vander Wal et al 2005 ). The pilot 
study of Vander Wal was followed-up by Dhurandhar et al (2007) who examined the 
effect of an egg breakfast on weight loss. In this study, overweight and obese 
subjects followed one of four diets for a period of eight weeks, diets contained either 
a bagel-based breakfast or a breakfast containing two eggs, eaten for at least five 
days per week, with or without energy restriction (4.18MJ). The group consuming an 
energy restricted diet with an egg based breakfast lost significantly more weight and 
attained a greater decrease in weight circumference than the group consuming an 
energy restricted diet with a bagel-based breakfast. In addition, there were no 
significant differences between the four groups in terms of plasma lipids, though the 
authors do not comment on changes in plasma lipids within each diet (Dhurandhar et 
al 2007).
12 7
Chapter 5 -T h e EDWINA Study
5.2 AIMS AND OBJECTIVES
The aim of the present study was to demonstrate that dietary cholesterol from two 
eggs a day produces no significant effect on plasma LDL-cholesterol. This was 
achieved by comparing the combined effects of increased dietary cholesterol, from 
two eggs per day, and energy restriction on body composition, plasma lipids and 
lipoproteins and other biochemical markers of CVD risk. A study was designed with 
two parallel groups of overweight and obese males and females who followed an 
energy restricted diet with or without eggs for 12 weeks.
5.3 MATERIALS AND METHODS
5.3.1 Subjects
Male and female volunteers aged 18-65 years were recruited from staff and students 
at the University of Surrey and from the general public through advertisements in 
local newspapers. Subjects were recruited if they were oveiweight or obese class 1 
(BMI 25-35 Kg/m2), and did not meet any of the exclusion criteria which included 
the following: total cholesterol >6.5mmol/L, TAG >2.5mmol/L; diabetes mellitus, 
previous history of cardiovascular disease; abnormal liver function or haematology 
and use of any drag likely to affect lipid metabolism. Subjects were also excluded if 
they were on any weight-losing dietary regime or had lost more than 3kg in the 
preceding 2 months.
Suitability for the study was assessed at a screening visit at which subjects were 
asked to complete a health questionnaire and undergo a number of measurements 
that included their height, weight, waist circumference and blood pressure. Subjects 
were also asked to provide a fasting blood sample for the measurement of total 
cholesterol, HDL cholesterol, TAG, glucose, a full blood count and liver function 
tests.
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Subjects were provided with dietary guidelines from a BHF publication entitled 
“How to lose weight for good” (Appendix II) together with individualised 
counselling from a qualified dietician. The diet aimed to reduce energy intake by 
between 2-4MJ (500-1000Kcals) per day, by limiting portion size and the 
consumption of both dietary fat and carbohydrate. Subjects allocated the two eggs 
per day were provided with medium sized, free range eggs from a single supplier for 
the duration of the study.
5.3.2 Study Design
The study was randomly controlled with a parallel design. The study was funded by 
the British Egg Information Seivice (SRCTN31221145) and granted favourable 
ethical approval by the University of Surrey Ethics Committee
(EC/2004/109/SBMS). Following screening suitable subjects were randomly 
allocated to one of the two groups. Subjects in each group were examined on four 
occasions, at baseline, following six and twelve weeks of intervention and finally 
after a one week washout period (13 weeks) (figure 5.1). At each visit a 30ml blood 
sample was taken for the measurement of plasma lipids and lipoproteins.
Buffy coat samples were taken at the baseline visit for the assessment of apo E 
genotype. Additional serum samples were also taken at baseline and 12 weeks for the 
measurement of serum non-cholesterol sterols -  detailed in chapter 6.
Figure 5.1. EDWINA Study Design. The study was a randomly controlled parallel design
129
Chapter 5 —The EDWINA Study
with 2 intervention groups. Subjects were seen on 4 occasions following an initial screening
visit.
Prior to the baseline and six week visits, subjects were asked to complete a four-day 
food diary to include one weekend day. Diaries were analysed by a dietician using 
WinDIETS professional software. These diaries were used to assess compliance, 
energy intake and the intake of macronutrients and dietary cholesterol. It is widely 
accepted that saturated fat intake is positively associated with plasma cholesterol, 
whilst cis-unsaturated fatty acids have been shown to have a cholesterol-lowering 
effect. For this reason, the PUFA: SFA ratio was compared at baseline and six weeks 
for each intervention group. Diet diary data was also used to estimate the predicted 
change in plasma cholesterol using the equation of Keys 1970 (Keys, 1970).
To standardise pre-dietary conditions and minimise variability introduced by acute 
dietary effects, all subjects were provided with a pre-meal containing less than three 
percent fat, to consume the night before their visit to provide a blood sample. 
Subjects were asked to consume the pre-meal before 8pm and then fast until their 
blood sample the following morning. Subjects were also requested to refrain from 
exercise and alcohol 24 hours before each visit, and not to consume dietary 
supplements or functional foods that may lower cholesterol i.e. products containing 
plant sterols and stands for two weeks prior to the study and for the duration of the 
intervention.
5.3.3 Biochemical Analysis
Biochemical analysis of plasma lipids and apoproteins was completed according to 
the methodologies described in Chapter 2. LDL subclasses were analysed using 
iodixanol density gradient ultracentrifugation in a 16 place near vertical rotor 
(Chapter 2 , Sections 2.3 and 2.4).
5.3.4 Anthropometric and blood pressure measurements
Blood pressure, body composition and waist circumference were measured as 
described in Chapter 2, Sections 2.5 and 2.6
130
Chapter 5 - The EDWINA Study
5.3.5 Statistical Analysis
The study was designed to test two possible outcomes; that the cholesterol-enriched, 
energy-restricted diet could either be ‘equivalent’ or ‘superior’ in its effects on 
plasma LDL cholesterol to that of the energy-restricted diet alone.
To test for an ‘equivalent’ effect, the largest clinically acceptable difference in 
plasma LDL cholesterol between diets was pre-defmed with an increase in LDL-C 
concentration >2% (above normal day-to-day variation) considered unacceptable. 
Alternatively, if the diet including two eggs per day produced additional weight loss 
the effect would be deemed “superior” and require a pre-study calculation of the size 
of statistical difference between dietary treatments after 12 weeks (Millar & Burke, 
2002).
An approximate sample size for each group of 25 was estimated on a predicted loss 
in body weight that would accompany an energy restriction of 4.18MJ/day (1000 
Kcals/day) for 12 weeks. This estimate included an allowance for a subject drop-out 
rate of 25%, and for 50% of the subjects to under achieve the target weight loss.
Data was tested for normality using the Shapiro-Wilk test. Data that did not follow a 
normal distribution was log transformed and tested for normality again before 
running parametric tests. Data was screened for outliers and the decision to include 
data was based on the mean and 5% trimmed mean values. Based on this information 
no outliers were excluded from analysis.
Data was grouped and the effect of time and diet analysed using a mixed repeated 
measures ANOVA. Additionally, changes in variables between the final visit of the 
intervention (12 week) and the washout visit (13week) were analysed using a 
Student’s t-test for paired data. Diet diary data was analysed using a paired t-test 
within groups for baseline and 6 week data, between groups data for baseline and 6 
weeks was analysed using an independent-t test. All data was analysed using SPSS 
software version 14 (SPSS Inc, Chicago,).
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5.4 RESULTS
5.4.1 Baseline Characteristics
A total of 67 male and female volunteers were screened, of these 14 failed to meet 
the inclusion criteria due to hyperlipidemia or medication likely to influence lipid 
metabolism. The remaining 53 subjects were randomly assigned to two energy 
restricted diets, either with two eggs per day or no eggs for 12 weeks. Of the 26 
subjects assigned to the control group, five subjects withdrew; one due to pregnancy, 
two due to personal reasons, one who had shingles at the time of the six week visit 
and who had been unable to follow the diet during this period and one who did not 
return for their six week visit and could not be contacted. Of the 27 subjects who 
were assigned to eating two eggs per day, three withdrew; one due to an intolerance 
to the study diet, and two because of personal reasons.
There were no significant differences between groups at baseline. However, there 
were significant differences between males and females within groups for body 
weight, waist circumference and percentage body fat, with males being heavier, and 
having a larger waist circumference and lower body fat percentage than females in 
both groups. In the group avoiding eggs, plasma TAG was also significantly higher 
in males (Table 5.1).
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Energy Restriction - 2 Eggs/day Energy Restriction - Avoiding Eggs
Male Female Total Group Male Female Total Group
(n=8) (n=16) (n=24) (n=5) (n=16) (n=21)
Age (years) 48 43 44.9 46 42 43
(±6.7) (±8.8) (±8.4) (±12.3) (±10.1) (10.5)
Body Weight 93.8 77.8* 83.1 96.0 77.6* 82.0
(kg) (±6.7) (±10.9) (±16.6) (±15.8) (±12.6) (±15.3)
Waist 107 91** 96.2 105 £9** 93
Circumference (±16) (±8.3) (±13.5) (±8) (±10) (±11.8)
(cm)
BMI (kg/m2) 30.3 29.1 29.5 30.1 28 28.5
(±5.4) (±2.7) (±3.7) (±4.7) (±4.1) (±4.2)
% Body Fat 30.4 38.6* 35.8 28.4 36.5* 34.6
(±9.7) (±5.4) (±7.9) (±5.5) (±6.9) (±7.4)
T-Cholesterol 5.55 5.29 5.38 5.32 5.27 5.29
(mmol/L) (±0.91) (±1.26) (±1.14) (±0.85) (±1.07) (±0.99)
TAG (mmol/L) 1.32 1.23 1.26 1.89 1.20* 1.39
(±0.83) (±0.39) (±0.56) (±0.56) (±0.49) (±0.59)
Glucose 5.94 5.51 5.77 6.12 5.72 5.81
(mmol/L) (±0.47) (±0.67) (0.94) (±0.42) (±0.60) (0.59)
Table 5.1: Subject baseline characteristics. Data is displayed as mean ± standard 
deviation, no significant differences were observed between groups for any of the screening 
criteria * p<0.05 between genders within group. **p<0.01 between genders within group
5.4.2 Dietary Composition
Dietary composition was assessed at baseline and at six weeks. After six weeks both 
energy restricted diets, with and without eggs, had produced significant reductions in 
energy intake of 2.22kJ/day and 2.48kJ/day respectively (p<0.01). At baseline there 
was no significant difference in dietary cholesterol intake between groups, whereas 
after six weeks, the group consuming two eggs per day showed a significant mean 
increase in dietary cholesterol of 304mg/day (109%, p<0.01). In contrast, the group 
not consuming eggs achieved a significant reduction in dietary cholesterol (-44%, 
p<0.01) (Figure 5.2).
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Figure 5.2. Dietary cholesterol intakes at baseline and 6 weeks. The group consuming 2 
eggs per day significantly increased their intake of dietary cholesterol at 6 weeks whilst the 
control group avoiding eggs significantly reduced their intake. There was a significant 
difference in dietary cholesterol intake between groups at 6 weeks but not at baseline.** 
within group significantly different from baseline p<0.01 t significant difference between 
groups at 6 weeks p <0.01. Bars represent means ±SEM
The percentage contribution of macronutrients to total energy intake for the two 
egg/day and control groups are given in Figure 5.4.
There was no difference in the percentage energy intake between groups at baseline 
for total fat, carbohydrate and protein. In addition, there was no difference in the type 
of dietary fat consumed by each group. At six weeks there was a significant 
difference between groups in the contribution of total fat and protein to energy intake 
(p = 0.014 and p =0.027 respectively).
A significant reduction in energy intake from total fat (p=0.015), total carbohydrate 
(p<0.01), SFA (p=0.014) and MUFA (p=0.016) was observed in the group 
consuming two eggs per day. Similarly, there was a significant reduction in energy 
from total fat (p=<0.01), total protein (p<0.044), SFA, MUFA and PUFA (p<0.001) 
in the control group. (Table 5.2)
134
Chapter 5 -T he EDWINA Study
Energy Restriction - 2 Eggs/Day Energy Restriction - Avoiding Eggs
Baseline 6 Weeks % Change Baseline 6 Weeks % Change
Energy 9.43 7.21** -25 8.58 6.10** -29
(MJ) (±2.40) (±2.4) (±2.23) (±1.50)
Total Fat (g) 82 55* -33 68 36**' -47
(±35) (±28) (±17) (±13)
SFA (g) 38 21* -45 28 14**t -50
(±26) (±10) (±9) (±7)
PUFA (g) 13 12 -8 13 g * * * t -38
(±5) (±8) (±4) (±3)
MUFA (g) 31 22* -29 26 -46
(±11) (±12) (±8) (±4)
Cholesterol (mg) 278 582** 109 258 -44
(±143) (±138) (±93) (±67)
Total 286 218* -24 271 219 -19
Carbohydrate (g) (±59) (±65) (±80) (±115)
Total Protein (g) 86 51 -6 76 68*' - 1 1
(±21) (±21) (±15) (±13)
Alcohol (g) 26 16 -38 24 14* -42
(±26) (±24) (±28) (±18)
Table 5.2 Dietary intakes at baseline and following 6 weeks of intervention. Values are 
means ±  standard deviation. *^<0.05, **p<0.01, ***p<0.001 within group sifferences. +p<0.05,
p<0.01 between group differences
Dietary modification resulted in an increase in the P:S ratio within both groups, 
which was significant in the group consuming two eggs per day (P=0.018), but not in 
the control group (Table 5.3). There was no significant difference in the P:S ratio 
between groups, either at baseline or at 6 weeks.
P:S Ratio Baseline P:S Ratio 6 Weeks
Energy Restriction including two 0.45 (±0.30) 0.59 (±0.29)*
eggs per day
Energy restriction avoiding eggs 0.51 (±0.20) 0.61 (±0.27)
Table 5.3: P:S ratio at baseline and 6 weeks. The PUFA:SFA (P.'S) ratio was assessed at 
baseline and 6 weeks for both intervention groups. A Significant increase in the P:S ratio 
was observed in the 2egg/day group only (*p<0.05 significantly difference within group).
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5.4.3 Body Composition
Changes in body weight and body composition are shown in Table 5.4. Both groups 
achieved significant weight loss over the 12 week period with an average weight loss 
of 3.3kg and 4.4kg in the groups consuming and avoiding eggs respectively. Weight 
loss in the egg-fed group was primarily achieved by a reduction in body fat mass 
(2.49Kg fat mass, 75% of total weight loss), whilst in the control group the loss of fat 
mass accounted for 52% of the total weight loss, with more weight being lost from 
the fat free mass compartment (2.27Kg). Both groups achieved the most weight loss 
between baseline and 6 weeks. There was no significant effect of diet and no 
significant diet x time interaction.
Energy Restriction - + 2 Eggs/Day 
n=24
Energy Restriction -Avoiding Eggs 
n=21
Baseline 6 Weeks 12 Weeks Baseline 6 Weeks 12 Weeks
Body Weight (kg) 83.11(±16.56)
80.78
(±15.98)
79.81**
(±16.00)
81.97
(±15.32)
78.53
(±14.84)
77.58**
(±14.74)
BMI (kg/m2) 29.54(±3.75)
28.71
(±3.71)
28.36
(±3.69)
28.53
(±4.19)
27.34
(±4.16)
27.01
(±4.14)
Waist
Circumference
(cm)
96.24
(±13.50)
95.46
(±12.11)
96.55
(±10.51)
93.02
(±11.75)
89.36
(±10.54)
93.43
(±9.88)
% Body Fat 35.83(±7.91)
35.15
(±7.24)
34.32
(±7.90)
34.61
(±7.37)
33.86
(±8.36)
32.84
(±8.89)
Body Fat Mass 
(kg)
30.25
(±11.51)
28.76
(±9.40)
27.76
(±9.58)
28.54
(±9.54)
27.01
(±10.41)
25.90
(±10.28)
Lean Mass (kg) 52.63(±9.21)
52.10
(±10.24)
52.07
(±10.47)
53.19
(±10.56)
51.66
(±9.97)
50.92
(±9.65)
Table 5.4. Body weight and composition. Results are mean ± standard deviation. 
Measurements of body weight and composition were taken at baseline and 6 and 12 
weeks following intervention. Both groups achieved significant and comparable 
weight loss with most weight loss occurring between baseline and 6 weeks. **p<0.01
(one way ANOVA within group).
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5.4.4 Plasma Lipids and Lipoproteins
5.4.4.1 Plasma Cholesterol
Despite an overall reduction in the mean concentration of plasma cholesterol in both 
the egg-fed and control groups, there was no significant effect of diet, whilst the 
effect of time and the diet x time interaction approached significance (P=0.073 and 
p=0.072 respectively). As predicted by the increased weight loss at 6 weeks, the 
control group showed a greater reduction in total cholesterol at this midway point 
than after 12 weeks (Table 5.5).
Total cholesterol- 
baseline (0 week)
Total cholesterol 
6week
Total Cholesterol 
12 week
2 eggs/day 5.38 5.34 5.10
n=24 (±1.14) (±1.15) (±1.24)
Control 5.29 4.71 5.07
n=21 (±0.99) (±0.94/ (±0.91)
Table 5.5 Plasma cholesterol response to dietary intervention. Values are means± 
standard deviation. There was no significant effect of time or diet x time interaction
The actual changes in plasma cholesterol between baseline and 6 weeks are 
compared with predicted changes as calculated by the equations of Keys in Table 
5.6. Key’s equations predicted an increase in plasma cholesterol in the egg fed group 
and a small decrease in the control group. Although there was no significant 
difference in the egg-fed group, overall they achieved a 0.04mmol/l reduction, while 
Keys predicted an increase of 0.09mmol/L (p=0.008). There was a significant 
difference between the predicted and actual reduction in the control group (p<0.05).
Predicted A plasma 
cholesterol concentration 
(mmol/L)
Baseline -  6 weeks
Actual A plasma cholesterol 
concentration (mmol/L) 
Baseline -  6 weeks
2 eggs/day 0.09 -0.04
(±0.12) (±0.01)
Control -0.06 -0.58
(±0.11) (±0.77) *
* p<0.05 significantly different to predicted response
Table 5.6: Mean predicted and actual changes in plasma cholesterol concentration 
(mmol/L) ±SD between baseline and 6 weeks.
138
To
tal
 C
ho
les
te
ro
l 
(m
m
ol
/L
)
Chapter 5 -T he EDWINA Study
Energy restriction Including 2 eggs/ day Energy restriction- Avoiding eggs
7.0
6.0
5.0
4.0
8.0
Figure 5.4. Box and whisker plots for changes in plasma cholesterol in egg fed and 
control groups. Boxes represent the inter-quartile range (50% of cases), whiskers the 
smallest and largest values. The median is shown as a black line within the box.
5.4.4.2 Plasma LDL-Cholesterol
5.4.4.3 Method o f LDL Measurement
In this study, LDL-cholesterol was determined by two methods; directly using a 
commercially available kit, and indirectly by calculation using the Friedewald 
equation.
While the LDL-C values produced by both methods were found to be comparable 
(R~ = 0.88), there was a consistent difference in LDL-C of approximately 0.5mmol/L 
(Figure 5.5). A paired samples t-test indicated a significant difference between 
methods at all time points. However, since the direct measurement of LDL-C is
reported to provide greater accuracy due to the lack of interference from plasma
TAG in excess of 4mmol/L, these values were used in preference to the calculated 
values to examine the effect of weight loss and dietary cholesterol on LDL.
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Comparison of direct- LDL vs calculated Baseline LDL Cholesterol
Time
- -o- - 2eggs/day direct
- -a- - control direct
-■—2 eggs/day calculated 
-*—control calculated
Baseline LDL-C Friedwald calculation
Linear Regression
Baseline LDL-C Direct method - 0.2« + 0.78 * FRIEDWALD 
R-Square = 0.88
Figure 5.5. Comparison of methods for the measurement of LDL-C. The two methods 
were positively correlated methods,, with the direct measurement of LDL-C showing a 
consistently lower results at all time points (p<0.05)
5.4.4.4 Plasm a LDL Cholesterol Response
The response of plasma LDL-C was similar to that of total plasma cholesterol. An 
overall reduction in LDL-C was observed in both groups, but this was not found to 
be significant for the main effects of diet, time and diet x time interaction (Table 5.7 
and Figure 5.6).
LDL-C baseline LDL-C 6 weeks LDL-C 12 weeks
2 eggs/day 3.11 3.06 2.95
•rt-<NIIe (±0.76) (±0.78) (±0.78)
Control 3.02 2.76 2.89
N=21 (±0.66) (±0.49) (±0.51)
Table 5.7 Plasma LDL-C response to dietary intervention.
Values are means (mmol/L) ± standard deviation.
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Figure 5.6: Box and whisker plot for LDL-C Response. Boxes represent the interquartile 
range (50% of cases), whiskers the smallest and largest values. The median is shown as a 
black line within the box. There was no significant effect of diet or diet x time interaction.
5.4.4.5 LDL Phenotype
Changes in the percentage of sdLDL and peak LDL density are shown in Figure 5.7. 
Although there were no significant changes in plasma LDL-C, the composition of 
LDL has an important role in determining CVD risk therefore it was valuable to 
assess compositional changes in LDL.
There was no significant effect of time or diet on LDL phenotype in tenns of the 
percentage of sdLDL, and LDL peak density. Between groups repeated measures 
ANOVA showed no significant diet x time interaction.
There was no overall change in LDL phenotype (pattern ‘A’ or ‘B') in the egg-fed 
group. In the control group, one subject converted from, pattern B to pattern A, while 
two subjects showed conversion from pattern A to B. In these two subjects, there was 
a marked increase in plasma TAG, (79% and 65%), that was not accompanied by 
any significant change in body weight. In addition, these subjects showed no 
increases in plasma total or LDL cholesterol.
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Figure 5.7: Box and Whisker Plots Showing LDL Subclass distribution. Boxes represent 
the inter quartile range (50% of cases), whiskers the smallest and largest values. The median 
is shown as a black line within the box. Top panel =  percentage AUC of small dense LDL 
(peak density >1.31 g/L), bottom panel =  LDL peak density g/L. Labelled data points denote 
outliers. Outliers were not excluded based on the 5% trimmed mean.
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5.4.4.6 Plasma Apoproteins
The changes in plasma apo B and apo A-I mirrored the LDL-C and HDL-C 
responses respectively with an overall reduction in these apoproteins observed over 
the twelve week intervention (Table 5.8 and Figure 5.8). There was a significant 
main effect of time for apo B (p=0.012) and a significant diet time interaction 
(p=0.001) which is accounted for by the greater reduction in apo B at 6 weeks in the 
control group corresponding to changes in LDL-C and total cholesterol.
There was no significant effect of time for apo A-I and diet x time interaction 
approached significance (p=0.076).
Energy restriction- 2 eggs/day
QApo B (g/L)
Baseline 6wk 12wk Baseline 6wk 12wk
Figure 5.8: Box and whisker plots showing apoprotein distribution. Boxes represent the 
inter-quartile range (50% of cases), whiskers the smallest and largest values. The median is 
shown as a black line within the box. There was a significant effect of time and a significant 
diet x time interaction for apo B, whilst the diet x time interaction for apoA-I approached
significance.
□ Apo B (g/L) 
■ Apo AJ <g/L)
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Energy Restriction - 2 Eggs/Day 
n=24
Energy Restriction - 
n=21
No Eggs
Baseline 6 Weeks 12 Weeks Baseline 6 Weeks 12
Weeks
Apo B (g/L)
0.92
(±0.25)
0.92
(±0.25)
0.85
(±0.26)
0.92
(±0.19)
0.76
(±0.18)
0.86
(±0.23)
Apo A-I (g/L) 1.25(±0.27)
1.24
(±0.27)
1.16
(±0.28)
1.22
(±0.27)
1.11
(±0.20)
1.19
(±0.20)
apoB:apoA-l
ratio
0.76
(±0.27)
0.77
(±0.25)
0.77
(±0.27)
0.78
(±0.20)
0.69
(±0.15)
0.73
(±0.21)
Table 5.8 Apoprotein response to dietary intervention.
Values are mean±SD
5.4.4.7 HDL-Cholesterol
The HDL response to the dietary interventions is shown in Table 5.9 and Figure 5.9. 
The change in the concentration of plasma HDL-C corresponded to the observed 
change in total plasma cholesterol, with an overall reduction after 12 weeks. Plasma 
HDL-C was relatively low at baseline, suggesting the co-existence of other 
components of the metabolic syndrome, such as low HDL, with elevated BMI and 
waist circumference. There was a significant effect of time (p=0.008), and though the 
diet x time interaction approached significance (P=0.053), there was no overall 
significant effect of diet.
Plasma HDL-C concentration (mmol/L)
Baseline 6 weeks 12 weeks
2 eggs/day 1.15 1.11 1.03
n=24 (±0.28) (±0.31) (±0.31)
Control 1.13 0.96 1.05
N=21 (±0.36) (±0.35) (±0.32)
Table 5.9. Plasma HDL-C response to dietary intervention.
Values are means (mmol/L)± standard deviation.
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Energy restriction + 2 eggs / day Energy restriction - Avoiding eggs
175-
0.25-
Baseline 6wk 12wk Baseline 6wk 12wk
Figure 5.9: Box and whisker plot for the HDL-C response. Boxes represent the 
interquartile range (50% of cases), whiskers the smallest and largest values. The median is 
shown as a black line within the box. There was a significant effect of time, however there 
was no significant effect of diet. Diet x time interaction approached significance.
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5.4.4.8 Plasma TAG Response
The plasma TAG responses to the dietary interventions are shown in Table 5.10 and 
Figure 5.10.
Since plasma TAG was not normally distributed according to the Shapiro Wilks test, 
values were log transformed before parametric tests were performed. The Shapiro 
Wilks test of the transformed data indicated that it was normally distributed and 
therefore a repeated measured mixed ANOVA was performed. Plasma TAG 
displayed the least variability over time of all the lipid measurements. There was no 
significant effect of time, diet, or diet x time interaction.
Baseline 6 weeks 12 weeks
2 eggs/day 1.26 1.30 1.15
n=24 (±0.56) (±0.62) (±0.44)
Control 1.39 1.26 1.37
N=21 (±0.59) (±0.48) (±0.72)
Table 5.10. Plasma TAG response to dietary intervention.
Values are means (mmol/L)± standard deviation.
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Figure 5.10. Box and whisker plot for TAG response. Boxes represent the interquartile 
range (50% of cases), whiskers the smallest and largest values. The median is shown as a 
black line within the box. There was no significant effect of diet or diet x time interaction.
5.4.5 Markers o f Insulin Resistance
Being overweight, obese, and/or an elevated waist circumference is common to all 
definitions of MetS these definitions also include markers of insulin resistance. 
Fasting plasma glucose and insulin were assessed at each visit together with the 
HOMA-IR (Table 5.11). Subjects in both groups had a mean fasting glucose 
>5.6mmol/L, suggesting impaired fasting glycaemia. Fasting insulin was mildly 
elevated, and HOMA values for insulin indicated impaired glucose tolerance (table 
5.11). There were no significant differences between groups and no significant diet x 
time interaction.
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Energy Restriction + 2 Eggs/Day Energy Restriction - Avoiding Eggs
Baseline 6 Weeks 12 Weeks Baseline 6 Weeks 12 Weeks
Fasting Glucose 5.65 5.70 5.66 5.81 5.76 5.71
mmol/L (±0.63) (±0.52) (±0.64) (±0.59) (±0.43) (±0.53)
Fasting Insulin 62.9 54.6 54.0 44.1' 48.2 45.9
pmol/L (±68.8) (±46.9) (±53.6) (±40.6) (±37.5) (±36.5)
HOMA-IR 2.14 1.84 1.83 1.44 1.59 1.47(±2.54) (±1.65) (±1.85) (±1.55) (±1.45) (±1.37)
Table 5.11 Markers of insulin resistance. Values are means ±  standard deviation. No 
significant effects of diet or diet x time interactions were observed.
5.4.6 One W eek W ashout- Effects on Body W eight and Plasma Lipids
Following the 12 week visit, all subjects were requested to return to their habitual 
diet for one week, after this time they returned to the university to provide a final 
blood sample. The results from measurements taken at 12 weeks and 13 weeks 
(washout) are shown in Table 5.12. Although there was little reduction in weight 
between time points, the difference was considered significant in both groups. This 
may, in part, be due to a continuation of the diet in some individuals. The control 
group also showed a significant decrease in HDL-C, this was in line with the 
reduction in total cholesterol and LDL-C, although these were not considered 
significant.
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Energy Restriction +  2 Eggs/Day Energy Restriction - Avoiding Eggs
12 Week 13 Week 12 Week 13 Week
Weight 79.8 79.5 77.58 77.92
(kg) (±16) (±16.9) f (±14.74) (±14.79) f
Waist 96.5 96.1 93.43 93.47
Circumference
(cm)
(±10.5) (±9.4) (±9.88) (±9.32)
Total Cholesterol 5.10 5.17 5.07 4.77
(mmol/L) (±1.24) (±1.28) (±0.91) (±0.88)
LDL-C 2.95 2.83 2.89 2.77
(mmol/L) (±0.78) (±1.02) (±0.51) (±0.57)
HDL-C 1.03 1.01 1.05 0.93
(mmol/L) (±0.31) (±0.30) (±0.32) (±0.38) f
TAG 1.15 1.27 1.37 1.29
(mmol/L) (±0.44) (±0.55) (±0.72) (±0.68)
t  p<0.05 between 12 week and 13 week visits
Table 5.12: Changes in body composition and plasma lipids following a one week 
washout period. Significant differences were observed in body weight between 12 and 13 
week visits in both the control and egg fed groups. HDL-C was significantly reduced 
following the washout period in the control group alone. Values are mean ±SD
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5.5 DISCUSSION
The aim of this study was to test the hypothesis that weight loss, resulting from an 
energy restricted diet, would negate the potential cholesterol-raising effect of 
increased dietary cholesterol. This study was of a parallel design, with two groups 
each of whom followed an energy restricted diet either avoiding eggs or including 
two eggs per day.
Both the egg fed and control groups achieved similar and predictable weight loss. 
After six weeks of intervention, the egg-fed group had increased their intake of 
dietary cholesterol by an average of 297mg/day. At baseline the daily cholesterol 
intake of both inteivention groups was not significantly different, although it was 
higher than expected (227 and 258 mg/day in the egg-fed and control groups 
respectively). Eggs are a major source of dietary cholesterol and it is likely that 
participants who regularly consume eggs were attracted to the study, producing a 
higher than expected intake at baseline.
The dietary guidelines provided by a trainee dietician were those of the BHF 
publication “So you want to lose weight for good”. These guidelines focus on the 
replacement of dietary fat with carbohydrate, together with a restriction on alcohol 
consumption. The reported energy intakes, corresponding weight loss and changes in 
the intake of dietary cholesterol suggested good compliance to the dietary guidelines. 
Volunteers also appear to have achieved a reduction in energy intake from the 
appropriate macronutrient groups, in particular, a reduction in dietary fat was 
achieved by reducing primarily, the intake of saturated fat, resulting in an increase in 
the P:S ratios in both intervention groups.
Although there was no significant effect on total cholesterol, both groups showed 
evidence of a decrease in plasma total cholesterol with parallel reductions in LDL-C 
and HDL-C. The significant reduction in both the concentration of plasma apo B and 
LDL-C would suggest that there was a significant reduction in LDL particle number 
without any change in the composition of LDL. However, the concentration of LDL- 
C as measured directly, did not reach significance which may indicate the limitations 
of the method in terms of its specificity for LDL-C. Although the reduction in HDL-
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C is inconsistent with a reduction in CHD risk, there was no significant effect on the 
HDL:LDL ratio which suggests that the corresponding reduction in the more 
atherogenic lipoproteins may have compensated for the increased risk associated 
with a reduction in HDL-C.
5.5.1 Dietary factors affecting plasma lipids
The plasma concentration of total and LDL cholesterol is determined by both 
endogenous and exogenous factors. It is widely accepted that the composition of our 
diet can influence lipid-mediated CHD risk, with the intake of dietary saturated fatty 
acids (chiefly SFA with 12 to 16 carbons) being positively associated with risk 
through its LDL-raising effects. While, this latter effect of saturated fat was founded 
on evidence from both epidemiological and intervention studies, the idea that dietary 
cholesterol increases CHD risk by raising plasma LDL cholesterol, is a much more 
contentious issue.
Prospective studies of egg consumption and CVD risk are inconsistent in terms of the 
risk associated with increased egg consumptions. A minority of studies indicate that 
egg consumption increases CVD risk. However, these studies include a number of 
potentially uncontrolled confounding variables. Other prospective studies have found 
no association between dietary cholesterol (in the form of eggs) and CVD risk. Data 
from the Framingham study has shown no differences in serum cholesterol between 
tertiles of egg consumption (0-2 eggs, 3-6eggs and >7eggs per week) (Dawber,1982). 
Hu et al (1999) investigated the relationship between egg consumption and CVD in 
two prospective studies: the Health Professionals Follow-up Study and the Nurse’s 
Health Study. It was concluded that the consumption of up to one egg per day does 
not affect CVD risk, unfortunately neither of these studies measured serum/plasma 
total cholesterol. In the Health Professionals Follow-up study and the Nurse’s Health 
Study, egg intake was positively associated with bacon consumption, in males and 
females, and with whole milk, red meat and a reduced intake of fruit and vegetables 
in men only. These epidemiological observations suggest that eggs are a surrogate 
marker for a poor diet and increased SFA intake, and that it is these components of 
the diet that increase CVD risk and not the increased dietary cholesterol.
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A wealth of epidemiological evidence fails to support a link between dietary 
cholesterol, egg consumption and CVD (Mann 2000). However, interventions 
investigating the effects of increased dietary cholesterol, chiefly in the form of eggs, 
on plasma lipids have demonstrated either no effect of egg consumption on plasma 
lipids (Edington et al 1987, Flynn et al 1979) or a small increase in plasma total and 
LDL-cholesterol. Ginsberg et al (1994, 1995) demonstrated a positive dose-response 
relationship between dietary cholesterol and plasma total-HDL and LDL-cholesterol 
in both healthy young men and women (Ginsberg et al 1994, Ginsberg et al 1995). 
However, since these results were part of a study with carefully controlled conditions 
and dietary intakes, they may not translate into free-living subjects.
In the present study, both intervention diets produced favourable effects on plasma 
lipids which may somewhat be accounted for by positive changes in the P:S ratio. 
The P:S ratio of the diet has previously been shown to affect the serum cholesterol 
response to increased dietary cholesterol in the form of eggs (Weggemans 2003, 
amongst others). Schonfeld et al (1982) showed a significant increase in serum 
cholesterol following three eggs/day and a diet with a P:S ratio of 0.25-0.40. When 
the P:S ratio was increased to 0.8 this effect was no longer significant. Likewise, the 
addition of six eggs/day to a diet with a P:S ratio of 0.25-0.40 produced a significant 
increase in serum cholesterol but this was insignificant when six eggs per day were 
incorporated into a diet with a P:S ratio of 2.5 (Schonfeld et al. 1982). A study by 
Zanni in 1987 has also reported a similar effect of fatty acid composition with diets 
high in SFA and cholesterol having a greater effect on plasma cholesterol than diets 
with equivalent amounts of PUFA and added dietary cholesterol (Zanni et al 1987).
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5.5.2 The effect o f energy restriction and weight loss on plasma lipids
A number of studies have shown reduction in plasma cholesterol concentration 
following weight loss. A meta analysis by Datillo and Kris-Etherton (1992) 
estimated that for each 1kg reduction in body weight there would be a 0.05mmol/L 
reduction in plasma cholesterol concentration. The absolute reduction in plasma 
cholesterol achieved in the present study (0.28 and 0.22mmol/L in the egg fed and 
control groups respectively) was similar to that estimated by the weight loss achieved 
in the control group (-4.4kg = -0.22mmol/L T-Chol) yet was greater than that 
predicted in the egg fed group (-3.3kg = -0.17mmol/L T-Chol).
While many studies have addressed the separate effects of increased dietary 
cholesterol or the effect of weight loss on plasma lipids, only one study to date has 
considered the combined effect of weight loss and increased dietary cholesterol. 
Lacombe et al (1986) investigated the effect of a low energy diet supplemented with 
four eggs/day in normal subjects. In this study, subjects achieved a reduction in body 
weight of between 1.3 and 4.5kg over a four week period. The study was a cross over 
design and demonstrated a sequence effect of the diets. Those who received their 
usual diet supplemented with four eggs/day displayed a reduction in plasma 
cholesterol when provided with an energy restricted, egg supplemented diet for a 
further four weeks, whereas those who received the energy restricted diet first 
showed an increase in plasma cholesterol. The subjects who took part in this study 
had a relatively high intake of dietary cholesterol prior to beginning the study, it 
could be proposed that the effect seen by Lacombe et al was reproduced in the 
present study (Lacombe et al. 1986). In addition, one subject in the egg-fed group 
responded to the diet with more than a 50% increase in total cholesterol, despite 
achieving a weight reduction of 7.9ICg. For this subject the initial intake was 
69mg/day whilst the average for the group was 278mg/day, this response 
corresponds to that observed in the study by Lacombe in which the low fat high 
cholesterol diet was given as the first leg of the crossover. The effect of baseline 
cholesterol intake on responsiveness to dietary cholesterol has also been 
demonstrated by Hopkins (1992). Data from a meta-analysis of 27 studies that used 
controlled dietary intakes, suggests that those with a low baseline intake of
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cholesterol in the diet show greater responses in serum cholesterol following addition 
of cholesterol to the diet (Figure 5.1 l)(Hopkins 1992).
Figure 5.11 The effects of 
added dietary cholesterol on 
total serum cholesterol. The
response to added dietary 
cholesterol is greatest when 
baseline intakes are low. (taken 
from (Hopkins 1992)
A#4td Otatary ChoiMtarol (MfMiy)
However, despite convincing evidence in the literature to link the baseline intake of 
dietary cholesterol with the response to increased dietary cholesterol, there was no 
evidence of any association between reported baseline intakes of cholesterol and 
either the absolute change in plasma cholesterol or the percentage change between 
baseline and the 12 week visit.
The dietary advice that was provided to volunteers aimed to achieve an energy 
restriction through reductions in both dietary fat and carbohydrate. The advice did 
not promote extreme reductions in either dietary fat or dietary carbohydrate. 
However, the increased dietary cholesterol of the egg-fed group is likely to be 
comparable to that achieved following a low carbohydrate diet such as Atkins. The 
lipid response in the control group is consistent with that of previous studies that 
showed a reduction in lipid levels following weight loss (Dengel et al 1995), 
however these changes were not significant in the current study which may be due to 
a smaller amount of weight loss than that achieved on other studies.
The neutral or favourable effects of low carbohydrate diets on plasma lipids suggests 
that weight loss may be superior in influencing plasma total and LDL cholesterol 
than dietary components. While the equal weight loss and comparable reductions in 
plasma LDL cholesterol in both groups in the present study would support this, there 
was no evidence of any associations between body weight, weight or fat loss and the
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change in plasma lipids. The study groups were small and thus the variation in 
outcome measures within groups large because of the within subject variability 
associated with plasma lipids and body weight. Moreover, the absence of weight 
maintained, egg-fed and non egg-fed control groups meant that it was not possible to 
discriminate between the effects of weight loss and dietary cholesterol on plasma 
lipids.
Recent studies suggest that the high satiety index of eggs may promote greater 
weight loss when eaten at breakfast as part of an energy restricted diet (Vander Wal 
et al 2005, Dhurandhar et al, 2007). In the present study, subjects were instructed to 
eat two eggs per day with no imposed limitations on meal timing. The weight loss 
achieved by the egg-fed and non egg-fed groups was comparable which suggests that 
superior weight loss is only attained when eggs are consumed at breakfast and that 
the increases in subjective satiety would not be observed following an egg-based 
evening meal or are not continued through to the following day. Since the time of 
day and/or the form in which eggs are eaten may influence satiety, this study was 
clearly neither designed or powered to test this hypothesis.
5.5.3 M echanism s by which weight loss and dietary cholesterol may affect 
cholesterol homeostasis.
The concentration of plasma LDL-cholesterol is regulated to a major exent by the 
levels of intracellular cholesterol which are controlled by the activity of LDL 
receptors present on the cell membrane (Brown and Goldstein, 1986). Increases in 
LDL-C associated with dietary cholesterol and SFA have been attributed to down 
regulation of LDL receptor activity (Miller et al 1981, Dietschy 1998). Weight loss, 
when achieved through a low carbohydrate diet, has been shown to enhance LDL 
receptor activity. It is conceivable that the weight loss achieved in the present study 
was more effective in terms of modulating LDL receptor activity than the increased 
dietary cholesterol, resulting in an equal reductions in plasma LDL and HDL 
cholesterol in both intervention groups.
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Weight loss and dietary cholesterol may also modulate plasma lipid levels through 
effects on cholesterol homeostasis in terms of absoiption, biosynthesis and excretion. 
Nestel and Poyer (1976) have demonstrated that hypo-responders to dietary 
cholesterol were more likely to suppress cholesterol synthesis in response to a 
cholesterol challenge, while hyper-responders compensate less efficiently through 
increased cholesterol excretion (Nestel and Poyser, 1976). A recent study 
investigating the influence of weight loss on cholesterol metabolism, revealed that a 
weight reduction of ~12ICg reduces the rate of cholesterol synthesis in women 
(Santosa et al, 2007). This study supports the previous findings of Di Buono et al,
(1999), who observed that a modest reduction in body weight of 3-8Kg resulted in a 
reduction in cholesterol synthesis. Similar findings were produced in a study that 
reported a loss in body weight of 3kg in response to energy and fat restriction. The 
weight loss and plasma cholesterol response was similar to the present study, and 
explained by a reduction in the fractional synthetic rate of cholesterol (Raeini-Sarjaz 
2001).
In conclusion, this study provides evidence that eggs should not be excluded from an 
energy restricted diet, as weight loss appeared to be more powerful in determining 
plasma lipid levels than dietary cholesterol. This study was insufficiently powered 
and inappropriately designed to test whether eggs produce superior weight loss. It 
could be proposed that for the satiety index of eggs to produce weight loss, they 
must be eaten at breakfast with the aim of reducing energy intake at subsequent 
meals. The subjects on this study were not given specific instructions as to what time 
of day to eat the eggs, and thus the potential of eggs to produce superior weight loss 
warrants further investigation.
Although this study showed an overall reduction in plasma lipids following an 
energy restricted diet, with or without eggs, the lipid response was highly variable 
between individuals. Cholesterol homeostasis is maintained though a number of 
mechanisms which include endogenous synthesis and absorption of dietary 
cholesterol, differences in the activities of these pathways and the response to weight 
loss between individuals may partially explain the variability in plasma cholesterol 
response. The variability in the plasma cholesterol response to weight loss observed 
in this study will be explored in the following chapter.
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CHAPTER 6 -  Genetic and Metabolic Influences on the Plasma Lipid 
Response to Increased Dietary Cholesterol and Weight 
Loss in the EDWINA Study.
Abstract
Backsround_____________________________ ____________________________
The plasma lipid response to changes in dietary fa t and cholesterol are highly 
variable between individuals. A number o f  factors contribute to this variation 
including physiological factors and genetic polymorphisms. It has been suggested 
that polymorphisms in the apo E  gene affect cholesterol absorption and consequently 
cholesterol synthesis. More specifically, the apo E4 isoform has been associated with 
higher rates o f  cholesterol absorption suggesting that apo E4 carriers will 
demonstrate an exaggerated response to increases in dietary cholesterol. In addition, 
rates o f  cholesterol synthesis and absorption have been shown to be elevated and 
reduced respectively in subjects who are overweight and obese, and responsive to 
weight loss and dietary cholesterol.
Study Aim and Hypothesis ______ _______________ _____________________
The aim o f this study was to evaluate possible sources o f variation in plasma lipid 
response to increased dietary cholesterol and weight loss in the EDWINA Study, with 
focus on the influences o f  apo E genotype, and markers o f cholesterol absorption and 
synthesis. The hypothesis was that the expression o f apo E4 will be associated with 
higher rates o f  cholesterol absorption and lower cholesterol synthesis, and thus be 
more responsive to increased dietary cholesterol and weight loss.
Methods_____________________________________________________________
Participants o f  the EDWINA study were retrospectively genotyped fo r  the apo E  
polymorphism. Serum samples were collected at baseline and at the end o f the 12 
week intervention fo r the measurement o f  plasma markers o f  cholesterol synthesis 
(lathosterol and desmosterol) and absorption (cholestanol and sitosterol)
Results_______________________________________ _______________________
Following weight loss, both egg-fed and non egg-fed groups demonstrated a 
reduction in serum lathosterol and increase in serum cholestanol which were 
significant in the egg-fed group (p <0.05). Carriers o f  the apo E4 allele 
demonstrated significantly higher serum sitosterol to cholesterol ratio at baseline, 
but there were no significant changes in markers o f cholesterol absorption or 
synthesis in response to increased dietaiy cholesterol and weight loss in this group.
Conclusions _______________________ ______________________________
The reduction in plasma cholesterol concentration associated with weight loss in 
EDWINA may be explained, in part, by decreased endogenous cholesterol synthesis, 
as indicated by the decrease in plasma lathosterol. Whilst carriers o f  the apo E4 
allele showed elevated cholesterol absorption, apo E genotype did not explain the 
variability in plasma cholesterol response.
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6.1 INTRODUCTION
Cholesterol can be both endogenous and exogenous in origin, being synthesised in 
the liver and peripheral tissues or absorbed from the diet respectively. Cholesterol 
homeostasis is maintained, in the main, by intestinal cholesterol absorption, 
endogenous cholesterol synthesis and the excretion of cholesterol as bile acids. If 
homeostasis is to be maintained then increases in intestinal cholesterol absoiption 
must be accounted for, in part or in whole, by a compensatory decrease in 
endogenous synthesis (Santosa et al 2006). The plasma cholesterol response to 
dietary cholesterol has been shown to be highly variable between individuals with 
the existence of consistent hypo and hyper-responders (Katan et al. 1986). A 
phenomenon also observed in the EDWINA study detailed in chapter 5 (figure 6.1). 
It can be proposed that these differences in response occur, in part, due to differences 
or changes in one or more of the vectors of cholesterol homeostasis. Numerous 
physiological and genetic factors influence cholesterol absorption and synthesis, and 
perturbation of these mechanisms by one or more sources may result in a failure to 
compensate and, in the case of increased dietary cholesterol, may lead to an increase 
in plasma total-cholesterol.
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6.1.1 Physiological and Therapeutic Factors Affecting Cholesterol Homeostasis
There are several physiological factors that influence the pathways of cholesterol 
absoiption and synthesis. These have been reviewed by Santosa et al (Santosa et al. 
2007b) and include circadian rhythm (Jones & Schoeller 1990), body weight (Di 
Buono et al. 1999), plant sterols and stands (Jones et al. 2000), and drugs which 
target cholesterol absoiption (Sudhop et al. 2002) or synthesis (Miettinen et al. 
2000). In a population that is becoming increasingly overweight, the impact of 
obesity and weight loss on cholesterol metabolism, and the subsequent response to 
dietary fat and cholesterol is of immediate relevance to public health.
Miettinen et al measured cholesterol metabolism using a sterol balance approach and 
found that obesity was positively and significantly correlated with cholesterol 
synthesis (Miettinen et al, 1971). On the other hand, the efficiency of cholesterol 
absoiption in the gut, has been shown to be reduced in obese subjects (Miettinen & 
Gylling, 2000). Dietary management of obesity primarily involves energy restriction 
to promote weight loss. Weight loss of 3-Skg, achieved by an energy restriction of 
~4MJ/day, has been shown to reduce absolute cholesterol synthesis which may, in 
part, account for the corresponding reduction in plasma total cholesterol (Di Buono 
et al 1999). A study by Raeini-Sarjaz et al showed a reduction in cholesterol 
synthesis following low fat, and low fat plus energy-restricted diets, with resultant 
weight loss, though this study was a cross-over study and did not investigate the 
effect of the order of diets on its outcome measures (Raeini-Sarjaz et al. 2001). 
Santosa et al explored the relationship between cholesterol homeostasis and weight 
loss. In this study, hypercholesterolaemic women with a BMI>25 lcg/m2 achieved an 
energy deficit of 30% through a combination of dietary restriction (<30% energy 
from fat) and exercise. Subjects lost on average 11.2kg which resulted in significant 
reductions in plasma total and LDL cholesterol, together with a reduction in 
cholesterol fractional synthetic rate. No reciprocal relationship between synthesis and 
absoiption was observed (Santosa et al. 2007a).
Rates of cholesterol synthesis have been shown to be elevated and cholesterol 
absorption lower in subjects expressing features of the metabolic syndrome. Chan et
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al used plasma non-cholesterol sterols to assess cholesterol homeostasis in obese 
males defined as having the metabolic syndrome by the NCEP ATP III criteria. In 
this study, obese subjects had significantly lower levels of campesterol, a marker of 
cholesterol absorption, and significantly higher levels of lathosterol, a marker of 
cholesterol synthesis, when compared to controls (Chan et al. 2002). More recently, 
Gylling et al examined cholesterol absoiption in overweight subjects with MetS, 
according to NCEP criteria, as compared to matched controls. In this study, which 
also measured non-cholesterol sterols as markers of absoiption and synthesis, 
lathosterol and desmosterol were significantly higher and sitosterol and cholestanol 
significantly lower in MetS subjects compared to controls. However, when this data 
was adjusted for BMI and waist circumference plasma plant sterols were no longer 
significantly lower in the MetS group, suggesting that body weight was the major 
contributing factor to disruption of cholesterol homeostasis. In addition, data for the 
whole group (controls and MetS) revealed that BMI and waist circumference were 
associated with the cholesterol synthesis to absorption ratio (Gylling et al. 2007). 
Insulin resistance and other characteristics of the metabolic syndrome form the basis 
of type II diabetes. In a study by Simonen et al, serum markers of cholesterol 
synthesis were significantly higher in overweight type II diabetics compared to 
normal weight diabetic controls, while serum markers of cholesterol absoiption were 
significantly lower, suggesting that body weight has an important role in modulating 
cholesterol homeostasis (Simonen et a l 2006). Other studies that have addressed the 
impact of insulin resistance and type II diabetes on cholesterol homeostasis have 
confirmed the pattern of elevated synthesis and reduced absoiption, though some 
have also found no association with body weight (Pihlajamalci et a l 2004).
Briones et al measured cholesterol absorption in three groups of diabetics with either 
normal lipids, hypercholesterolemia or hypertriglyceridaemia, as compared to 
matched non-diabetic controls. In this case, significantly lower rates of cholesterol 
absoiption were only observed in hypertriglyceridaemic diabetics compared to non­
diabetics with equivalent concentrations of plasma TAG. Cholesterol absoiption was 
also shown to be inversely related to plasma TAG (Briones et a l 1986). Pihlajamalci 
et al demonstrated elevated concentrations cholesterol precursors in plasma, 
suggesting an increased rate of cholesterol synthesis in subjects with insulin 
resistance, that was independent of body weight (Pihlajamalci et a l 2004). Simonen
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et al have also investigated the influence of energy restriction on plasma lipids and 
cholesterol metabolism in overweight subjects with type 2 diabetes mellitus. In this 
study, a very low energy diet (97ICJ/day) resulted in significant weight loss 
accompanied by a significant reduction in plasma total and LDL cholesterol and 
plasma markers of cholesterol synthesis. Moreover, the estimated reduction in 
cholesterol synthesis was associated with a reciprocal increase in cholesterol 
absorption, as estimated by the ratio of serum cholestanol to cholesterol. There was 
no significant changes in either the serum sitosterol or campesterol to cholesterol 
ratios (Simonen et al. 2002a).
6.1.2 Dietary cholesterol and cholesterol homeostasis
The metabolic responses to increased dietary cholesterol may include a reduction in 
endogenous synthesis, decreased absorption and increased biliary excretion. Jones et 
al demonstrated a small reduction in cholesterol synthesis with increasing dietary 
cholesterol, while McMurry et al observed a 50% reduction in cholesterol synthesis 
following the addition of 900mg cholesterol to the diet. (Jones et al. 1996a,McMurry 
et al. 1985). On the other hand, cholesterol absoiption has been shown to be reduced 
as the cholesterol content of a meal was increased in an acute feeding study (Ostlund 
etal. 1999).
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6.1.3 The influence o f genotype on cholesterol metabolism and response to 
dietary cholesterol and weight loss
Baseline total plasma cholesterol has been shown to influence the response to dietary 
cholesterol (Hopkins, 1992). As baseline cholesterol values are partially determined 
by genotype, this suggests a possible role for genotype in explaining inter-individual 
variability in lipid changes following dietary intervention.
Twin studies have estimated that genotype accounts for around 50% of the variation 
in fasting plasma total cholesterol (Heller et al, 1993). A number of genetic 
polymorphisms have been identified which contribute to the variability in response to 
dietary intervention. Of these, the most extensively studied have been those of 
apoprotein E, with polymorphisms in this gene estimated to account for 7-17% of the 
variability in baseline plasma cholesterol levels (Dallongeville et al. 1992, Davignon 
et al. 1988, Boerwinkle & Sing 1987)
6.1.3.1 Apolipoprotein E  Genotype
Apolipoprotein (apo) E is a 299 amino acid protein that is synthesised primarily in 
the liver and brain. The gene coding apo E is located on the long aim of chromosome 
19 in a cluster with apo C-I and apo C-II. This genetic polymorphism is based on a 
cysteine-arginine interchange at positions 112 and 158. This gives rise to three major 
isoforms; E2. E3 and E4, and thus six apo E phenotypes: E2/E2, E2/E3, E2/E4, 
E3/3/, E3/E4 and E4/E4 which are present at different frequencies in the population. 
The frequency of the homozygote genotypes is estimated to be 1%, 64% and 2% for 
E2/E2, E3/E3 and E4/E4 respectively, whilst the frequencies of the heterozygote 
genotypes is estimated to be approximately 19%, 10% and 4% for E3/E4, E2/E3 and 
E4/E2,(Ye & Kwiterovich, Jr. 2000, Eichner et al 2002).
Apo E is a component of chylomicrons, VLDL and HDL. Polymorphisms in the 
apo E gene affect ligand binding of the triacylglyeerol-rich lipoproteins and HDL to 
hepatic LDL and apo E receptors. Consequently, apo E genotype can, in part, explain 
variations in plasma lipids. For example, when compared to E3 and E4 genotypes, 
earners of the E2 allele exhibit, a reduced clearance of chylomicrons and remnants, 
from the plasma, reduced hepatic cholesterol levels and increased LDL receptor
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activity (Gregg & Brewer 1988). Apo E genotype has also been shown to influence 
the absoiption of dietary cholesterol and endogenous cholesterol synthesis. 
Kesaniemi et al (1987) examined the influence of apoE genotype on rates of 
cholesterol absorption and synthesis using the continuous cholesterol-p-sitosterol 
feeding method, this group found lower rates of absoiption and higher rates of 
synthesis in E2 earners compared with carriers of the E3 or E4 isoform. The reverse 
was found for carriers of the E4 allele, which displayed increased rates of cholesterol 
absorption and a reciprocal decrease in synthesis (Kesaniemi YAC et al. 1987). 
Using the same technique Gylling et al demonstrated significantly lower rates of 
cholesterol absorption among male E2 earners and significantly higher cholesterol 
absoiption amongst E4 carriers when compared to E3 (Miettenen 1992). Similarly 
Gylling et al demonstrated lower cholesterol absoiption in male E2 carriers (Gylling 
et al 1995).
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6.2 AIMS AND OBJECTIVES
The response to dietary fat and dietary cholesterol has been shown to be highly 
variable. In EDWINA (Chapter 5), the mean reduction in plasma total cholesterol 
was similar in both the egg-fed and control group following an energy restricted diet 
but there was marked variability in response between individuals. The variability in 
plasma lipid response was not explained by correlations with body weight.
Previous studies have addressed the impact of dietary cholesterol and energy 
restriction on cholesterol homeostasis independently and to date no study has 
investigated the variation in response to the combined effect of these interventions.
The aim of the present study was to investigate the variability in plasma cholesterol 
response to energy restriction and dietary cholesterol, with focus on the influence of, 
and inter-relationships between apo E genotype, cholesterol synthesis and absoiption 
with changes in plasma lipids observed following weight loss. The hypothesis of this 
investigation was that carnage of the apo E4 allele, and high absorbers of cholesterol 
(low synthesisers) will be associated with greater responsiveness to dietaiy 
cholesterol. The concentration of various plasma sterols was determined as surrogate 
markers of cholesterol synthesis and absoiption.
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6.3 M A TERIA LS AND M ETH O DS
6.3.1 Subjects
Subjects were healthy male and females participating in the Eggs in a Diet for 
Weight loss in Normolipidaemic Adults (EDWINA)study (Chapter 5). All subjects 
were either overweight or obese (class 1) and normolipidaemic.
6.3.2 Study Design
The study was randomly controlled, with a parallel design. This study formed part of 
the larger EDWINA study and was granted favourable ethical approval by the 
University of Surrey Ethics Committee (EC/2004/109/SBMS). Subjects were 
randomly allocated to follow an energy restricted diet with or without eggs for 12 
weeks, as detailed in Chapter 5. Samples were taken for the measurement of plasma 
non-cholesterol sterols at baseline and following the 12 week intervention. Buffy 
coat was also stored at baseline for the extraction of DNA and assessment of apo E 
genotype.
F igu re 6.2. S tu dy D esign . The study was a randomly controlled parallel design with tw o  
intervention groups. Sam ples w ere taken at baseline and fo llow in g 12 w eeks for the 
measurement o f  non-cholesterol sterols. B uffy coat sam ples w ere taken at baseline for D N A  
extraction and restriction isotyping for ApoE.
6.3.3 Biochemical A nalysis
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The biochemical analysis of plasma lipids and apolipoproteins was earned out 
according to the methodologies described previously in Chapter 2.
6.3.4 ApoE Restriction Isotyping
Apo E genotype was characterised using the restriction isotyping method of Hixson 
and Vernier (1990) described previously in Chapter 2 section 2.5.
6.3.5 Measurement o f Serum Non-Cholesterol Sterols.
There are a number of techniques available for the assessment of cholesterol 
absorption and synthesis. The gold standard for the measurement of cholesterol 
absoiption is to perform a sterol balance study, which calculates the mass absoiption 
of cholesterol as the balance between dietary cholesterol intake and fecal cholesterol 
excretion. Although this method is the gold standard, it is time consuming and the 
collection of faeces is unacceptable for many volunteers. The rate of incorporation of 
deuterium into free cholesterol in the red cell membrane 24 hours after ingestion has 
been used as a measure of cholesterol synthesis, but this technique is also time 
consuming and labour intensive.
A less invasive technique for the assessment of changes in cholesterol homeostasis is 
the measurement of serum non-cholesterol sterols that have been proposed as 
indicators of cholesterol metabolism (Miettinen et al. 1990). Lathosterol and 
desmosterol are precursors in the cholesterol synthetic pathway which are thought to 
appear in the serum at a rate that is proportional to their formation. The concentration 
of lathosterol and desmosterol in serum is positively associated with cholesterol 
synthesis and the activity of HMG-CoA reductase (Bjorkhem et al. 1987,Miettinen, 
Tilvis, & Kesaniemi 1990,ICempen et al. 1988). Plant sterols such as sitosterol and 
campesterol are consumed in similar amounts to dietary cholesterol, though less than 
one percent is typically absorbed. Despite this low absorption of plant sterols their 
concentration in serum has been shown to be positively associated with the fractional 
absoiption of cholesterol (Tilvis & Miettinen 1986). Cholestanol is the 5-ethyl 
derivative of cholesterol which is present in the serum at a ratio of around 1/500 to 
1/800 the concentration of cholesterol (Seyama Y 2003). Cholestanol has been used
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as a marker of cholesterol absorption to differentiate between subjects with either 
relatively high or low rates of cholesterol synthesis or absorption (Hoenig et a l  
2006).
In the current study serum non-cholesterol sterols were measured using gas 
chromatography mass spectrometry (GC-MS)(Ahmida et al. 2006) at Newcastle 
Royal Infirmary. Briefly serum was saponifed using a 4% solution of potassium 
hydroxide in ethanol and sterols extracted with hexane. Following extraction samples 
were derivatised to trimethylsilyl ethers using Trimethylchlorosilane (TMCS) and N, 
0-Bis(trimethylsilyl)trifluoroacetamide (BSTFA). lpL of derivatised sample was 
injected into a Micromass Quattro II mass spectrometer with Hewlett Packard 5890II 
GC and autosampler. Samples were separated on a J&W®DB5-MS, 30m (0.25pm x 
0.32mm id) column and detected using mass spectrometry in positive ion mode. 
Following separation peaks were quantitated from an external calibration cuive.
Seram non cholesterol sterols are expressed as a ratio of mmol per mole of total 
serum cholesterol.
6.3.6 Statistical Analysis
All data was analysed using SPSS version 14 (SPSS inc. Chicago, USA).
Data was tested for normality using the Kolmogorov-Smimov test. Data that did not 
follow a normal distribution was log or square root transformed, depending on the 
distribution of scores, and retested for normality before running parametric tests. The 
results were screened for outliers but included data based on the mean and 5% 
trimmed mean values. On this basis, no outliers were excluded from analysis. 
Changes in all variables measured between baseline and the end point visit (within 
group, over time) were analysed using a two-tailed, Student’s (-test for paired data. 
Between group data was analysed using an independent Students (-test.
Differences in biochemical parameters amongst apo E genotypes at baseline, were 
assessed using a one way between groups ANOVA. The interaction between 
genotype, diet (egg fed or non-egg fed) and time (baseline and 12 weeks) was 
assessed using a factorial MANOVA. Correlations between variables were assessed
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using the Pearson product-moment correlation. Correlations were also assessed using 
partial correlations, controlling for body weight.
Genotyping of subjects identified one subject who was homozygous for the E2 allele. 
Plasma lipids for this subject were within the inclusion/exclusion limits of the study 
but with moderately elevated TAG (2mmol/L at baseline). Plasma apo E, on the 
other hand, was two-fold higher than the average of other participants (0.1 g/L) and 
therefore this subject was excluded from analysis.
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6.4 R E SU L T S
6.4.1 Baseline Characteristics o f  Subjects
Table 6.1 shows the baseline characteristics of the subjects including plasma non­
cholesterol sterols, total plasma apo E and body weight. Subjects were initially 
recruited according to elevated body weight. They also displayed moderately 
elevated plasma desmosterol and sitosterol to cholesterol ratios.
Energy Restriction Including 2 E ggs/ Day Energy Restriction A void ing E ggs
M ales Fem ale Total
Group
M ales Fem ales
N =15
Total
Group
Body Weight (kg) 93.8 77.8* 83.1 96.04 78.74* 82.4
{±6.7) (±10.9) (±16.6) (±15.8) (±13.0) (±15.59)
Desmosterol 40.3 42.5 41.8 59.1 38.9* 43.1
( 102mmol/mol
cholesterol)
(±8.9) (±12.7) (±11.4) (±9.1) (±11.6) (±14.4)
Lathosterol 137.7 129.9 132.5 176.0 113.4 129.0
( 102mmol/mol
cholesterol)
(±38.2) (±53.1) (±47.9) (±59.8) (±67.1) (±69.6)
Cholestanol 117.7 115.9 116.5 100.6 137.08 128.0
( 102mmol/mol
cholesterol)
(±23.0) (±24.5) (±23.5) (±7.7) (±39.5) (±37.8)
Sitosterol 119.3 132.3 128.0 100.1 156.5 142.4
( 102mmol/mol
cholesterol)
(±22.0) (±49.2) (±42.0) (±20.6) (±76.1) (±70.6)
Serum Apo E 0.048 0.044 0.046 0.044 0.046 0.047
(g/L) (±0.016) (±0.011) (±0.013) (±0.020) (±0.013) (±0.012)
Apo4 Carriers (n) 1 3 4 1 2 3
T ab le  6.1 B ase lin e  non  ch o lestero l stero ls and ap oE  p h en otyp e d istr ib u tion  for  egg  
fed and con tro l grou p s. Differences between males and females for lathosterol and 
cholestanol in the non egg-fed group (p=0.08 and p=0.059 respectively). There were no 
significant differences between egg-fed and non egg-fed for the total group.
* =p<0.05 between genders within group.
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6.4.2 Baseline Associations o f  Non-Cholesterol Sterols with Anthropometric, 
Biochemical and Dietary Parameters.
Associations between the concentration of plasma non-cholesterol sterols and 
anthropometric, biochemical and dietary parameters for the whole group (n=44) are 
shown in Table 6.2. Markers of cholesterol synthesis (desmosterol and lathosterol) 
showed a positive association with one another (r =.50, p<0.01). Lathosterol was 
negatively related to markers of cholesterol absorption: cholestanol and sitosterol (r- 
0.65,p<0.01 and r=-0.71, p<0.01 respectively). Although there appeared to be no 
relationship between desmosterol and cholestanol, there was a weak negative 
association between desmosterol and sitosterol (r=-0.29, p=0.06). The markers of 
cholesterol absorption (cholestanol and sitosterol) also showed a positive correlation 
with one antoher (r=0.807, p<0.01).
Baseline markers of cholesterol synthesis, desmosterol and lathosterol, were 
positively associated with body weight (r =0.38, p<0.05 and r=0.44, p<0.01 
respectively). The baseline intake of dietary cholesterol was positively associated 
with markers of cholesterol synthesis (desmosterol r =0.32, p<0.05 lathosterol r = 
0.37, p<0.05), and negatively associated with markers of cholesterol absorption 
(cholestanol r=-0.31, p<0.05: sitosterol r=-0.37, p<0.05).
Partial correlations that controlled for body weight, showed there to be no significant 
associations between serum non-cholesterol sterols and biochemical, anthropometric 
or dietary variables.
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D esm osterol Lathosterol Cholestanol Sitosterol
(Synthesis) (Synthesis) (Absorption) (Absorption)
Desmosterol r 1 0.504** -0.223 -0.29
102mmol/mol 
cholesterol P
0.000 0.15 0.06
Lathosterol r 0.50** 1 -0.651** -.0708**
102mmol/mol 
cholesterol P
0.000 0.000 0.000
Cholestanol r -0.22 -0.65** 1 0.807**
102mmol/mol 
cholesterol P
0.15 0.000 0.000
Sitosterol r -0.29 -0.71** 0.807** 1
102mmol/mol
cholesterol P
0.06 0.000 0.000
Body Weight r 0.38* 0.44** -0.173 -0.185
Kg P 0.012 0.003 0 .261 0.250
T-Chol r 0.06 -0.23 0.119 0.148
mmol/L P 0.70 0.13 0.442 0.338
LDL-C r 0.04 -0.21 0.080 0.135
mmol/L P 0.79 0.18 0.604 0.383
HDL-C r -0.19 -0.33* 0.316* 0.38*
mmol/L P 0.22 0.03 0.036 .012
TAG r 0.43** 0.46** -0.351* -0.41**
mmol/L P 0.004 0.002 0.019 0.006
Dietary r 0.32* 0.37* -0.31* -0.37*
Cholesterol P 0.031 0.02 0.046 0.014
Mg/day
T ab le  6.2. B aselin e C orrela tion s o f  S eru m  n on -ch o lestero l stero ls w ith  b od y  w eigh t, 
p lasm a lip ids and d ietary  ch o lestero l. Significant associations are shown in red *p<0.05,
**p<0.01 Pearson's Correlations
6.4.3 Apo E Genotype and Baseline Lipids and Non-Cholesterol Sterols
Plasma lipids, non-cholesterol sterols and markers of insulin resistance are shown, 
according to apo E genotype, in Table 6.3. No significant differences were observed 
between apo E genotypes for plasma lipids, glucose or insulin, or for plasma non­
cholesterol sterols, with the exception of plasma sitosterol This latter marker of 
cholesterol absorption was significantly higher (p=0.01) in E4 carriers compared to 
E3 homozygotes and E3/E2 heterozygotes (Figure 6.3).
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E2/E3 E3/E3 E3/E4
n= 6 n=31 n=7
80.3 83.3 82.4
Body Weight (kg) (±14.4) (±15.7) (±20.1)
5.15 5.44 5.02
Total Cholesterol (mmol/L) (±1.01) (±1.07) (±1.21)
2.92 3.15 2.82
LDL-C (mmol/L) (±0.75) (±0.70) (±0.77)
1.32 1.09 1.21
HDL-C (mol/L) (±0.26) (±0.31) (±0.38)
1.30 1.30 1.34
TAG (mmol/L) (±0.19) (±0.58) (±0.78)
5.65 5.81 5.74
Glucose (mmol/L) (±0.90) (±0.85) (±0.50)
42.7 47.2 93.7
Insulin (pmo/L) (±17.20) (±51.6) (±82.3)
Desmosterol 39.9 43.4 40.3
( 102 mmol/mol cholesterol) (±15.0) (±13.2) (±9.4)
Lathosterol 132.4 134.24 114.9
( 102 mmol/mol cholesterol) (±51.9) (±59.9) (±60.0)
Cholestanol 115.3 120.2 133
( 102 mmol/mol cholesterol) (±9.6) (±33.8) (±29.2)
Sitosterol 114.2 125.7 191.2*
( 102 mmol/mol cholesterol) (±37.3) (±48.1) (±75.2)
0.055 0.044 0.047
ApoE (g/L) (±0.014) (±0.012) (±0.012)
T ab le 6.3 B aselin e B ioch em ica l and A n th rop om etric  P aram eters A ccord in g  to A po E 
G enotype. No significant differences were observed between apo E genotypes, with the 
notable exception of the ratio of serum sitosterol to cholesterol which was significantly 
higher in carriers of the E4 allele. Values are mean ±SEM *p<0.05
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F igu re 6.3. B aselin e seru m  n on -ch o lestero l stero ls accord in g  to ap oE  gen otype. The
serum sitosterol to cholesterol ratio w as significantly higher in carriers o f  the E4 allele. 
Bars represent mean ±SEM**p=0.01
6.4.4 The Impact o f Weight Loss and Increased Dietary Cholesterol on Plasma 
Non-Cholesterol Sterols
Table 6.4 shows plasma non-cholesterol sterols at baseline and following 12 weeks 
of dietary intervention. At 12 weeks, the egg-fed group showed a significant 
reduction in serum lathosterol (-11.83%, p<0.05), this group also displayed a 
significant increase in serum cholestanol (+5%, p<0.05). The non-egg fed group 
exhibited a similar reduction in serum lathosterol and increase in cholestanol, though 
this was to a lesser extent and was insignificant. There were no significant 
differences between treatment groups in tenns of the absolute reduction in serum 
non-cholesterol sterols (Figure 6.4).
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Energy Restriction Including 2 Energy Restriction Avoiding Eggs
Eggs/day (n=24) (n=2 0 )
B aselin e 12 W eek s % A B aselin e 12 W eek s % A
Desmosterol
(102 mmol/mol 
cholesterol)
47.75
(±11.43)
40.12
(±11.44)
-1 .04
(±24.52)
43 .16
(±14.37)
41.15
(±15.81)
-3 .29
(±20.12)
Lathosterol 132.47 115.90* -11 .83 129.03 116.02 -6 .25
(102 mmol/mol 
cholesterol)
(±47.93) (±52.17) (±22.46) (±69.59) (±62.38) (±25.90)
Cholestanol 116.47 122.60* 5.00 127.97 132.39 4.03
(102 mmol/mol 
cholesterol)
(±23.51) (±29.09) (±10.31) (±37.76) (±38.80) (±10.92)
Sitosterol 127.98 125.42 -0.61 142.38 142.82 0.49
(102 mmol/mol 
cholesterol)
(±42.04) (±40.31) (±16.28) (±70.62) (±77.17) (±18.99)
Table 6.4. Plasma Non-Cholesterol Sterol Response to Dietary Intervention.
Values are mean±standard deviation. *=p<0.05 significantly different to baseline.
15
10
5
©la* 0£
CJ
©JZ -5CJ
o
E -10
o
E
E -15o
< -20
-25
-30
I Energy Restriction Including 2 
Eggs Per Day 
• Energy Restriction Avoiding 
Eggs
Desmosterol
-1.63
-1.77
*  --
Lathosterol
-16.58
-13.35
Cholestanol
6.13
5.19
f t
Sitosterol
-2.56
1.61
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6.4.5 The Influence o f ApoE Genotype on Responsiveness to Energy Restriction 
and dietary cholesterol.
Figures 6.5 and 6.6 show the serum non-cholesterol sterol response to dietary 
intervention according to apo E genotype, and the non-cholesterol sterol response to 
energy restriction as marginal means respectively. There was a significant genotype 
x diet interaction for desmosterol (p=0.041), while the gene x diet interaction for 
lathosterol was of border line significance (p=0.095). There was a significant effect 
of genotype on plasma sitosterol (p=0.03), with E4 carriers showing higher serum 
sitosterol to cholesterol ratios than E3 homozygotes and E2 earners. There was no 
significant main effect of diet or genotype on plasma cholestanol or gene x diet 
interaction.
There was no significant effect of apo E genotype or a genotype x diet interaction for 
total or LDL cholesterol. There was also no evidence of an influence of apo E 
genotype on weight loss achieved through energy restriction.
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F igu re 6.5 Serum  n on -ch o lestero ls resp on se to d ietary in terven tion  accord in g  to 
apo E gen otype. B oxes represent the interquartile range (50%  o f  cases), whiskers the 
sm allest and largest values. The m edian is shown as a black line within the box.
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F igu re 6 .6 . Serum  non ch o lestero ls tero l resp on se to d ietary  in terven tion . Data is
rep resen ted  as m argin al m eans.
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6.5 DISCUSSION
The lipid response to energy restriction, with or without the addition of two eggs per 
day was shown to be highly variable between individuals. The phenomenon of hypo 
and hyper-responsiveness to an increase in dietary cholesterol has been widely 
documented over a range of cholesterol intakes (Mistry et a l  1981,Ginsberg et al. 
1994, Ginsberg e t al. 1995,ICatan e t a l  1986). It has been proposed that these 
differences occur due to heterogeneity in cholesterol homeostasis, with some subjects 
demonstrating an ability to compensate for increased dietary cholesterol through the 
reduction of cholesterol synthesis (McNamara e t a l  1987). The interaction of 
cholesterol synthesis, absoiption and excretion, together with the effects of 
polymorphisms of genes involved in these processes are all believed to contribute to 
the variability in cholesterol response. The aims of this study were to investigate the 
effect of two weight losing, energy restricted diets on serum markers of cholesterol 
absorption and synthesis, and to assess the impact of apo E genotype on the 
variability in plasma cholesterol response.
The main findings of this study were a reduction in serum lathosterol (a marker of 
cholesterol synthesis) and an increase in serum cholestanol (a marker of cholesterol 
absoiption) in response to weight loss. The response to weight loss, in terms of 
cholesterol absoiption and synthesis was not modulated by apo E genotype despite 
earners of the apo E genotype exhibiting an elevated baseline serum sitosterol 
concentration.
6.5.1 The effect o f Weight Loss on Serum Markers of Cholesterol Synthesis
In the present study, an energy restricted diet with or without the addition of two 
eggs per day resulted in equal and significant weight loss in both egg-fed and control 
groups (described in detail in Chapter 5). Changes in body weight have been shown 
to influence plasma lipids and cholesterol homeostasis, with elevated cholesterol 
synthesis and reduced cholesterol absorption being obseived in obesity (Miettinen 
and Gylling 2000). In the current study, baseline body weight was significantly and 
positively associated with baseline serum markers of cholesterol synthesis expressed 
in relation to serum cholesterol. These markers of synthesis were also positively
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related with one another, and with plasma TAG and dietaiy cholesterol intake. The 
positive correlation of plasma TAG with desmosterol and lathosterol, and negative 
association with cholestanol and sitosterol is consistent with evidence from the 4S 
study indicating the highest levels of synthesis and lowest levels of absoiption in 
subjects with elevated triacylglycerol (Miettenen et a l  2003). These relationships 
were no longer significant when controlling for body weight, which suggests that the 
latter is an important determinant of cholesterol homeostasis. In the current study, 
both intervention groups showed evidence of a reduction in serum lathosterol to 
cholesterol ratio after weight loss, though this reduction was only significant in the 
egg-fed group. In common with the changes in plasma total cholesterol, the change 
in serum lathosterol following intervention was highly variable between subjects, 
ranging from -59 to +28% in the egg-fed group and -55to +44% in the non-egg fed 
group.
There are currently no studies that have addressed combined effects of weight loss 
and increased dietary cholesterol on cholesterol homeostasis. Studies addressing the 
effect of weight loss alone have demonstrated a reduction in cholesterol synthesis 
following moderate weight loss (Santosa et a l  2007, Di Buono et a l  1999, Raeini- 
Sarjaz et a l  2001). Santosa et al. measured cholesterol synthesis following weight 
loss using deuterium incorporation. In this study, overweight and obese subjects 
(average BMI 31 Kg/m2) followed an energy restricted diet and exercise plan to 
achieve an average reduction in body weight of-14.5%. A reduction in plasma total 
and LDL-C concentrations was accompanied by a significant reduction in cholesterol 
fractional synthetic rate (FSR), with no effect on cholesterol absorption (Santosa et a l 
2007a). Di Buono e t a l  assessed the effects of an energy restricted AHA step 1 diet 
on weight loss and cholesterol homeostasis in obese men. Cholesterol synthesis was 
measured by deuterium incorporation and the FSR found to be significantly lower 
following an average weight loss of 7% of starting body weight (Di Buono et a l 
1999). Cholesterol absorption and synthesis was measured in subjects participating in 
the EDWINA study using serum markers making direct comparison with studies 
using more tranditional methodologies, such as deutrum incorporation, difficult. 
However, despite differences in methodology a reduction in cholesterol synthesis, 
measured by serum lathosterol, was observed in both intervention groups and this 
was significant in the egg fed group. It is possible that a greater reduction in
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cholesterol synthesis was not observed in the EDWINA study as subjects lost, on 
average, less weight than that reported in previous interventions (4 % and 5% of 
body weight in the egg fed and control groups respectively).
In studies addressing the influence of increased dietary cholesterol on cholesterol 
homeostasis, cholesterol synthesis was found to be reduced following elevated 
cholesterol intake (Jones et al. 1996). McNamara et a l  addressed the effects of 
increased dietary cholesterol as part of a high PUFA or high SFA diet on cholesterol 
synthesis in mononuclear lymphocytes. They showed that high intakes of cholesterol 
(>800mg/day) were associated with a significant reduction in cholesterols synthesis 
(-21 and -24%) regardless of fat composition (McNamara et al  1987). The reduction 
in cholesterol synthesis associated with increased dietary cholesterol may help to 
explain the significant reduction in serum lathosterol observed in the egg fed group 
of the current study. This reduction in the marker of cholesterol synthesis in the egg 
fed group was of a greater magnitude compared to the control group despite controls 
achieving slightly greater weight loss that was greater in magnitude (3.3kg vs -4.4 kg 
in egg fed and control group respectively).
On the other hand has, Klass et al. showed a significant reduction in cholesterol 
synthesis in response to increased dietary cholesterol in subjects with a BMI greater 
than 27 lcg/m2. In lean subjects this effect was not observed instead these subjects 
showed an increase in the rate of bile acid production via the alternative pathway. 
This data suggests that increased dietary cholesterol affects different pathways of 
cholesterol homeostasis depending on body weight (Klass et al. 2006). The subjects 
in the present study were overweight with subsequent weight loss reducing serum 
lathosterol, a marker of cholesterol synthesis. This reduction in lathosterol supports 
previous findings suggesting that energy restriction leads to a reduction in cholesterol 
synthesis (Di Buono et al  1999). It can be proposed that a significant reduction in 
serum lathosterol was only observed in the egg-fed group due to the additional 
feedback inhibition of the synthetic pathway by dietary cholesterol as suggested by 
Klass et a l  (Klass et a l  2006).
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Studies in normal weight individuals are needed to assess the impact of weight loss 
and increased dietary cholesterol on serum markers of cholesterol synthesis in order 
to determine if there is an additional effect of dietary cholesterol on the reduction in 
cholesterol synthesis in overweight and obese subjects alone. In addition, 
measurements of cholesterol excretion would provide further information to help 
understand the effects of weight loss and increased dietary cholesterol on 
mechanisms of cholesterol homeostasis.
6.5.2 The Effect o f Weight Loss on Serum Markers on Cholesterol Absorption
Cholesterol absorption efficiency has been negatively associated with BMI, 
indicating reduced absoiption efficiency in obesity (Miettinen and Kesaniemi 1988) 
It has also been suggested that there is a reciprocal relationship between cholesterol 
synthesis and cholesterol absorption. This reciprocal relationship of elevated 
cholesterol synthesis and reduced cholesterol absoiption has been observed in 
subjects with obesity (Miettinen and Gylling 2000), insulin resistance (Pihlajamaki et 
a l  2004), the metabolic syndrome (Chan et a l  2002,Gylling et a l  2007) and type 2 
diabetes (Simonen et al. 2002b). While a number of trials have assessed the effects 
of weight loss on cholesterol synthesis, few have investigated changes in cholesterol 
absoiption following weight loss. A recent study by Santosa e t a l  observed a 
significant reduction in cholesterol synthesis following weight loss with no effect on 
cholesterol absoiption (Santosa et a l 2007). However, two studies which used serum 
non-cholesterols as surrogate markers observed an increase in cholesterol absoiption 
following weight loss. In obese subjects with components of the metabolic 
syndrome, a weight loss of ~6kg resulted in a significant increase in serum levels of 
sitosterol and campesterol, but no reciprocal increase in serum markers of cholesterol 
synthesis were observed (Simonen et al. 2000). In obese subjects with type 2 
diabetes, a weight loss of ~16kg, following a 3 month very low calorie diet, resulted 
in a significant reduction in serum markers of cholesterol synthesis (lathosterol and 
desmosterol). There was also a significant increase in serum cholestanol with no 
effect on serum sitosterol (Simonen et a l  2002). In the present study, a reduction in 
serum lathosterol in the egg-fed group was accompanied by a small but significant 
increase in the ratio of serum cholestanol to cholesterol. This finding is consistent
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with the idea that a reciprocal relationship exists between these vectors of cholesterol 
homeostasis and suggests that the significant increase in serum cholestanol to 
cholesterol ratio is due to the greater reduction in serum lathosterol in the egg-fed 
group.
A relationship between fasting plasma glucose and cholesterol absoiption and 
synthesis has been observed by Stranberg e t a l  where elevated fasting glucose was 
associated with the highest rates of synthesis and lowest rates of absorption when 
measured using serum non cholesterol sterols (Stranberg et al. 1996). Studies in 
subjects with type 2 diabetes or insulin resistance have shown a reciprocal 
relationship between cholesterol absoiption and synthesis in both weight maintained 
groups ((Pihlajamaki et a l  2004,Gylling et a l  2007) and following weight loss 
(Simonen,et a l  2002), suggesting a role of insulin in cholesterol homeostasis. It can 
be proposed from this, that a reciprocal relationship between absoiption and 
synthesis is only exists in subjects with insulin resistance. In the current study, 
subjects displayed impaired fasting glycaemia (glucose>5.6 mmol/L) together with 
mildly elevated fasting plasma insulin, which may account for the reciprocal 
relationship obseived between serum lathosterol and cholestanol and the significant 
increase in choelstanol in the egg-fed group.
Following the 12 week intervention there was no significant differences between 
groups for plasma cholestanol and sitosterol, despite an increased intake of dietary 
cholesterol in the egg-fed group. This finding suggests that an absorption maximum 
might have been reached by the egg-fed group. Previous reports have suggested that 
the maximum absorption of cholesterol occurs at intakes of dietary cholesterol of 
between 150 and 300mg/day, and not at higher intake levels (Wilson and Lindsay 
1965).
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6.5.3 The Influence o f Apo E  Genotype on Plasma Lipid Responsiveness to 
Weight Loss and Dietary Cholesterol
It has been suggested that polymorphisms in the apo E gene confer variable CVD 
risk, as a result of the differential effects of this polymorphism on plasma lipids, and 
an influence on the lipid response to diet. The distribution of apo E genotype in our 
study population was representative of previously reported frequencies in Caucasian 
populations (Eichner et a l  2002). E3/E3 homozygotes were the most common 
representing 69% of our study population, this was followed by E3/E4 (16%) and 
E2/E3 (13%). Only one subject was characterised as E2/E2 (2%) and no subjects 
were characterised as E4/E4 or E2/E4.
It has been estimated that apo E genotype accounts for 7% of the variation in total 
cholesterol in a Caucasian population (Davignon, Gregg, & Sing 1988). Differences 
between apo E protein isoforms in terms of their affinity for LDL and remnant 
receptors result in differences in plasma lipids between genotypes. The E2 isoform 
has low remnant and LDL receptor affinity (<2% of normal binding) resulting in 
elevated fasting triglycerides and lower plasma LDL-C due to up regulation of the 
LDL receptor. Conversely the E4 allele is associated with elevated plasma LDL-C 
due to down regulation of the LDL-receptor. While numerous studies have observed 
significant differences in plasma lipids between apo E genotypes (Boer et al. 
1997,Frikke-Schmidt et al. 2000,Davignon, Gregg, & Sing 1988), there was no 
difference in fasting plasma lipids between genotypes in the present study. This 
finding is potentially due to the small sample number in E2/E3 and E3/E4 groups or 
the absence of additional risk factors known to enhance differences obseived 
between genotypes, such as smoking status.
There is evidence to suggest that the efficiency of cholesterol absoiption and 
synthesis is genetically determined (Gylling & Miettinen 2002). While there are a 
number of polymorphisms now associated with rates of cholesterol absoiption and 
synthesis, the most extensively studied are those associated with the gene encoding 
apo E. Cholesterol absorption efficiency, measured using the double isotope 
continuous feeding method (Crouse et a l 1978), has been shown to be highest in 
carriers of the E4 allele and lowest in E2 carriers compared with the E3 wild type 
(Kesaniemi YAC, Enliolm C, & Miettinen TA 1987). In the present study, serum
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cholestanol and sitosterol were used as surrogate markers of cholesterol absoiption. 
The ratio of serum sitosterol to cholesterol was significantly higher in E4 carriers 
compared to E2 and E3, but no significant difference was observed for the ratio of 
serum cholestanol to cholesterol. In the same study by Kesaniemi e t a l  a reciprocal 
relationship between cholesterol absorption and synthesis was observed, in that E4 
earners not only showed the highest levels of cholesterol absoiption but also the 
lowest rates of cholesterol synthesis and vice versa for E2 earners. In the present 
study, no such reciprocal relationship was observed between absoiption and 
synthesis between the apo E genotypes.
To date one study has challenged the relationship between apo E genotype and rates 
of cholesterol absorption and synthesis. Von Bergman e t a l  assessed cholesterol 
synthesis and absorption in E2 and E4 homozygotes and found no differences in 
serum lathosterol, cholestanol and campesterol to cholesterol ratios between 
genotypes (von Bergmann et a l  2003). Von Bergman et a l  did not assess differences 
in the ratio of serum sitosterol to cholesterol, whereas in the present study, this was 
the only non-cholesterol sterol that was significantly different between apo E 
genotypes, suggesting that it may be a better marker of cholesterol absorption. Jones 
at al observed no difference in the rates of cholesterol synthesis between E2 and E4 
carriers on self-selected diets. However, in this case, the rates of absoiption were not 
reported and the presence of both homo and heterozygotes in relatively small groups 
may have influenced results (Jones et a l  1993). The lack of difference between 
genotypes for serum lathosterol and choelstanol, observed by von Bergman et a l, are 
in line with the findings of the present study in E2/E3 and E3/E4 heterozygotes. In 
the present retrospective study, the rarer homozygote genotypes were not represented 
and the small sample number in each genotype group may have contributed to a lack 
of difference in fasting lipids. This may also be reflected in the lack of difference 
between genotypes for the plasma non-cholesterol. The prospective genotyping of 
volunteers will be needed in future studies to achieve sufficient numbers of the less 
common heterozygotes and rare homozygotes.
The apo E genotype has also been implicated in the variable response to dietary fat 
and cholesterol (Sarkkinen e t al. 1998). A review by Masson et a l  has assessed the 
influence of apo E genotype on the lipid response to dietary cholesterol in fifteen
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individual studies. Of these studies, two demonstrated elevated fasting total 
cholesterol in E4 earners following a high cholesterol diet (Masson et al. 2003). For 
example, in a study by Gylling et al, the influence of apo E genotype and increased 
dietary cholesterol in the form of three egg yolks per day was assessed in 29 men. 
Following a six week intervention earners of the E3 and E4 showed a greater plasma 
LDL-C response to increased dietary cholesterol when compared to E2 earners 
(Gylling et al. 1997). Sarkinnen et a l  (1998) reported similar results for E4 
homozygotes and the total cholesterol response following the addition of ~300mg of 
cholesterol. In this study E4 homozygotes had a significantly greater total plasma 
cholesterol response to increased dietary cholesterol compared to E3/E4 and E3/E3 
genotypes, though in this study, differences in the LDL-C response were only of 
borderline significance (p=0.06) (Sarkltinen et a l  1998). The majority of studies (12 
of 15), reviewed by Masson e t a l  (2003) did not show a significant difference 
between genotype in the plasma lipid response to increased dietary cholesterol, but 
many studies had small numbers in the genotype groups and often grouped the rarer 
homozygotes with the more common heterozygotes i.e. E2/E2 and E2/E3. In the 
present study, no differences were obseived between apo E genotypes in terms of 
responsiveness to increased dietary cholesterol. This may, in part, be explained by 
the absence of rarer homozygotes and small sample number. Baseline cholesterol has 
also been shown to affect the plasma cholesterol response to added dietary 
cholesterol (Hopkins 1992), as no differences in baseline fasting lipids were 
observed between genotypes it can be proposed that this, in part, may have 
influenced the response to dietary cholesterol. The lack of evidence to support a 
difference in response to increased dietary cholesterol between apo E genotypes, in 
this and in previous studies, highlights the difficulty in addressing the impact of a 
single gene when multiple genetic and lifestyle interactions contribute to fasting lipid 
concentrations.
Few studies have addressed the influence of apo E genotype on weight loss. Kee et a l
(2000) observed hypo-responsiveness, in terms of total cholesterol, to weight loss in 
E4 earners following a 12 week weight reduction programme (Kee et al. 2000). In a 
recent study by Nieminen et a l (2007) the influence of apo E genotype on the weight 
loss response to a two week very low energy diet was assessed in 78 women. In this
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study, no difference in weight loss was observed between E2/E3, E3/E3 and E3/E4, 
E4/E4 genotypes, however the E2/E3 groups showed significantly greater reductions 
in plasma LDL and total cholesterol, in response to weight loss, compared to E3/E3 
and E3/E4, E4/E4 groups (Nieminen et al. 2007). In the present study, no difference 
was obseived between genotypes for either the amount of weight lost or the plasma 
lipid response to weight loss. Again similarities in baseline lipids and body weight 
may, in part, account for the lack of difference in response between groups.
6.5.4 Genetic Regulators o f Cholesterol Homeostasis
The influence of apo E genotype on cholesterol homeostasis and the lipid response to 
weight loss and dietary cholesterol was assessed in subjects participating in the 
EDWINA study. Whilst a significantly higher serum sitosterol to cholesterol ratio 
was associated with earners of the E4 allele, variability in the plasma total and LDL 
cholesterol response to dietary cholesterol and weight loss was not associated with 
apo E genotype. A number of genes have been identified which influence cholesterol 
homeostasis, of particular interest are those involved in cholesterol absorption. The 
ATP Binding cassette transporters (ABC) G5 and G8 are hemi-transporters identified 
as the result of mutations which result in the rare autosomal recessive disorder, 
sitosterolaemia. Although mutations in ABCG5 and G8 are associated with 
sitosterolaemia, other more common variants have been identified which influence 
cholesterol absoiption and plasma levels of plant sterols without yielding the 
sitosterolaemic phenotype. Two variants in ABCG8, D19H and T400K are 
associated with lower serum plant sterols and, by association, a lower rate of 
cholesterol absorption. The 19H (exon 1 mutation) of ABCG8 has also been 
associated with lower cholesterol absorption and a reciprocal increase in cholesterol 
synthesis together with lower plasma total and LDL cholesterol when compared to 
subjects without the allele (Gylling e t al. 2004). Furthermore, in the study by Gylling 
et a l the Q604E polymorphism of the ABCG5 gene was associated with reduced 
cholesterol absorption together with elevated BMI and serum insulin (Gylling et al 
2004). This data is in line with evidence to support reduced cholesterol absorption 
efficiency in insulin resistant subjects.
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The influence of polymorphisms in ABCG5 on the response to dietary cholesterol 
has been considered by Herron e t a l  In this study, subjects who were hetero or 
homozygote for the Q640E polymorphism of ABCG5 (C-G mutation at position 
1950) were compared with ABCG5 C/C homozygotes. In this randomised cross-over 
study subjects consumed an additional ~640mg of cholesterol per day as liquid 
pasteurised whole eggs or a cholesterol free placebo for thirty days. Following the 
intervention ABCG5 C homozygotes showed a significantly greater total cholesterol 
response to increased dietary cholesterol than ABCG5 G carriers (Herron et a l  
2006).
There is evidence to support a role for a variety of genetic polymorphisms in 
influencing both plasma fasting lipids and cholesterol homeostasis. In the present 
study, the influence of apo E genotype on both baseline characteristics and 
responsiveness to weight loss and dietary cholesterol was assessed. No significant 
differences were observed between genotypes for baseline fasting lipids, this 
observation is likely to account for the similar response to dietary intervention 
between genotypes. In the whole group, weight loss resulted in a reduction in serum 
lathosterol and a corresponding increase in cholestanol which was significant in the 
egg-fed group. The response in terms of cholesterol synthesis and absorption was 
still highly variable, which implicates the influence of other genetic factors and 
warrants further investigation.
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CHAPTER 7 - GENERAL DISCUSSION
The overall aim of this thesis was to address dietary strategies for the treatment of 
the dyslipidaemia associated with metabolic syndrome and obesity. The major 
dietary themes included: the effects of low fat or high MUFA diets and low and high 
glycaemic index in a weight maintenance diet; and weight reducing diets that 
contained either high or low dietary cholesterol, achieved by the addition or removal 
of eggs as the primary source of dietary cholesterol. An additional aim was to 
develop a rapid and high throughput technique for the measurement of the principal 
HDL subclasses for further characterisation of the dyslipidaemia associated with 
MetS.
While a predominance of small, dense LDL is well established as a phenotypic 
feature of the dyslipidaemia in metabolic syndrome, the role of HDL subclasses is 
less well understood. The characteristics of subjects involved in the RISCK study 
warranted further investigation into HDL subclasses and the influence of dietary 
modifications. The large sample size in RISCK also necessitated the development of 
a rapid and high throughput method for the measurement of HDL subclasses. 
Previous methods for the measurement of HDL subclasses were time consuming, 
technically demanding and required lengthy sample preparation of 24hours. Chapter 
3 describes a new method for the identification of the principal HDL subclasses 
(FIDL2 and HDL3). This method produced results that were comparable to those 
achieved with an established method (GGE), but with a shorter preparation time, 
with HDL subclass profiles being generated in a ran time of 2 hours and 30 minutes. 
Furthermore, this method facilitated the subdivision of HDL into three groups 
according to the percentage of HDL2 which were significantly distinct with respect 
to other lipid parameters, suggesting that the measurement of HDL subclasses may 
provide valuable information in CVD risk assessment. Subjects participating in the 
RISCK study were “at risk” of MetS due to the presence of multiple risk factors. In 
these subjects the average percentage of HDL2 was 40% putting the group as a whole 
into HDL subclass pattern II, however the majority of subjects (52%) had a HDL 
subclass pattern III. Pattern III was associated with elevated serum TAG and 
reduced HDL which are recognised components of MetS and an ALP. This provided
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evidence to suggest that the measurement of HDL subclasses may have clinical 
utility in the assessment of CVD, particularly in those with unremarkable total and 
LDL-cholesterol concentrations. Further work will be required to clarify the role of 
HDL phenotype in relation to MetS, an ALP and CVD risk, and the influence of 
dietary modification.
The RISCK study assessed the impact of five diets differing in the type and amount 
of dietary fat and carbohydrate on plasma lipids and lipoproteins. Predicted changes 
in dietary intakes, including targets for dietary MUFA and CHO were, on the whole, 
achieved. However, despite the intention to maintain body weight, there was a 
significant reduction in body mass on both low fat interventions (Diets D and E) and 
in the high MUFA high GI diet (Diet B). Both low fat diets with high (Diet D) or 
low (Diet E) GI, showed favourable effects on plasma lipids and other components 
of the metabolic syndrome, though no differences in end point measures were 
observed between the dietary groups after the 24 week of intervention. Despite 
significant reductions in HDL in all intervention groups no changes were observed in 
the percentage of HDL2. This may be accounted for, in part, by the absence of a 
significant change in serum TAG concentration which has been shown to account for 
up to 40% of variation in both LDL and HDL particle size (Krauss and Siri, 2004) 
The dietary modifications in the RISCK study have been previously associated with 
favourable effects on plasma lipids and lipoproteins (see Chapter 1). However, there 
was no evidence that any single combination of these strategies produced beneficial 
effects in terms of the reduction of lipid mediated risk. Moreover, the reduction in 
body mass appeared to be superior in affecting CVD risk than the modification of 
dietary fat and carbohydrate.
Limitations o f  the RISCK study
Subject compliance based on data from diet diaries was good, though it is well 
known that this is not always an accurate measure of true dietary intakes. Subject 
compliance may have varied over the course of the study, with greater adherence 
during the initial stages. An interim sample and measure of dietary intake at 12 
weeks would have been valuable in identifying early changes in plasma lipids that 
may have been associated with better dietary compliance.
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The RISCK screening tool identified subjects who were “at risk” of the metabolic 
syndrome which was reflected in their baseline characteristics. While the use of this 
tool in the initial identification of a high risk group may be useful, its role in 
monitoring the change in risk associated with dietary modification was limited. A 
continuous scoring algorithm would be useful in this assessment.
The study presented in Chapter 5 investigated the effects of energy restriction, with 
or without increased dietary cholesterol on plasma lipids and lipoproteins. Both 
groups achieved equal and significant reductions in energy intake with the group 
consuming eggs also achieving a significant increase in dietary cholesterol 
(+297mg/day). Although both groups achieved equal and significant weight loss, the 
small reductions in plasma lipids obseived did not reach significance. The high 
satiety index reported for of eggs (Holt et al 1995, Holt et al 2001), coupled with the 
a low energy content suggests that they may be of use in energy restricted diets. In 
the EDWINA study the weight loss achieved by those consuming eggs was not 
superior to that of the control group. Nevertheless, the absence of a cholesterol- 
raising effect in this group was encouraging, and would suggest that eggs may be 
consumed as part of a weight reducing diet with no adverse effects on plasma lipids.
Limitations o f  the EDWINA study
Compliance was assessed at baseline and at 6 weeks, but due to the limited staff 
resources, no dietary information was collected at 12 weeks. Additional dietary 
information would have been useful in the assessment of compliance and weight loss 
during the course of the study.
Although favourable changes in plasma lipids were observed on both diets, the 
study lacked additional control groups i.e. a weight maintained group and a group 
who followed a weight maintenance diet with the addition of two eggs per day. The 
inclusion of these extra groups would have helped to discriminate between the 
effects of increased dietary cholesterol and weight loss on plasma lipids.
Even though an overall reduction in plasma total and LDL cholesterol was observed 
in the EDWINA study, the response to weight loss and increased dietary cholesterol 
was highly variable between individuals. This phenomenon was first reported by
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Katan et al (1986) who identified the existence of consistent hypo and hyper 
responders to dietary cholesterol (Katan et al 1986). Possible contributors to the 
variability in response in the EDWINA study were examined further in Chapter 6. 
Participants of the EDWINA study were retrospectively genotyped for apo E, and 
biomarkers of cholesterol absorption and synthesis at baseline and following 12 
weeks of intervention. Carriers of the apo E4 allele demonstrated a significantly 
elevated concentration of serum sitosterol, which was indicative of an increased rate 
of cholesterol absorption in this group. On the other hand, differences in plasma 
lipids between genotypes was unremarkable. This finding disagrees with earlier 
studies that have addressed the influence of apo E genotype on plasma lipids (Boer et 
al. 1997, Frikke-Schmidt et al. 2000, Davignon, Gregg, & Sing 1988) but in this 
instance may be attributed to the small sample size and under representation of the 
rarer E4/E4 homozygotes. While there was no apparent association between apo E 
genotype and lipid response to weight loss and increased dietary cholesterol, changes 
in biomarkers of cholesterol absoiption and synthesis were obseived. Weight loss 
resulted in a reduction in serum lathosterol (a marker of synthesis) in both groups, 
but reached significance in the egg fed group. A reduction in lathosterol was 
accompanied by an increase in cholestanol (a marker of absorption) which again, 
was significant only in the egg fed group. The changes in both lathosterol and 
cholestanol suggest a reciprocal relationship between cholesterol absoiption and 
synthesis (Santosa et al 2007), but this relationship warrants further investigation.
Limitations o f  the study
Subjects participating in the EDWINA study were retrospectively genotyped, 
resulting in small sample numbers of each group and the under or absent 
representation of the rarer genotypes. The prospective genotyping of subjects with a 
larger sample size would be essential for investigating of genetic factors influencing 
the lipid response to dietary intervention
Additionally the absence of dietary information at 12 week made the association 
between dietary changes and changes in cholesterol absoiption and synthesis 
difficult to interpret.
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In both the RISCK and EDWINA studies, weight loss was accompanied by 
favourable changes in serum lipids and lipoproteins. In the EDWINA study weight 
loss of approximately 4-5% of initial body mass was associated with reductions in 
total and LDL cholesterol, but these changes were insignificant. In the RISCK study 
both low fat interventions (Diets D and E) were associated with a reduction in body 
weight of 1-1.6%, but in this case, the changes in plasma total, and LDL cholesterol 
were significant. There were also significant reductions in fasting plasma insulin and 
glucose. In RISCK, the sample size was significantly larger, but weight loss was 
associated with a significant reduction in waist circumference, a finding that was not 
apparent in the EDWINA study. An elevated waist circumference has been 
associated with increased plasma TAG (Lemieux et al 2001) and is a well recognised 
component of all definitions of MetS, with the more recent IDF definition placing 
primary importance on this characteristic (ref).
Evidence from the studies presented herein, would suggest that the reduction of body 
weight, and in particular central adiposity, is of primary importance in the reduction 
if lipid-mediated CVD risk. Energy restriction alone may be insufficient in reducing 
waist circumference, with weight loss potentially occurring from the loss of lean 
mass. The composition of energy restricted diets warrants further investigation. An 
energy restricted diet that is low or moderate in the contribution of total fat to energy 
intake (20-30% suggestion), with MUFA composing the majority of this fat (20% 
suggestion), and which contains carbohydrates with a low glycaemic impact, may 
represent the most beneficial in terms of reducing both body weight and plasma 
lipids.
Future directions
In the EDWINA study, apo E genotype appeared to make no contribution to the 
plasma lipid response to the dietary intervention. However, a number of studies have 
shown an association between apo E genotype and the lipid response to weight loss 
and modification to dietary fat and cholesterol. Carriage of the s4 allele was shown 
to result in reduced responsiveness, in plasma lipid reduction, to weight loss (Kee et 
al 2000). The s4 allele has also been shown to produce the greatest response in 
plasma lipids to modification of dietary cholesterol and fat (Miettinen et al 1991,
193
Chapter 7- General Discussion
Saiidtinen et al 1998, Friedlander et al 1995, Lopez-Miranda et al 1997). Although 
apo E is probably the most extensively studied genetic polymorphism in terms of 
dietary intervention, a number of other polymorphism have been identified which 
may be important in determining the lipid response to diet. Masson et al (2003) have 
reviewed the influence of genetic variation on the lipid response to diet. 
Polymorphisms in apo proteins (apo E, apo B ,Apo A-I, C-III and A-IV gene 
cluster), enzymes (LPL, HL and cholesterol 7 a hydroxylase) and the LDL receptor 
were included in this review. This review concludes that genetic polymorphisms in 
apolipoproteins make a significant contribution to the differences observed in the 
lipid responses to dietary intervention. In studies that specifically addressed the 
influence of the type of dietary fat, the Apo AI-75 (G/A) polymorphism showed an 
association with the LDL response to intervention with carriers of the A allele being 
more responsive to changes in dietary fat than earners of the common G allele 
(Lopez-Miranda et al 1994a , Lopez Miranda et al 1994b, Jansen et al 1997, Lopez- 
Miranda et al 1997, Mata et al 1998). On the other hand, evidence for an influence of 
apo B polymorphisms has been inconsistent, and the influence of polymorphisms in 
LPL and HL only investigated in studies with limited information on diet and dietary 
modifications.
It is important to appreciate, that the most common sources of CVD risk are 
polygenic in origin, with a large number of genes, and gene-environment 
interactions, exerting small effects on lipid phenotype and CVD risk. To quote 
Trujillo et al “Nurtigenomics is the scientific study of the way specific genes and 
bioactive food components interact” (Trujillo et al 2000). The individual variation in 
response to the dietary interventions described in this thesis warrants further 
investigation. This could include genomic, proteomic, metabolomic and even 
nutrigenomic approaches with the aim of achieving the ultimate goal, individualised 
nutrition. A metabolomics approach that provides complete biochemical data or 
“metabolome” for a subject may prove to be the most effective for the future design 
of an optimal diet for CVD risk reduction.
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APPENDIX-1
Appendix I- The RISCK Study
Exclusion Criteria Exclusion Drugs
Individuals smoking greater than 20 Oral Hypolipidaemics
cigarettes/day will be excluded due to the 
confounding influences of smoking on 
features of the metabolic syndrome and 
dietary habits.
FibratesBenzafibrate (Benzalip), Ciprofibrate (Modalim), Fenofibrate (Lipantil) and Gemfibrozil (Lopid)
Overall risk of CHD >30% over the next 10 
years using the tables of the British Cardiac 
Society and HEART UK.
StatinsAtorvastatin (Lipitor), Fluvastatin (Lescol), Pravastatin (Lipostat), Rosuvastatin (Crestor) and Simvastatin (Zocor)
A reported history of myocardial infarction 
or cancer.
Anion-exchange resinsColestyramine (Questran or Questran light) and Colestipol hydrochloride
Diabetes mellitus (fasting plasma glucose >7 
mmol/L).
Systemic CorticosteroidsGlucocorticoids, Prednisolone, Betamethasone (Betnelan, Betnesol), Cortisone acetate, Deflazacort (Calcort), Dexamethasone (Decadron), Hydrocortisone (Efcortesol, Hydrocortone, Solu-Cortef), Methylprednisolone (Medrone, Solu- medrone) and Traimcinolone, Fludrocortisone
Recent use of oral hypolipidemic therapy, 
systemic corticosteroids, androgens, 
phenytoin, erythromycin or thyroid 
hormones.
Those receiving drugs for regulating 
haemostasis but excluding aspirin or who 
have been exposed to any investigational 
agent within 30 days of the study.
AndrogensRestandol, Testosterone Enantate, Sustanon, Virormone, Mesterolone
Chronic coronary, renal or bowel disease or 
histoiy of cholestatic liver disease or
Anti-epilepticsPhenytoin (Epanutin)
pancreatitis.
Presence of gastrointestinal disorder or use 
of a drug, which is likely to alter 
gastrointestinal motility or nutrient 
absorption.
Anti-BacterialsMacrolides, Erythromycin (Erymax, Erythrocin and Erythroped), Azithromycin (Zithromax), Clarithromycin (Klaricid) and Telithromycin (Ketec)
History of substance abuse or alcoholism. Thyroid hormonesLevothyroxine sodium/Thyroxine sodium and Liothyronine (Tertroxin, Triiodothyronine)
Currently pregnant, planning pregnancy or 
having had a baby in the last 12 months.
Haemostatic drugs (but do not exclude those taking aspirin)Anti-coagulants Warfarin, Acenocoumarol or Nicoumalone (Sinthrome) andAllergy or intolerance to intervention foods.
Unwilling to follow the protocol and/or give 
informed consent.
Phenindione Anti-platelets, Clopidogrel (Plavix), Dipyridamole (Persantin)
Weight change of >3kg in preceding 2 
months.
Daily intake of EPA + DHA > lg/day.
Table Li. Appendix I. RISCK Exclusion Criteria
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APPENDIX-1
Study Foods Quantities Advice on how to achieve
Fat Spreads
Men 4 teaspoons
Use fat spreads on each slice o f bread you eat. 
If you do not use your daily amount o f spread 
on bread, add the rest to other foods such as 
jacket potatoes, vegetables and in cooking 
and baking.*Women 3 teaspoons
Cooking Oils
Men 1 tablespoon
You should aim to use the oils in cooking or 
to make a salad dressing*
Women 2 teaspoons
Cheese
Men
We do not need you to eat cheese everyday but aim to include three cheese 
sandwiches a week (with a generous portion o f  cheese). Alternatively use a 
similar quantity o f  cheese in recipes.*
Women
We do not need you to eat cheese everyday but aim to include two cheese 
sandwiches a week (with a generous portion o f  cheese). Alternatively use a 
similar quantity o f  cheese in recipes.*
Milk
Men & 
Women
Please use milk on the cereal provided, in your tea and coffee and in any 
recipes including milk.* If you do not drink tea or coffee, aim to have a 
small-medium glass o f  milk/day.
Breakfast
cereals/
Bread/Rice/
Potatoes
Men & 
Women
Please eat the study breakfast cereals, bread, rice and potatoes in the same 
quantities you eat in your usual diet less 1 portion/day of one of the foods, 
see below.
Food Reduce by:
Breakfast cereals 4 heaped tablespoons
Study Bread 1 medium slice
French Bread I VP slice
Study Rice, cooked 2 heaped tablespoons
Potatoes 1 egg-sized potato
Avoid pasta.
Snacks Men & 
Women
Please replace one snack that you normally eat during the day with one o f the 
biscuits we provide
Table I.iL Appendix I. RISCK Diet Guidelines-Diet A  and Run In
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Study Foods Quantities Advice on how to achieve how to achieve
Fat Spreads
Men
Women
4 teaspoons
3 teaspoons
Use your daily amount of fat spread on each 
slice of bread you eat. If you do not use all of 
your spread on bread, add the rest to other 
foods such as jacket potatoes, vegetables and 
in cooking and baking.*
Cooking Oils
Men 1 tablespoon
Women 2 teaspoons
You should aim to use the oils in cooking or 
to make a salad dressing*
Cheese
Men
We do not need you to eat cheese everyday but aim to include three cheese 
sandwiches a week (with a generous portion of cheese). Alternatively use a 
similar quantity of cheese in recipes.*________________________________
Women
We do not need you to eat cheese everyday but aim to include two cheese 
sandwiches a week (with a generous portion of cheese). Alternatively use a 
similar quantity of cheese in recipes.*________________________________
Milk
Men & 
Women
Please use milk on the cereal provided, in your tea and coffee and in any 
recipes including milk.* If you do not drink tea or coffee, aim to have a 
small-medium glass of milk/day.
Breakfast
cereals/
Bread/Rice/
Potatoes
Men & 
Women
Please eat the study breakfast cereals, bread, rice and potatoes in the same 
quantities you eat in your usual diet less 1 portion/day of one of the foods, 
see below.
Food Reduce by:
Breakfast cereals 4 heaped tablespoons
Study Bread 1 medium slice
French Bread 1 Vi” slice
Study Rice, cooked 2 heaped tablespoons
Potatoes 1 egg-sized potato
Avoid pasta.
Snacks Men & 
Women
Please replace one snack that you normally eat during the day with one of 
the biscuits we provide__________________________________________
Additional
foods Men & Women
Every day we would also like you to eat 1 tablespoon of the salad dressing 
provided OR 2 tablespoons of hazelnuts.____________________________
Table I.iii Appendix /. RISCK Diet Guidelines-Diet B. High M U F A ,  High GI
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Study Foods Quantities Advice on how to achieve how to achieve
Fat Spreads
Men 4 teaspoons
Use your daily amount o f fat spread on each slice 
o f bread you eat. If you do not use all o f  your 
spread on bread, add the rest to other foods such as 
jacket potatoes, vegetables and in cooking and 
baking.*
Women 3 teaspoons
Cooking Oils
Men 1 tablespoon
You should aim to use the oils in cooking or to 
make a salad dressing*
Women 2 teaspoons
Cheese
Men
We do not need you to eat cheese everyday but aim to include three cheese 
sandwiches a week (with a generous portion o f  cheese). Alternatively use a 
similar quantity o f  cheese in recipes.*
Women
We do not need you to eat cheese everyday but aim to include two cheese 
sandwiches a week (with a generous portion o f  cheese). Alternatively use a 
similar quantity o f  cheese in recipes.*
Milk
Men & 
Women
Please use milk on the cereal provided, in your tea and coffee and in any recipes 
including milk.* If you do not drink tea or coffee, aim to have a small-medium 
glass o f  milk/day.
Breakfast
cereals/
Bread/Rice/Pasta Men & 
Women
Please eat the study breakfast cereals, bread, rice and pasta in the same quantities 
you eat in your usual diet less 1 portion/day of one of the foods, see below.
Food Reduce by:
Breakfast cereals 4 heaped tablespoons
Study Bread 1 medium slice
Study Rice, cooked 2 heaped tablespoons
Study Pasta, cooked 2 heaped tablespoons
Avoid potatoes.
Snacks Men & 
Women
Please replace one snack that you normally eat during the day with one o f  the 
biscuits we provide
Additional foods Men & 
Women
Every day we would also like you to eat a tablespoon o f  the salad dressing 
provided OR 2 tablespoons o f hazelnuts.
Table I.iv. Appendix I. RISCK Diet Guidelines-Diet C. High M U F A ,  Low GI
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Study Foods Quantities Advice on how to achieve how to achieve
Fat Spreads
Men 4 teaspoons Use your daily amount of fat spread on each slice of bread you eat. If you do not use all of 
your spread on bread, add the rest to other 
foods such as jacket potatoes, vegetables and 
in cooking and baking.*Women 3 teaspoons
Cooking
Oils Men 1.5 teaspoons
You should aim to use the oils in cooking or 
to make a salad dressing*
Women 1.5 teaspoons
Cheese
Men
We do not need you to eat cheese everyday but aim to include three 
cheese sandwiches a week (with a generous portion of cheese). 
Alternatively use a similar quantity of cheese in recipes.*
Women
We do not need you to eat cheese everyday but aim to include two 
cheese sandwiches a week (with a generous portion of cheese). 
Alternatively use a similar quantity of cheese in recipes.*
Milk
Men & 
Women
Please use milk on the cereal provided, in your tea and coffee and in any 
recipes including milk.* If you do not drink tea or coffee, aim to have a 
small-medium glass of milk/day.
Breakfast
cereals/
Bread/Rice/
Potatoes
Men & 
Women
Please eat the study breakfast cereals, bread, rice and potatoes in the 
same quantities you eat in your usual diet plus 2 portions/day of either 
one or two of the foods, see below. For example you may choose to 
eat 2 extra slice/day or 1 extra slice of bread and 1 extra potato/day.
Food Increase by:
Breakfast cereals 4 heaped tablespoons
Study Bread 1 medium slice
French Bread IV2” slice
Study Rice, cooked 2 heaped tablespoons
Potatoes 1 egg-sized potato
Avoid pasta.
Snacks Men & 
Women
Please replace one snack that you normally eat during the day with one 
of the biscuits we provide
Table I.v. Appendix I. RISCK Diet Guidelines-Diet D. Low Fat, High GI
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Study Quantities Advice on how to achieve how to achieve
Foods
Fat Spreads
Men 4 teaspoons Use your daily amount of fat spread on each slice of bread you eat. If you do not use all 
of your spread on bread, add the rest to other 
foods such as jacket potatoes, vegetables and 
in cooking and baking.*Women 3 teaspoons
Cooking
Oils Men 1.5 teaspoons
You should aim to use the oils in cooking or 
to make a salad dressing*
Women 1.5 teaspoons
Cheese
Men
We do not need you to eat cheese everyday but aim to include three 
cheese sandwiches a week (with a generous portion of cheese). 
Alternatively use a similar quantity of cheese in recipes.*
Women
We do not need you to eat cheese everyday but aim to include two cheese 
sandwiches a week (with a generous portion of cheese). Alternatively use 
a similar quantity of cheese in recipes.*
Milk
Men & 
Women
Please use milk on the cereal provided, in your tea and coffee and in any 
recipes including milk.* If you do not drink tea or coffee, aim to have a 
small-medium glass of milk/day.
Breakfast
cereals/
Bread/Rice/
Pasta
Men & 
Women
Please eat the study breakfast cereals, bread, rice and pasta in the same 
quantities you eat in your usual diet plus 2 portions/day of either one of 
the two foods, see below. For example you may choose to eat 2 extra 
slices of bread/day or 1 extra slice of bread and 4 extra tablespoons of 
pasta/day.
Food Increase by:
Breakfast cereals 4 heaped tablespoons
Study Bread 1 medium slice
Study Rice, cooked 2 heaped tablespoons
Study Pasta, cooked 2 heaped tablespoons
Avoid potatoes.
Snacks Men & 
Women
Please replace one snack that you normally eat during the day with one of 
the biscuits we provide
Table Lvi Appendix /. RIS C K  Diet Guidelines-Diet E  Low Fat, Low GI
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APPENDIX-1
Total nutrient 
composition (per 
1 0 0  £) ASH BSH CSH BOA COA ABA/ABX BBA/BBX ABC
Energy (kJ) 2960 2960 1051 3700 3700 3663 3663 3661
Fat (g) 80.0 80.0 28.4 1 0 0 . 0 1 0 0 . 0 99.0 99.0 99.0
Protein (g) 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0
Carbohydrate
(g) 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0
Sugar (g) 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0
SAFA (g) 40.7 16.8 5.1 2 1 . 0 15.0 11.5 47.8 2 1 . 6
MUFA (g) 2 1 . 2 41.0 17.4 51.2 77.7 55.8 33.6 45.6
PUFA (g) 19.0 22.3 5.9 27.8 7.3 31.4 17.9 31.5
n-3 (g) 2 . 8 3.3 0 . 8 4.2 0 . 6 4.5 2.7 5.4
n- 6  (g) 16.1 19.0 5.1 23.7 6.7 26.8 15.1 26.2
total trans (g) 0 . 1 0 . 2 0 . 0 0 . 2 0 . 0 0.4 0.4 0.5
salt (g) 1.5 1.5 1.5 0 . 0 0 . 0 0 . 0 0 . 0 0 . 0
Vitamin E 0.004 0.004 0.004 0.004 0.004 0 . 0 0 . 0 0 . 0
SAFA (%  total
fat) 50.8 21.0 18.0 21.0 15.0 11.6 48.2 21.8
MUFA (%  total
fat) 26.5 51.2 61.3 51.2 77.7 56.3 33.9 46.1
PUFA (%  total
fat) 23.7 27.9 20.8 27.9 7.3 31.7 18.1 31.9
Fatty acid
composition ASH BSH CSH BOA COA ABA/ABX BBA/BBX ABC
(g per 1 0 0  g)
C8 0 . 8 8 0.16 0.08 0 . 0 0 0 . 0 0 0.64 0.26 0.64
CIO 0.75 0.14 0.08 0 . 0 0 0 . 0 0 0 . 6 6 0.27 0 . 6 6
C12 10.60 1.78 0.89 0 . 0 0 0 . 0 0 9.94 3.73 9.94
C14 3.42 0.63 0.32 0 . 0 0 0 . 0 0 3.62 1.40 3.62
C16-0 12.23 7.74 2.71 11.15 8 . 2 2 16.03 8.24 16.03
C16-1 0 . 0 0 0.34 0.09 0.74 0.36 0.19 0.13 0.19
C17-0 0 . 0 0 0.06 0.03 0.04 0.07 0.08 0.08 0.08
C17-1 0 . 0 0 0 . 1 0 0 . 0 0 0.19 0.09 0.06 0.03 0.06
C18-0 12.33 3.46 1 . 6 8 2.71 2.75 16.01 6 . 6 6 16.01
C18-1 20.79 48.21 14.26 76.51 55.58 32.79 44.13 32.78
C18-l-t 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0.13 0 . 0 0 0.13
C18-2 16.12 14.45 6.73 6 . 6 6 27.12 15.14 26.17 15.13
C18-2-t 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 1 0 0.08 0 . 1 0 0.06
C18-3 2.85 2.17 1.18 0.64 4.56 2.74 5.36 2.73
C18-3-t 0.06 0.06 0.07 0 . 0 0 0.31 0.19 0.42 0.19
C20-0 0.24 0.31 0.06 0.41 0.32 0.39 0.44 0.39
C20-1 0.27 0.32 0.14 0.24 0.29 0.38 0 . 8 8 0.38
C22-0 0.16 0.15 0 . 1 1 0 . 1 1 0.24 0.27 0.37 0.27
C22-1 0 . 1 1 0.09 0.06 0 . 0 0 0 . 0 0 0.14 0.35 0.14
C24-0 0.06 0 . 0 0 0 . 0 0 0.60 0 . 0 0 0 . 1 1 0.13 0 . 1 1
C24-1 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0.05 0 . 1 1 0.05
Total 80.00 80.00 28.40 1 0 0 . 0 0 1 0 0 . 0 0 99.00 99.00 98.95
Table I.viiL Composition of study fats
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HIGH GI FOODS LOW & MEDIUM GI FOODS
Breakfast cereals1 
Product GI value Product GI value
Balance 74(5) Kelloggs Just right 602
Branflakes 76(5) Mini wheats 59(7)
Rice pops 80(6) Porridge (jumbo oats) 40(6)
Bread1
Standard white sliced bread3 70(10) Warburtons All in One4 48
Standard wholemeal sliced 
bread3
71(12) Tescos finest multigrain 
batch bread2
62
Pasta1
♦TO AVOID ALL PASTA Penne Pasta 43(7)
Potatoes
Baked, old, white with skin 
Baked, old, white w/o skin 
Boiled, old, white 
Instant mashed 
Mashed Desiree Potatoes
69(5)
98(8)
96(9)
95(16)
102(13)
TO AVOID ALL 
POTATOES
Average of all values
*TO AVOID NEW 
POTATOES
92
Rice1
Basmati easy cook rice 68(8) Basmati rice 43(8)
Table I. ix Appendix I. Measured GI o f study foods values are mean (SEM). The 
GI o f study foods was measured at MRC HNR Cambridge or taken from published
tables/manufactures information.
1 All products were Sainsbury’s own label unless otherwise stated
2 Not measured at MRC HNR, GI value taken from published tables
3 Alternative brands were also provided to participants and assumed to have similar GI 
values
4 Not measured at MRC HNR, GI value based on manufacturer information
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APPENDIX II-The EDWINA Study
Inclusion Criteria 
D Aged 18-55
n Body Mass Index 25-35 kg/M2
° Total cholesterol < 6.5mmol/L
n Triglycerides < 3mmol/L
a Free from medication with the exception of minor analgesics
n Non or very light smokers (<10 cigarettes/ day
n Normal Full blood count and liver function profiles.)
Exclusion criteria
n A reported history of myocardial infarction or cancer.
D Diabetes mellitus (fasting plasma glucose >7 mmol/L).
D Chronic coronary, renal or bowel disease or history of cholestatic liver disease or
pancreatitis.
D Presence of gastrointestinal disorder or use of a drug, which is likely to alter 
gastrointestinal motility or nutrient absorption. 
a History of substance abuse or alcoholism.
D Currently pregnant, planning pregnancy or having had a baby in the last 12 
months.
n Allergy or intolerance to intervention foods.
n Unwilling to follow the protocol and/or give informed consent.
n Weight change of >3kg in preceding 2 months.
n Daily intake of EPA + DHA > 1 g/day.
Table ILL Appendix X. EDWINA study inclusion/exclusion criteria
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EDWINA Study -  Volunteer Information Sheet page 1
INFORMATION SHEET FOR VOLUNTEERS
1. Investigator: Dr. Bruce A. Griffin
2. Purpose of Study: Dietary cholesterol in eggs is often misperceived to 
raise blood cholesterol and in doing so Increase the risk of coronary heart 
disease. However, recent evidence suggests that a daily intake of 
between 1-2 eggs has no clinically significant effects on blood cholesterol 
or risk of coronary heart disease. There is also evidence to suggest that 
any small increase in blood cholesterol produced by eating eggs can be 
prevented by weight loss, and in addition that eggs can actually promote 
weight loss by decreasing appetite.
We wish to test the hypothesis that a daily consumption of 2 eggs when in 
combination with weight loss produces no adverse effects on blood 
cholesterol and other indicators of coronary heart disease risk. This will be 
achieved by placing two groups of normal, healthy volunteers onto an 
energy restricted, weight-losing diet for 12 weeks. One of the groups will 
be asked to consume 2 eggs per day while the other group will consume 
no eggs.
3. Procedures: This study has received ethical approval from the University 
Ethics Committee. As a participant in the study you will be asked to carry 
out the following:
a) Pre-study screening:
* You will be asked questions related to your diet, supplement intake and 
genera! health via a questionnaire either over the telephone or in person.
* You will be asked to provide a blood sample (10ml). This will tell us if you 
are in good health and meet the study requirements, it is essentia! that 
before you provide this blood sample, and If you are suitable for the study, 
ail subsequent blood samples, that you fast for 12 hours the night before, 
this means no eating or drinking, other than water, after your evening 
meat and before the blood sample the next morning. You must also 
refrain from alcohol and exercise 24 hours before giving blood.
To participate in the study you must be healthy and free of any known 
medical condition or prescribed medication, and be willing to be placed on 
an energy-restricted, weight losing diet and eat 2 eggs per day for 12 
weeks.
b) What volunteers will be asked to do if selected for the study
* You will be asked to provide a total of 5 blood samples (20ml each) after an 
overnight fast, over 14 weeks (12 weeks on diet preceded by 1 a week 'run- 
in' before diet and 1 week after the diet). These samples will be taken by a 
trained nurse. You will be provided with a Sainburys 'Ready meal1 for your 
evening meal the night before your blood sample.
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EDWINA Study -  Volunteer Information Sheet page 2
® Before-diet ‘run-in’ week: You will be asked to provide a blood sample and
follow your usual diet for 1 week. Dining this week you will be asked to 
complete a 7-day diet diary.
* Start of the 12 week diet: You will be asked to provide another blood 
sample and have your height and weight measured. A student dietitian will 
then give you dietetic advice on how to reduce your energy intake by 500 
kcals/day and provide you with a diet plan that needs to be followed for the 
duration of the study, if you are assigned to the egg group you will be 
supplied with eggs for 12 weeks. Your 2 eggs can be eaten at any time of the 
any and in any form. It is important that you do not consume any choiesterol- 
lowering functional foods such as spreads containing plant sterols (e.g. Flor- 
procative or Benecof) 2 weeks before commencing the study and for the 
duration of the study.
* Interim blood sample: You will be asked to provide a fasted blood sample 
after 6 ’weeks and complete a 7-day diet diary in the following week.
* End of diet and I week post-diet: You will be asked to provide a further 2 
fasting blood samples after 12 weeks on the diet and 1 week after you have 
stopped the diet
The study may include future examination of specific genes that control the 
absorption and production of cholesterol. The Volunteer Consent form 
includes a specific section relating to his issue.
c) Foreseeable discom forts:
A 12-hour fast is a clinically approved procedure before providing blood for 
analysis. However, if any discomfort or adverse effects are experienced as a 
result of fasting, please report them, i he volunteer will then be advised not to 
participate in the study. Some discomfort may be experienced when 
providing blood samples where the needle enters the vein. Slight bruising 
may occur. This is not detrimental to your health in any way. Volunteers on 
the energy-restricted diet may experience hunger pangs at the start of the 
study. These must be reported immediately where dietetic intervention will be 
given
d) Benefits to be expected from the research
* This study will confirm that egg consumption produces no adverse effects on 
blood cholesterol when accompanied by weight loss
It may also provide evidence that egg consumption helps to promote weight 
loss
e) Confidentiality
* Any Information obtained from you will be kept confidential.
* A code number will be used to identify test results or information that you 
provide.
* The only persons with access to this information will be the investigators.
* No names will be used in any report or publications related to this work.
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EDWINA Study -  Volunteer Information Sheet page 3
f) Compensation for injury
* You will be reimbursed for any travel expenses. Evidence of proof of travel 
must be provided.
* You will be paid £100 upon fuli completion of the study. There is no part 
payment for completing part of the study.
g) Voluntary participation statement
° Participation in this study is completely voluntary.
* You may either refuse to participate or discontinue participation at any time 
without any penalty or loss of benefits to which you are otherwise entitled. 
However, if you withdraw from this study before it is completed, you will not 
receive payment.
if you have any questions / concerns about the study
Please contact: Dr. Bruce Griffin (Tel: 01483-879724 E-mail:
B.Griffin@surrey.ac.uk) who will be pleased to answer any questions you 
may have.
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BHF-How to lose weight fo r good
Guidelines used to achieve energy restriction in the EDWINA study (Chapter 5)
Individual needs were assessed by a dietician and subjects advised to achieve this 
goal using a target number of portions of the food groups shown below. Subjects 
were also provided with details of portion size for a number of common foods. 
Subjects randomised to the two egg per day diet were advised that two eggs were 
equal to one portion in the “meat, fish and alternatives” group.
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How much is a portion?
Fruitand vegetables'have 7-8 portion) per dayi
tfadfltsCite eg cauiftc^ sr.cactnge. pals.clircti muivMrrii tctretcsc. u*i saieds.cuutgettes trcccol. frjncn ossns pappir:
2 Brge utrespccns
iatad jrat oa mnxacucirntKr.cncn pspper 1 mil ootM
toWIK’ 1 msdum
WhamftBhflutt ag. I ippta I pear. 1 cranga 1 tunara. 1 psdcti
Tmsdttut n altutalMCS eg pe»ct~si prteJppis. raspOemte and psars 3 arga satrespccnt
Stsvesd fruit *g lpp*s. tnutart. cosrrns 4 orge Uttcspccre
Lara; fruits 1 sea rrtfton cr pftaippra Y grapsflut
irreimjft 1 i gripes I JptKttts, 2 ptums i I NM fruits ’ «n*osrriss
tredfruit sgritsns 1 tUCy Oc* rnatcMMXMs
lruit>Mee •/T.Homum xie pat day/ 1 mi glass cr small cattcn
Bread, other ceroak and potatoes there 7-8 portions per day!
ktjWta cetall sgtlsfcsc orcnspws 3 tattepocce
Muail 2 ladeposes
Sdaddad wtiaat 1
Wsatao* 1
firs ad cr talst 1 orga «c» imedutn tract)
frsad ten or tcri
fctta trajd I mrr or pincuis
Chapins 1 mil
Cladtes 3
Crnptraam 4
hart nun brsad 1 mil
bce.psam ttoiad 2 nsdped tlOKSfocre
Bread other cereals and potatoes (hare 7-8 pcrtions per day) Cortt...
tbsM.pun.toled 3 ns apedtiCKipccre
fag nocdM.CKsasCT rjr pectat
hctltcas 2 egg sue
Segal pun or ottttarrvon & Men h
Cruirpst.'p*(le1 3
Wjnn 3
Wit car 3 smillsKa
kUy oar 3
Milk and dairy hoods [have 2 - 3 portions per day)
Mat Iptsrsra&ry tawi strmwci cr tattar stu s»immei| 1 madum glass cCCrttl (h pop
Ycghun.ptain or favoured toa fit and to* sugar 1 small pet I50g |5cd
Cfisess prctetaay cw tit 1 matctitex sea 43c ]l?i cd Ifrts. Csmsmte-o fcum. reduced 1st ensiitt Stttdtod Au smart as good)Ttia trsni pcrtKin sirs ensaws ira nirtdy
Ctwin ovsass - igm tns su's cr 2 small rraurccass. 93g (3od
Cottage cnssss 1 srga poo 2Xg loop
Srcrregs ttae igtw 3 smut pet iHjgliosj
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M ut, flsh and aiternar lv»i Ihov* 2 • J  portion* pat day)
I sen maat Iks bsar.pcflir-iam. Bmtoc!>c*sn /tiatwut * r ( 3 slcas ipn amount tns sie d a poet ol piayngcartel
fen • a n te  cr oiy asmea*
fen tngers 3
tggs 2
idled bs«ts in tomato sauce |c# tugar and salt 1 pcsstia!’ i  taosispoms
lantas 4 tablespoons cocked
lean: eg tedktidsy ctsans Putter talte.cndt psas 4 tablespoons cooke-d
Mjts cr peanut butter 2 tabhspoms
(•tty md aagary roods ’.see amount; baiow.t
Fata inarm 2 pcrucns par dayl
Spr oadng rata and oils
k jttir  or manair n s spread 3 teaspoon
la # t s t  spread 2 teaspoons
3i liny type' 3 teaspoon
Otesshgs and sauces
Mlycnraisa 3 teaspoon
l a #  cat: to  mayonne ea 2 teaspoons
Etua obsess dnsng 3 teaspoon
Salad cream 3 tablespoon
lo# osl:r« tdttd croinr 2 tablespoons
-Gravy if # n «  sauce ImuM 3 tablespoon
■Gravy cr #nits saucs I made #rthccrnflout| 4 tablespoons
Occasional roods <ham 1 portion par day or 7 par #ee«l
Sugar 3 teaspoons
.lam ar tensy 1 neaped tsasp:*:o
Cnsps pralsrapry t # t a t 1 smal packet
Croam 1 tablespoon
toecrearn 1 smal scoop
bKu its. plain 2
Sic; ol cake V,
D au ^ru t tt
Caneh pasiry V.
Cneccuta I small tiarot 2 mini tats
Sweats 1 smai tuPe.big
Fttstry n  savoury dam i d  pori, p*s. sluslip) rol. ^
qucne tertana
Kara sice ol cake or tail l sausage rol may teem tdttir mpractclt You may #eritr slvcupyou' #eekly'iacion'or 
sate! INI pastries tc Pave at #s(*«r>ds ora time rtftefi you kno#ycu #cutd Iks to aijoyaspicBl Boat for ajumpts, 
arts dcuoMut #odd pa 2 portcfe.sc i day s rations
AicoTvdlc dmls Imixl- 2 p« day or 7 ■ Hparweafcl
>dndry strsnotn tsar or agar 1 small iCfl ml $ pntj
Wne 1 giass ICOmi ■]!fioal
Spirits 1 tct maasural.B ml |1 tl o<*
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Recipes including two eggs per day were made available to the group consuming 
two eggs per day in an attempt to aid compliance. Examples of these recipies are 
detailed below:
B a k e d  F r i t ta ia  f o r  O n e
Makes 1 serving
40 minutes (15 mins prep)
2 eggs
1 small courgette, sliced 
1 small tomato, diced 
6 mushrooms, sliced 
1 teaspoon low-fat spread/olive oil
1 egg size potato, cooked and diced (optional) (leftover boiled potatoes are useful)
2 spring onions, chopped
1 clove garlic, minced or pressed
2 tablespoons chopped fresh parsley
1 matchbox sized piece (40g) low-fat cheddar cheese grated 
salt to taste (optional) 
freshly ground black pepper 
dried or fresh basil
Preheat oven to 350°F (175°C). Grease or spray a baking dish with non-stick spray. 
Beat eggs in a fairly large bowl. Meanwhile, heat low-fat spread (or oil) in a frying 
pan and saute the vegetables of your choice together with the garlic. When tender, 
add vegetables to the beaten eggs. Add parsley, cheese and seasonings and stir. 
Pour into the prepared baking dish and bake for 20-25 minutes until set. Let stand 
for 2 minutes, then cut into wedges and enjoy.
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S a l a d  N ic o i s e
Makes 4 servings
250g (1 packet) green beans, cooked and drained
4 egg sized potatoes, thinly sliced
4 medium tomatoes, sliced
8 hard boiled eggs
8-10 pitted drained olives
Lettuce (try using a variety o f  lettuce leaves)
Reduced fat or non-fat French dressing
Arrange lettuce leaves on each of 4 salad plates. Mound about Vi cup of the beans in 
the centre of each. Arrange potato, tomato and egg slices in petal fashion around 
beans. Sprinkle each salad with about 1 tablespoon of the olive slices, and sprinkle 
with dressing.
H e r b e d  D e v i l l e d  E g g s
Makes 3 Servings 
6 hard boiled eggs 
2 tablespoons cottage cheese 
2 tablespoons low fat plain yoghurt 
1 tablespoon finely chopped onion 
1 teaspoon prepared mustard (Dijon style)
XA teaspoon dried (or fresh) parsley 
% teaspoon dill
V8 teaspoon garlic powder (or crushed fresh garlic)
dash hot pepper sauce
salt and pepper to taste (optional)
Cut eggs in half. Put yolks in small bowl and with a fork, mash yolks together with 
cottage cheese and yoghurt. Stir in remaining ingredients. Season with salt and 
pepper, if desired. Fill egg halves. Chill before serving.
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O m e le t te  P i q u a n t
Makes 3 Servings
V2 sweet red and/or green pepper chopped 
100ml water, divided
1 can (240g) sweet com 
Chopped green chillies (to taste)
2 tablespoons finely chopped spring onions 
1 clove garlic, crushed or pressed
6 eggs
1 Tablespoon low-fat spread 01* olive oil or cooking spray 
150ml prepared taco sauce 
Fresh lettuce leaves
In small saucepan, combine pepper and 2 Tablespoons of the water. Cover and cook 
over medium heat, stirring occasionally, until pepper is tender, about 4 to 5 minutes. 
Add com, chillies, onion and garlic powder. Cook, stirring occasionally, until heated 
through. Keep warm.
In small bowl, beat together eggs and remaining water until blended. For each 
omelette, heat 1 teaspoon of the low-fat spread (or oil) in a small frying pan over 
medium -high heat until just hot enough to sizzle a drop of water. Pour in V3 of the 
egg mixture. With an inverted pancake turner (or fish slice) carefully push cooked 
portions at edges toward centre so uncooked portions can reach the hot pan surface, 
tilting the pan and moving cooked portions as necessary. When top is thickened and 
no visible liquid egg remains, spoon V3 of the reserved com mixture across centre of 
omelette. With pancake turner, fold sides of omelette over com mixture. Slide from 
pan onto plate. Spoon on V3 taco sauce. Garnish with lettuce leaves, if desired. 
Repeat for remaining omelettes.
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G a r d e n  O m e le t te
Makes 4 servings
2 Tablespoons reduced-fat salad dressing
1 Shredded carrot
2 Chopped spring onions 
lA Green pepper, chopped 
lA Cucumber chopped
1 medium tomato, chopped 
8 eggs
200ml skimmed milk 
4 teaspoons olive oil, divided 
salt to taste (optional)
In small saucepan over medium heat, cook dressing, carrots, onions, and peppers 
until tender. Stir in cucumber and tomatoes. Set aside; keep warm.
Beat together eggs, milk, and salt, if desired. In small frying pan over medium heat, 
heat 1 teaspoon oil until just hot enough to sizzle a drop of water. Pour in lA of the 
egg mixture. Mixture should set immediately at edges. With inverted pancake 
turner (or fish slice) carefully push cooked portion at edges toward centre, tilting pan 
and moving cooked portions so uncooked portions can reach hot pan surface. When 
top is thickened and no visible liquid egg remains, fill with % of the vegetable 
mixture. Fold omelette in half and serve. Repeat for remaining omelettes.
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Makes 2 servings
4 eggs
50ml skimmed milk 
2 teaspoons dry mustard 
80g reduced fat cheddar cheese 
1/3 onion, chopped 
1/3 red pepper, chopped 
1/3 green pepper, chopped 
Salsa, optional
1 wholewheat pita bread shell, halved
Whisk together eggs, milk, onion, red and green peppers, and mustard. Heat a small 
frying pan to medium high and pour egg mixture into pan. Scramble eggs until 
firmbut still moist. Just before eggs are set, add cheese and warm until melted.
Warm pita pockets in microwave for 20 seconds (or under the grill). Open one pita 
half and spoon % of the egg mix into the shell. Repeat with other pita half. Serve 
hot.
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V e g g ie  F r i t ta ta
Makes 4 servings
8 eggs
2 dessertspoons olive oil 
2 cloves garlic, finely chopped 
Vi teaspoon salt (optional)
Vi teaspoon pepper
1 teaspoon thyme
Vi onion, chopped
Vi red pepper, chopped
4 Large tablespoons of broccoli
80g reduced-fat grated cheddar cheese
Heat 1 dessertspoon of olive oil over medium heat in a small skillet/fiying pan. Add 
the onion, red pepper, garlic and thyme. Saute until onion is soft. Microwave 
covered broccoli for 2 minutes on high (or steam until tender). Remove the 
vegetables from the skillet and add to broccoli.
Beat the eggs, salt and pepper together. Put the remaining 1 dessertspoon of olive oil 
in the skillet/fiying pan on medium heat. Pour the egg mixture into the pan and 
scatter the vegetables on top. Turn the heat to low and cook until the frittata is 
golden brown on the bottom and the egg is beginning to set, approximately 7 
minutes. Place the frittata under the grill (protecting the handle of the pan) and cook 
until it is almost firm. Add cheese to the top and again put under the grill until 
completely set and cheese is melted. Slide onto plate and cut into wedges.
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